UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Form 10-K
|
|
|
þ
|
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the Fiscal Year Ended
December 31, 2010
|
or
|
o
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
Commission File Number
000-23019
KENDLE INTERNATIONAL
INC.
|
|
|
Ohio
|
|
31-1274091
|
(State or other jurisdiction
of incorporation or organization)
|
|
IRS Employer
ID No.
|
441 Vine Street, 500 Carew Tower
Cincinnati, Ohio 45202
513-381-5550
Securities Registered Pursuant to Section 12(b) of the
Act:
|
|
|
Title of Each Class
|
|
Name of Each Exchange on Which Registered
|
|
Common Stock, no par value
|
|
The NASDAQ Stock Market LLC
(NASDAQ Global Select Market)
|
Securities Registered Pursuant to Section 12(g) of the
Act:
None
Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities
Act. Yes o No þ
Indicate by check mark if the registrant is not required to file
reports pursuant to Section 13 or Section 15(d) of the
Act. Yes o No þ
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been
subject to such filing requirements for the past
90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any,
every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of
Regulation S-T
(§ 232.405 of this chapter) during the preceding
12 months (or such shorter period that the registrant was
required to submit and post such files.) Yes
o No o
Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of
Regulation S-K
(§ 229.405 of this chapter) is not contained herein,
and will not be contained, to the best of registrants
knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this
Form 10-K
or any amendment to this
Form 10-K. þ
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of
large accelerated filer, accelerated
filer and smaller reporting company in
Rule 12b-2
of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated
filer o
|
|
Accelerated
filer þ
|
|
Non-accelerated
filer o
(Do not check if a smaller reporting company)
|
|
Smaller reporting
company o
|
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12b-2
of the Exchange
Act). Yes o.
No
þ
The aggregate market value of the Registrants Common Stock
at June 30, 2010, held by non-affiliates was $163,278,167
(based on the $11.52 closing price of the Companys Common
Stock on The NASDAQ Global Select Market LLC on June 30,
2010).
As of March 3, 2011 14,981,841 shares of no par value
Common Stock were issued and 14,958,789 shares of no par
value Common Stock were outstanding.
Documents
Incorporated by Reference
Portions of the Registrants Proxy Statement to be filed
with the Commission for the Registrants 2010 annual report
to shareholders for the fiscal year ended December 31,
2010, are incorporated by reference into Part III. See
Exhibit Index on page 45.
Kendle
International Inc.
Form 10-K
Annual Report
For the Fiscal Year Ended December 31, 2010
Table of
Contents
2
This Annual Report on
Form 10-K
contains certain statements that are forward-looking
statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements are subject to a
number of assumptions, risks and uncertainties, many of which
are beyond the control of Kendle International Inc. (the Company
or Kendle). See Item 1A Risk
Factors for further information.
The forward-looking statements speak as of the date made and are
not guarantees of future performance. Actual results or
developments may differ materially from the expectations
expressed or implied in the forward-looking statements, and the
Company undertakes no obligation to update any such statements.
PART I
General
Kendle International Inc., an Ohio corporation established in
1989, is a global clinical research organization (CRO) that
provides a broad range of Phase I-IV global clinical development
services to the biopharmaceutical industry. The Company augments
the research and development activities of biopharmaceutical
companies by offering high-quality, value-added clinical
research services and proprietary information technology
designed to reduce drug development time and expense. The
Company is managed in two reportable segments, Early Stage and
Late Stage. The Early Stage business currently focuses on the
Companys Phase I operations, while Late Stage is comprised
of clinical development services related to Phases II
through IV.
Early
Stage
The Early Stage reportable segment is focused on the high-end
scientific exploratory medicine area, from
First-in-Human
studies through
proof-of-concept
stages, in the Companys Toronto, Canada and Utrecht, The
Netherlands locations. The Company also provides full support
for Phase I studies in established compounds, including
bioequivalence and pharmacokinetics studies, at its Morgantown,
West Virginia location. In the fourth quarter of 2010 the
Company made a decision to close the Early Stage component of
operations at its Utrecht location. Please see Note 9 to
the Consolidated Financial Statements, as well as the
Companys
Form 8-K
filed with the Securities and Exchange Commission on
February 14, 2011 for further details.
Late
Stage
The Late Stage reportable segment includes four reporting units:
Clinical and Data Monitoring; Project Management &
Late Phase; Regulatory, Safety, Site and Medical Affairs; and
Biostatistics and Statistical Programming. This segment has a
global reach that enables the Company to meet its
customers needs by accessing specific patient populations
in large urban areas as well as emerging markets/regions all
over the world.
The Clinical and Data Monitoring unit (C&DM) conducts
Phase II through IV clinical trials worldwide.
C&DM provides a wide range of services including clinical
monitoring, data management and study reports to assist
customers with their drug development efforts.
The Project Management & Late Phase (PM &
LP) unit oversees all steps of a study, from award through close
out of a study. This unit also designs and conducts Phase IIIB
and IV studies worldwide.
The Regulatory, Safety, Site and Medical Affairs unit provides
regulatory expertise and consulting services at every stage of
drug and device development, from early development to market
and post market. This unit designs, among other things, clinical
programs and clinical trial protocols, reviews programs and
provides gap analysis to assist sponsors in achieving their
clinical development strategies. The unit also provides
consulting services for nonclinical development for small
molecules, biologicals, vaccines and devices. This unit focuses
on health economics, outcome research, scientific events and
medical education services. Additionally, this unit has safety
experts that assist customers with the collection, analysis and
reporting of accurate drug safety data.
3
The Biostatistics and Statistical Programming unit offers full
service statistical support for Phase I to IV clinical
trials and submissions. The unit has biostatisticians that can
supply comprehensive statistical analysis plans on a turnkey
basis or on a consulting basis.
The Company believes that the outsourcing of drug development
activities by biopharmaceutical companies will increase as these
companies strive to grow revenues through an accelerated drug
development cycle while responding to cost containment
pressures. The CRO industry, by specializing in clinical trial
management, often performs the needed services with a higher
level of expertise or specialization at a faster pace and at a
lower cost than a biopharmaceutical company could perform such
services internally.
Acquisition
Activity
In June 2008, the Company completed its acquisition of
DecisionLine Clinical Research Corporation (DecisionLine) and
its related company. DecisionLine is a clinical research
organization located in Toronto, Ontario specializing in the
conduct of early phase studies. The acquisition supports the
overall goal of strategic business expansion, and, in
particular, expansion of Phase I studies.
Business
Strategy
The Companys strategy is to continue to enhance its
reputation as a high-quality, global provider of a full range of
CRO services. This year has been a challenging one for the CRO
industry, for the Company and for its customers. The Company has
been affected by the repercussions of merger and acquisition
activity in the global biopharmaceutical industry and the
resultant reprioritization of their pipelines, search for cost
efficiencies and right sizing of their workforces resulting in
lower new business authorizations and higher than historical
cancellations. In the near term, the Companys strategy is
to adapt to the current state of flux in the industry and bring
stability back to the Companys operations. The
Companys longer term strategy remains steadfast and
consists of the following strategic initiatives:
|
|
|
|
|
Driving growth in the Companys core competency in Phases I
through IV clinical trials, while increasing profitability
through its enhanced global platform.
|
|
|
|
Meeting the specific development pipeline needs for the
Companys targeted customers.
|
|
|
|
Gaining share in the CRO market through further penetration in
the large (greater than $10 million in contract value)
trial sector as well as continued expansion in mid-sized trials.
|
|
|
|
Expanding the Companys geographic footprint with a focus
on high-growth regions such as Latin America, and Asia/Pacific.
|
|
|
|
Setting the stage for business mix expansion.
|
|
|
|
Continuing to enhance infrastructure to support expansion and
growth of the Company.
|
Customers
and Marketing
Net service revenues from the top five customers accounted for
approximately 26% and 27% of the Companys total net
service revenues for the years ended December 31, 2010 and
2009. No customer accounted for more than 10% of the
Companys net service revenues in either 2010 or 2009.
Segment and geographic information for the Company is contained
in Note 13 to the Consolidated Financial Statements.
Backlog
Backlog consists of anticipated net service revenue from
contracts, letters of intent and other forms of commitments
(collectively defined as backlog) that either have not started
but are anticipated to begin in the near future, or are in
process and have not been completed. Amounts included in backlog
represent anticipated future net service revenue and exclude net
service revenue that has been recognized previously in the
Consolidated Statements of Operations. Once contracted work
begins, net service revenue is recognized in the Consolidated
Statements of
4
Operations. Backlog at December 31, 2010, was approximately
$828 million compared to approximately $830 million at
December 31, 2009. The majority of the Companys
backlog is from large established biopharmaceutical firms with
annual revenues greater than $1 billion. Backlog arising
from contracts with small biotech firms with no revenues or
large biopharmaceutical partner are not material to the Company.
The Company continues to experience high levels of cancellations
and delays between proposals and awards due to budget reductions
and pipeline reprioritizations at large pharmaceutical
companies, drug failures due to efficacy and safety, and
regulatory actions related to drugs in development among other
things. The average duration of the contracts in backlog
fluctuates from quarter to quarter based on the contracts
constituting backlog at any given time. The Company generally
experiences a longer period of time between contract award and
revenue recognition with respect to large contracts covering
global services. Additionally, as a result of biopharmaceutical
companies starting to award trials earlier in the cycle than
they have historically, we are seeing the time duration between
award and revenue recognition elongate as study designs continue
to be reviewed and revised. As the Company competes for and
enters into large contracts that are global in nature, the
Company expects the average duration of the contracts in backlog
to increase and may be affected by changes in foreign exchange
rates. Fluctuations in foreign exchange rates caused backlog to
decrease by approximately $6.6 million as of
December 31, 2010, primarily as a result of the weakening
of the Euro throughout 2010. Based on its 2010 experience,
quarterly revenue as a percentage of the beginning of the
quarter backlog averaged approximately 10%.
No assurance can be given that the Company will be able to
realize the net service revenues that are included in the
backlog. Backlog is not necessarily a meaningful indicator of
future results for a variety of reasons, including, but not
limited to, the following: (i) contracts vary in size and
duration, with revenue from some studies realized over a number
of years; (ii) the scope of contracts may change, either
increasing or decreasing the value of the contract; and
(iii) studies may be terminated or delayed at any time by
the studys sponsor or by regulatory authorities due to
efficacy, safety or funding concerns, among other reasons.
Competition
The Company competes primarily against in-house research and
development departments of biopharmaceutical companies,
universities, teaching hospitals and other full-service CROs,
some of which possess substantially greater capital, technical
expertise and other resources than the Company. CROs generally
compete on the basis of past performance for a customer, medical
and scientific expertise in specific therapeutic areas, the
quality of services provided, the ability to manage large-scale
trials on a global basis, medical database management
capabilities, the ability to provide statistical and regulatory
services, the ability to recruit investigators, the ability to
recruit patients into studies, the ability to integrate
information technology with systems to improve the efficiency of
clinical research, an international presence with strategically
located facilities and financial viability and price.
The CRO industry is highly fragmented with hundreds of CROs
ranging from small, limited-service providers to full-service,
global drug development corporations. Some of the large
multi-national full-service CROs competing with the Company
include Covance, Inc., PAREXEL International Corporation,
Pharmaceutical Product Development, Inc., ICON plc, PRA
International, PharmaNet Development Group, Inc. and Quintiles
Transnational Corporation.
Government
Regulation
The Companys clinical services are subject to industry
standards for the conduct of clinical research and development
studies that are contained in regulations for Good Clinical
Practice (GCP). The Food and Drug Administration (FDA) in the
United States and the European Agency for the Evaluation of
Medicinal Products in Europe (EMEA), along with other regulatory
bodies, require that clinical trial test results submitted to
the regulatory bodies be based on studies conducted in
accordance with GCP.
In addition, the International Conference on
Harmonization Good Clinical Practice Guidelines
provides guidance on GCP. The Company implements and revises its
standard operating procedures to facilitate GCP compliance.
5
Employees
As of December 31, 2010, the Company employed approximately
3,105 associates, about 61% of whom were located outside the
United States. None of the Companys associates are covered
by a collective bargaining agreement and the Company believes
its overall relations with its associates are good. Associates
in certain of the Companys
non-U.S. locations
are represented by workers councils as required by local
laws.
Available
Information
The Company maintains a web site at the address
www.kendle.com. The Company is not including
the information contained on its web site as a part of, or
incorporating it by reference into, this Annual Report on
Form 10-K.
The Company makes available free of charge through its web site
its Annual Reports on
Form 10-K,
Quarterly Reports on
Form 10-Q
and Current Reports on
Form 8-K,
and amendments to these reports, as soon as reasonably
practicable after it electronically files such material with, or
furnishes such material to, the Securities and Exchange
Commission (SEC).
Required filings by the Companys officers and directors
with respect to the Company furnished in electronic form are
also made available on its web site as is the Companys
Proxy Statement for its annual meeting of shareholders. These
filings also may be read or copied at the SECs Public
Reference Room located in Washington, D.C. The SEC also
maintains an Internet site
(http://www.SEC.gov)
that contains reports, proxy statements and other information
regarding issuers that file electronically with the SEC.
Certain statements contained in this Annual Report on
Form 10-K
that are not historical facts constitute forward-looking
statements, within the meaning of the Private Securities
Litigation Reform Act of 1995, and are intended to be covered by
the safe harbors created by that Act. Reliance should not be
placed on forward-looking statements because they involve known
and unknown risks, uncertainties and other factors that may
cause actual results, performance or achievements to differ
materially from those expressed or implied. Forward-looking
statements generally contain the words believe,
expect, may, anticipate,
intend, estimate, project,
plan, assume, seek to or
other similar expressions, although not all forward-looking
statements contain these identifying words. Any forward-looking
statement speaks only as of the date made. The Company
undertakes no obligation to update any forward-looking
statements to reflect events or circumstances arising after the
date on which they are made.
Statements concerning, without limitation, expected financial
performance and results, plans and objectives, prospects,
on-going business strategies and possible future action which
the Company intends to pursue to achieve strategic objectives
constitute forward-looking information. Implementation of these
strategies and the achievement of such financial performance are
each subject to numerous conditions, uncertainties and risk
factors. The risk factors listed below are those deemed to be
material by the Company. Additional risks and uncertainties not
currently known may materially adversely affect the
Companys business, financial condition
and/or
results of operations.
Risks
Related to Our Industry
The
Company depends on the biopharmaceutical industry for most of
its revenue.
The Companys revenues depend on the outsourcing trends,
size of the drug-development pipeline and research and
development expenditures of the biopharmaceutical industry.
Economic factors and industry trends that affect companies in
the biopharmaceutical industry affect its business. A slowdown
in research and development spending or a reprioritization of
the drug development pipelines or limited access to capital to
fund projects in the biopharmaceutical industry could negatively
affect the Companys net service revenues and results of
operations. Mergers and acquisitions in the biopharmaceutical
industry and the related rationalization of the drug-development
pipelines could result in delay or cancellation of certain
existing projects.
6
The
CRO industry is highly competitive.
The CRO industry is comprised of a wide range of competitors
including small, niche providers as well as large multi-national
full-service global clinical research organizations. These
companies compete based on a variety of factors, including
reputation for quality, performance, price, scope of service
offerings and geographic presence. Some of the Companys
competitors have greater financial resources and a wider range
of service offerings over a greater geographic area.
Additionally, the Companys customers have in-house
capabilities to perform services that are provided by CROs.
These factors potentially could have a negative impact on the
Companys ability to win business awards.
Revenue
and earnings growth rates in the future may not be as robust as
in the past.
Current economic conditions including pharmaceutical company
mergers, drug development pipeline reprioritization, and cost
containment efforts by customers including reduction of research
and development spending, among other things, have, and may
continue to impact the CRO industry and, in particular, the
Companys sales and revenue growth rates. There can be no
assurance that growth rates will recover to the level
experienced in the past.
Change
in government regulation or healthcare reform could adversely
affect the Company.
Government agencies regulate the drug development process
utilized by the Company in its work with biopharmaceutical
companies. Changes in regulations that simplify the drug
approval process or increases in regulatory requirements that
lessen the research and development efforts of the
Companys customers could negatively affect the Company. In
addition, any failure on the Companys part to comply with
existing regulations or in the adoption of new regulations could
impair the value of its services and result in the termination
of or additional costs under its contracts with customers.
Comprehensive healthcare reform could reduce the demand for
services which could reduce revenues. Legislation creating
downward pressure on the prices for drugs that pharmaceutical
and biotechnology companies can charge or the removal of these
drugs from reimbursement formularies could reduce the amount of
revenue the Company could earn from projects outsourced to it.
Healthcare reform outside the U.S. could also adversely
impact the Companys revenues and profitability.
Risks
Related to Our Business
The
Companys contracts may be delayed, terminated or reduced
in scope with little or no notice.
Many of the Companys contracts provide for services on a
fixed-price basis and may be terminated or reduced in scope with
little or no notice. Cancellations may occur for a variety of
reasons, including the failure of the product to satisfy safety
requirements, the Customers inability to manufacture
sufficient quantities of the drug, unexpected results of the
product or the customers decision to terminate the
development of a product.
The loss, reduction in scope or delay of a large contract or the
delay of multiple contracts could have a material adverse effect
on the Companys results of operations; although its
contracts entitle it to receive payments for work performed in
the event of a cancellation. Cancellation or delay of a large
contract or multiple contracts could leave the Company with
under-utilized resources and thereby negatively affect its net
service revenues and results of operations. The Company believes
its aggregate backlog is not necessarily a meaningful indicator
of future net service revenues and financial results.
The
fixed price nature of many of the Companys contracts could
result in financial losses.
Because many of the Companys contracts are structured as
fixed price, it is at financial risk if it initially underbids
the contract or overruns the initial cost estimates. Such
under-bidding or significant cost overruns could have a material
adverse effect on the Companys business, results of
operations, financial condition and cash flows.
7
The
Companys backlog may not be indicative of future
results.
The Company includes in backlog anticipated revenues from
projects currently in process plus written awards, signed
contracts, letters of intent and other awards believed to be
firm commitments. These contracts vary in size and duration and
may be subject to changes in scope, delays or cancellations. If
the Company is successful in securing future contracts that are
larger and more global in nature, the rate at which backlog is
converted into revenue may be slower than the Companys
historical experience. Additionally, as a result of
biopharmaceutical companies starting to award trials earlier in
the cycle than they have historically, we are seeing the time
duration between award and revenue recognition elongate as study
designs continue to be reviewed and revised. The portion of
backlog that may be performed in
non-U.S. subsidiaries
is exposed to fluctuations in the applicable foreign currencies
which could affect the amount of revenue ultimately recognized.
Fluctuations in foreign exchange rates caused backlog to
decrease by approximately $6.6 million at December 31,
2010.
The
economic climate has caused the Company to rapidly adjust from a
robust growth strategy to a cost containment strategy in a short
period of time, which has placed, and is expected to continue to
place, significant demands on it.
The Company has had to adapt to a rapidly changing economic and
industry environment. Historically, the Company had grown
rapidly, both organically and through acquisitions. In 2009 and
continuing through 2010, the Company experienced lower new
business authorizations than in its recent past, combined with
higher than historical levels of cancellations. This placed
significant stress upon the organization to adjust from building
toward expected future growth to taking rapid actions to
preserve profitability. As a result, the Company embarked on
reduction in force and cost containment initiatives which could
have an unfavorable impact on the future operations should the
environment quickly recover. Additionally, certain geographic
regions could grow at faster rates than other geographic
regions, resulting in the Company hiring associates in those
regions (i.e. Latin America and Asia/Pacific) at a more
accelerated pace than in other regions.
If the
Company is unable to attract suitable investigators and
volunteers for clinical trials, the Companys business may
suffer.
The clinical research studies the Company operates rely upon the
accessibility and willing participation of physician
investigators and volunteer subjects. Investigators supervise
the administration of study drugs to patients during the course
of a clinical trial. Volunteer subjects generally include people
from the communities in which the studies are conducted. The
Companys clinical research business could be adversely
affected if we are unable to attract suitable investigators or
clinical study volunteers on a consistent basis.
If the
Company is required to write off goodwill or other intangible
assets acquired in its business combinations, its financial
position and results of operations would be adversely
affected.
The Company had goodwill and other acquisition-related
intangible assets of approximately $248.0 million and
$258.8 million as of December 31, 2010 and
December 31, 2009, respectively, which constituted
approximately 51% and 48%, respectively, of its total assets at
these periods. The Company periodically (at least annually
unless triggering events occur that cause an interim
evaluation), evaluates goodwill and other acquired intangible
assets for impairment. Any future determination requiring the
write off of a portion of the Companys goodwill or other
acquired intangible assets could adversely affect its results of
operations and financial condition. Should current economic
conditions continue, the annual or an interim evaluation (if
required as indicated above) could result in an impairment of
the Companys goodwill. In connection with its annual
evaluation of goodwill for the year ended December 31,
2010, the Company determined that a portion of the goodwill
related to its Early Stage segment was impaired and as a result
wrote off approximately $7.3 million of the goodwill
related to this segment. See Note 5 to the Consolidated
Financial Statements for further detail on goodwill and
amortizable intangible assets.
The
Companys indebtedness could adversely affect its business
and financial condition.
As of December 31, 2010, the Company had
$142.5 million (in par value) of convertible debt
outstanding and an additional $35 million of borrowing
capacity under a revolving line of credit. The Company also
maintains a
8
$5.0 million multicurrency facility that is renewable
annually and used in connection with its European operations.
For a description of the Companys indebtedness and that of
its subsidiaries, see Liquidity and Capital Resources section of
Managements Discussion and Analysis of Financial Condition
and Results of Operations.
The Companys level of indebtedness will have several
important effects on its future operations. For example, the
Company will be required to use a portion of its cash flow from
operations for the payment of principal and interest due on its
outstanding indebtedness. In addition, the Companys
outstanding indebtedness and leverage could increase the impact
of negative changes in general economic and industry conditions,
as well as competitive pressures. The level of the
Companys outstanding indebtedness may affect its ability
to obtain additional financing for working capital, capital
expenditures or general corporate purposes.
General economic conditions as well as conditions affecting the
Companys operations specifically, including, but not
limited to, financial and business conditions, many of which are
beyond its control, may affect its future performance. As a
result, these and other factors may affect the Companys
ability to make principal and interest payments on its
indebtedness. The Companys business might not continue to
generate cash flow at or above current levels, including levels
required to service its indebtedness. Moreover, if the Company
is required to repatriate foreign earnings to fund its debt
service, it may not be able to accomplish this in a tax
efficient manner and may, therefore, incur additional
income taxes. If the Company cannot generate sufficient cash
flow from operations in the future to service its indebtedness,
it may, among other things:
|
|
|
|
|
Seek additional financing in the debt or equity markets;
|
|
|
|
Seek to refinance or restructure all or a portion of its
indebtedness;
|
|
|
|
Sell selected assets;
|
|
|
|
Reduce or delay planned capital expenditures
|
These measures might not be sufficient to enable the Company to
service its indebtedness. In addition, any financing,
refinancing or sale of assets might not be available on
economically favorable terms, if at all.
Furthermore, the Companys credit facility contains certain
restrictive covenants which may affect, and in many respects
significantly limit, managements choices in responding to
business, economic, regulatory and other competitive conditions.
The
Companys access to funds under the Facility or its money
market fund holdings is dependent on the solvency and liquidity
of the participating lenders or fund sponsors.
The Company draws on its money market fund holdings or uses its
revolving credit facility to provide liquidity to fund its
operating needs. The balances fluctuate depending on the
Companys needs and cash flows. If a party to the Facility
or the sponsors of the money market funds becomes insolvent or
unable to honor its commitments, the Company could have
insufficient cash to meet its obligations and may be required to
seek alternative forms of capital at rates and with terms and
conditions not as favorable as those under its current Facility.
The
Company may be exposed to risk from its various
counterparties.
The global economy has shown signs of volatility and continues
to show signs of fragility; its impact may be far reaching. As a
result, the Company may be exposed to risks related to defaults
from its suppliers and customers, as well as, from the
counterparties to its purchased call options and sold warrants
that are beyond the Companys control. Key suppliers could
fail to deliver agreed upon goods or services. Customers may not
be able to obtain financing for their clinical trials with the
Company, which may result in the delay or cancellation of these
trials. Additionally, customers may not be able to pay or may
pay receivables more slowly than in the past resulting in bad
debt expenses or poor cash flows. The purchasers of the call
options and sold warrants could become insolvent resulting in an
inability to honor their commitments or in unanticipated
dilution should the target conversion price terms be met.
9
The
Companys international operations are subject to numerous
risks.
The Company has international operations in many foreign
countries, including, but not limited to, South Africa, India
and countries in Eastern Europe, the Asia Pacific region and
Latin America. These operations are subject to risks and
uncertainties inherent in operating in these countries,
including government regulations, potential highly inflationary
economies, currency restrictions and other restraints,
burdensome taxes, government takeovers of assets and political
instability. These risks and uncertainties could negatively
impact the Companys ability to, among other things,
perform large, global projects for its customers or repatriate
cash. Furthermore, the Companys ability to deal with these
issues could be affected by applicable U.S. laws and the
need to protect its assets in those locations.
The
Companys financial results are exposed to exchange rate
fluctuations.
The Companys Consolidated Financial Statements are
denominated in U.S. dollars. For the year ended
December 31, 2010, approximately 59% of the Companys
net service revenues were derived from operations outside the
United States compared to 57% in the same period of 2009. The
Company strives for contractual protection to limit the foreign
currency fluctuation risk exposure in contracts with its
customers where possible, but that protection is not always
achievable or adequate to insulate the Company from significant
fluctuations. Additionally, due to the uncertainties regarding
the timing of and currencies involved, it is impracticable to
implement hedging instruments to match the Companys
foreign currency inflows and outflows. As a result, changes in
foreign currency exchange rates could significantly affect the
Companys results of operations, financial position and
cash flows as well as its ability to finance large acquisitions
outside the United States.
The
Companys quarterly operating results may
vary.
The Companys operating results may vary significantly from
quarter to quarter and are influenced by a variety of factors,
such as:
|
|
|
|
|
Exchange rate fluctuations;
|
|
|
|
Timing of contract amendments for changes in scope that could
affect the value of a contract and potentially impact the amount
of net service revenues from quarter to quarter;
|
|
|
|
Commencement, completion, execution or cancellation of large
contracts;
|
|
|
|
Collections of accounts receivable;
|
|
|
|
Progress of ongoing contracts and retention of customers;
|
|
|
|
Timing of and charges associated with completed acquisitions or
other events; and
|
|
|
|
Changes in the mix, both in terms of geography and type of
services.
|
The Company believes that operating results for any particular
quarter are not necessarily a meaningful indication of future
results. Although fluctuations in quarterly operating results
could negatively or positively affect the market price of the
Companys common stock. These fluctuations may not be
indicative of future overall operating performance.
The
Companys business depends on the continued effectiveness
and availability of its information technology infrastructure,
and failures of this infrastructure could limit its
operations.
To remain competitive in the Companys industry, it must
employ information technologies that capture, manage, and
analyze the large streams of data generated during the clinical
trials we manage in compliance with applicable regulatory
requirements. In addition, because the Company provides services
on a global basis, it relies extensively on its technology to
allow the concurrent conduct of studies and work sharing around
the world. As with all information technology, the
Companys systems could become vulnerable to potential
damage or interruptions from fires, blackouts,
telecommunications failures and other unexpected events, as well
as to break-ins, sabotage or intentional acts of vandalism.
Given the extensive reliance of the Companys business on
this technology and the substantial investment in new technology
infrastructure, any substantial disruption or resulting loss of
data that is
10
not avoided or corrected by its backup measures could harm its
business and operations. Although the Company carries property
and business interruption insurance, the coverage may not be
adequate to compensate for all losses that may occur.
The
Companys business depends on the successful implementation
and deployment of its enterprise wide reporting solution and
failure could harm the Companys ability to manage its
business and obtain accurate financial reporting.
The Company made a significant investment in an enterprise
resource planning solution implementation of which began in
2010. When fully implemented, this major initiative is intended
to integrate pricing, sales, project accounting, time reporting,
trial management, human resources, billing and general ledger
programs to provide management and financial reporting. The
delay in implementation or failure of this project could result
in, among other things, an inability to manage our business,
bill and collect accounts receivable or accurately report our
financial results. This new technology will also rely on third
parties for processing and storing of data which exposes the
Company to additional risks.
The
Companys business could expose it to potential liability
for personal injury claims that could affect its financial
condition.
The Companys business involves clinical trial management
which includes the testing of new drugs on human volunteers.
This business exposes the Company to the risk of liability for
personal injury or death to patients resulting from, among other
things, possible unforeseen adverse side effects or improper
administration of a drug or device. Many of these volunteers and
patients are already seriously ill and are at risk of further
illness or death. Any claim or liability could have a material
adverse effect on the Companys financial position and its
reputation if, as a result, it were required to pay damages or
incur defense costs in connection with a claim and if:
(i) such claim is outside the scope of indemnification
agreements the Company has with customers and collaborative
partners, (ii) an indemnification agreement is not
performed in accordance with its terms or (iii) its
liability exceeds the amount of any applicable indemnification
limits or available insurance coverage. The Company might also
not be able to purchase adequate insurance for these risks at
reasonable rates in the future.
The
nature of the Companys business exposes it to litigation
and regulatory risk.
The nature of the Companys business exposes it to
litigation risk, and it is a party to lawsuits in the ordinary
course of its business. While the Company does not believe that
the resolution of any currently pending lawsuits against it
will, individually or in the aggregate, have a material adverse
effect on its business, financial condition or results of
operations, it is possible that one or more lawsuits to which it
is currently a party to or to which it subsequently becomes a
party to, could adversely affect it in the future. In addition,
failure to comply with applicable regulatory requirements can
result in actions that could adversely affect the Companys
business and financial performance.
If the
Company fails to hire, retain and integrate qualified personnel,
it will be difficult for it to achieve its financial and
operational goals.
The Companys success depends to a significant extent upon
the skills, experience and efforts of its senior management team
and its ability to hire qualified personnel in the geographic
regions and therapeutic areas in which it operates. The loss of
any of the Companys executive officers or other key
employees, without a properly executed transition plan, could
have an adverse effect on it. In addition, there has been
substantial competition among both CROs and biopharmaceutical
companies for qualified personnel. Difficulty recruiting or
retaining qualified personnel
and/or
unexpected recruiting costs could affect the Companys
ability to meet financial and operational goals.
11
New
standards or changes in existing accounting standards issued by
the Financial Accounting Standards Board (FASB), SEC or other
standard setting bodies may adversely affect the Companys
financial statements and could entail significant expenditures.
The application of these standards often requires the use of
estimates and assumptions that may materially differ from actual
results.
The Companys consolidated financial statements are
currently subject to the application of U.S. Generally
Accepted Accounting Principles (GAAP), which is periodically
revised
and/or
expanded. Accordingly, the Company is required to adopt new or
revised accounting standards issued by recognized authoritative
bodies, including the FASB. It is possible that future changes
in standards may change the current accounting treatment and
that such changes could have a material adverse effect on the
Companys operating results and financial condition. (See
Note 1, Critical Accounting Policies, specifically New
Accounting Pronouncements for known changes in standards.)
The preparation of the Companys consolidated financial
statements in compliance with GAAP often requires management to
make estimates and assumptions based on available information at
that time. These estimates and assumptions may ultimately differ
from actual results and the impact could have a material adverse
effect on the Companys financial position and results of
operations.
Risks
related to our Common Stock
Market
conditions have caused significant volatility in the
Companys stock price.
The market price of the Companys common stock has
historically experienced and is expected to continue to
experience some volatility because:
|
|
|
|
|
The Companys number of shares outstanding is significantly
less than that of its peers, causing relatively small
adjustments to have a substantial impact on earnings per share
and relatively small market activity to cause substantial
volatility.
|
|
|
|
General conditions in the economy and financial markets and
other developments affecting the Company or its competitors have
caused the market value of the Companys common stock to
decline.
|
This volatility and valuation decline has affected securities
issued by many companies in many industries, in addition to the
Companys common stock, often for reasons unrelated to
their operating performance. Future valuation declines may cause
the Companys total market capitalization to decrease to a
level which could result in a potential impairment of the
Companys goodwill.
The
Companys convertible note hedge and warrant transactions
may affect the trading price of its common stock.
In connection with the issuance of the Companys
Convertible Notes (see Note 7), the Company entered into
convertible note hedge transactions with the participating
Underwriter and JP Morgan Chase (collectively, the
counterparties). The convertible note hedge transactions are
comprised of purchased call options and sold warrants. The
purchased call options are expected to reduce exposure to
potential dilution upon the conversion of the Convertible Notes.
The Company also entered into warrant transactions with such
counterparties. The sold warrants have an exercise price that is
approximately 70% higher than the closing price of the
Companys common stock on the date the Convertible Notes
were priced. The warrants are expected to provide the Company
with some protection against increases in our stock price over
the conversion price per share. In connection with these
transactions, the counterparties, or their affiliates:
|
|
|
|
|
May enter into various
over-the-counter
derivative transactions or purchase or sell the Companys
common stock in secondary market transactions; and
|
|
|
|
May enter into, or may unwind, various
over-the-counter
derivatives or purchase or sell the Companys common stock
in secondary market transactions, including during any
conversion reference period with respect to a conversion of the
Convertible Notes.
|
12
These activities may have the effect of increasing, or
preventing a decline in, the market price of the Companys
common stock. In addition, any hedging transactions by the
counterparties, or their affiliates, including during any
conversion reference period, may have an adverse impact on the
trading price of the Companys common stock. The
counterparties, or their affiliates, are likely to modify their
hedge positions from time to time prior to conversion or
maturity of the Convertible Notes by purchasing and selling
shares of the Companys common stock or other instruments,
including
over-the-counter
derivative instruments, that they may wish to use in connection
with such hedging. In addition, the Company intends to exercise
its purchased call options whenever the Convertible Notes are
converted, although not required to do so. In order to unwind
any hedge positions with respect to the potential exercise of
the purchased call options, the counterparties or their
affiliates would expect to sell shares of common stock in
secondary market transactions or unwind various
over-the-counter
derivative transactions with respect to the Companys
common stock during the conversion reference period for any
Convertible Notes that may be converted.
The effect, if any, of any of these transactions and activities
in connection with the Convertible Notes on the market price of
the Companys common stock will depend in part on market
conditions and cannot be ascertained at this time, but any of
these activities could adversely affect the trading price of the
Companys common stock and, as a result, the number of
shares and value of the common stock received upon conversion of
the Convertible Notes.
Anti-takeover
provisions in the Companys charter documents and under
Ohio law may make an acquisition of the Company, which may be
beneficial to its stockholders, more difficult, which could
depress its stock price.
Certain provisions of the Companys Articles of
Incorporation and Code of Regulations and of Ohio law make it
difficult for a third party to acquire control of it without the
consent of its Board of Directors (Board). These anti-takeover
defenses may discourage, delay or prevent a transaction
involving a change in control of the Company, and, accordingly,
could limit the price that investors may be willing to pay for
its common stock, including transactions in which holders of
common stock might receive a premium for their shares over the
market price. In cases where Board approval is not obtained,
these provisions could also discourage proxy contests and make
it more difficult for existing shareholders to elect directors
of their choosing and cause the Company to take other corporate
actions they desire.
These provisions include:
|
|
|
|
|
The authorization of undesignated preferred stock, the terms,
rights, privileges and restrictions of which may be established
and shares of which may be issued without shareholder approval;
|
|
|
|
Limitations on persons authorized to call a special meeting of
shareholders; and
|
|
|
|
Advance notice procedures required for shareholders to nominate
candidates for election as directors or to bring matters before
an annual meeting of shareholders.
|
In addition, the Company has adopted a shareholder rights plan
that may have anti-takeover effects, which will make its
acquisition by another company more difficult. The
Companys shareholder rights plan provides that, in the
event any person or entity acquires 15% or more of its
outstanding common stock, its shareholders will be entitled to
purchase shares of common stock, or in certain instances, shares
of the acquirer, at a discounted price. The rights are intended
to discourage a significant share acquisition, merger or tender
offer involving the Companys common stock by increasing
the cost of affecting any such transaction and, accordingly,
could have an adverse impact on a takeover attempt that a
shareholder might consider to be in the Companys best
interests.
|
|
ITEM 1B.
|
UNRESOLVED
STAFF COMMENTS
|
None.
The Company leases all of its facilities. The Companys
principal executive offices are located in Cincinnati, Ohio.
Early in 2008, the Company entered into a lease extension for
these offices which extended the term of the
13
lease from 2009 to 2019 and increased the amount of space leased
from approximately 122,000 square feet to approximately
143,000 square feet. The lease extension also provides the
Company with an opportunity to lease additional space in the
future.
In addition, the Company leases substantial facilities in
Durham, North Carolina; Toronto, Canada; Munich, Germany;
Camberley, United Kingdom; Edinburgh, United Kingdom; Utrecht,
The Netherlands; and Mexico City, Mexico. The Companys
Early Stage operations are located in Morgantown, West Virginia,
Toronto, Canada and Utrecht, The Netherlands. The Company has
previously announced its intention to close the Utrecht Early
Stage location in early 2011. The Company also maintains offices
in various other North American, European and Asia-Pacific,
including Australian and Indian locations, as well as in Latin
America and South Africa.
Management believes that such offices are sufficient to meet its
current needs and does not anticipate any difficulty in securing
additional space, as needed, on terms acceptable to the Company.
|
|
ITEM 3.
|
LEGAL
PROCEEDINGS
|
The Company is party to lawsuits and administrative proceedings
incidental to the normal course of business. The Company
currently is not a party to any pending material litigation,
nor, to the Companys knowledge, is any material litigation
currently threatened against the Company.
|
|
ITEM 4.
|
REMOVED
AND RESERVED
|
PART II
|
|
ITEM 5.
|
MARKET
FOR REGISTRANTS COMMON EQUITY, RELATED SHAREHOLDER MATTERS
AND ISSUER PURCHASES OF EQUITY SECURITIES
|
Shares of the Companys Common Stock are listed on The
NASDAQ Global Select Market
LLC®
and are traded under the symbol KNDL. The following
table sets forth the high and low prices for shares of the
Companys Common Stock for the periods indicated.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010 Quarterly
|
|
First
|
|
|
Second
|
|
|
Third
|
|
|
Fourth
|
|
|
Ranges of stock price
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
High
|
|
$
|
21.79
|
|
|
$
|
19.67
|
|
|
$
|
13.57
|
|
|
$
|
11.59
|
|
Low
|
|
|
17.00
|
|
|
|
11.44
|
|
|
|
7.68
|
|
|
|
8.86
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2009 Quarterly
|
|
First
|
|
|
Second
|
|
|
Third
|
|
|
Fourth
|
|
|
Ranges of stock price
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
High
|
|
$
|
25.66
|
|
|
$
|
23.13
|
|
|
$
|
17.33
|
|
|
$
|
18.88
|
|
Low
|
|
|
15.05
|
|
|
|
8.28
|
|
|
|
9.57
|
|
|
|
14.71
|
|
The number of holders of record of Kendle International Inc.
common stock was 139 as of March 8, 2011. This total
excludes shares held under beneficial ownership in nominee name
or within clearinghouse positions of brokerage firms or banks.
The Company has not paid dividends on its Common Stock since its
initial public offering in August 1997. The Company does not
currently intend to pay dividends in the foreseeable future and,
in any event, is restricted from paying dividends under the
terms and conditions of its credit facility.
14
Performance
Graph
The following graph compares the five-year cumulative total
shareholder returns of the Companys Common Stock with the
NASDAQ Composite Index and the NASDAQ Health Services Index.
COMPARISON
OF 5 YEAR CUMULATIVE TOTAL RETURN*
Among
Kendle International Inc., The NASDAQ Composite Index
And The NASDAQ Health Services Index
|
|
|
* |
|
$100 invested on
12/31/05 in
stock or index, including reinvestment of dividends. |
Fiscal year ending December 31.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dollar Value of $100 Investment at December 31,
|
|
|
2005
|
|
2006
|
|
2007
|
|
2008
|
|
2009
|
|
2010
|
Kendle International Inc.
|
|
|
100.00
|
|
|
|
122.18
|
|
|
|
190.05
|
|
|
|
99.92
|
|
|
|
71.13
|
|
|
|
42.31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NASDAQ Composite
|
|
|
100.00
|
|
|
|
111.74
|
|
|
|
124.67
|
|
|
|
73.77
|
|
|
|
107.12
|
|
|
|
125.93
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NASDAQ Health Services
|
|
|
100.00
|
|
|
|
109.80
|
|
|
|
117.78
|
|
|
|
87.97
|
|
|
|
99.96
|
|
|
|
100.19
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities
Authorized Under Equity Compensation Plans:
The information required for Securities Authorized Under Equity
Compensation Plans can be found in Part III, Item 12,
Security Ownership of Certain Beneficial Owners and Management
of this Annual Report on
Form 10-K.
15
|
|
ITEM 6.
|
SELECTED
FINANCIAL DATA
|
CONSOLIDATED
STATEMENTS OF OPERATIONS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Years Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
2007(1)
|
|
|
2006
|
|
|
|
|
|
|
(In thousands except per share data)
|
|
|
|
|
|
Net service revenues
|
|
$
|
333,766
|
|
|
$
|
416,688
|
|
|
$
|
475,092
|
|
|
$
|
397,584
|
|
|
$
|
283,471
|
|
Reimbursable
out-of-pocket
revenues
|
|
|
114,493
|
|
|
|
135,224
|
|
|
|
203,489
|
|
|
|
171,234
|
|
|
|
90,465
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
448,259
|
|
|
|
551,912
|
|
|
|
678,581
|
|
|
|
568,818
|
|
|
|
373,936
|
|
Cost and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct costs
|
|
|
171,600
|
|
|
|
210,586
|
|
|
|
247,436
|
|
|
|
204,161
|
|
|
|
152,826
|
|
Reimbursable
out-of-pocket
costs
|
|
|
114,493
|
|
|
|
135,224
|
|
|
|
203,489
|
|
|
|
171,234
|
|
|
|
90,465
|
|
Selling, general and administrative
|
|
|
135,239
|
|
|
|
144,659
|
|
|
|
155,577
|
|
|
|
125,744
|
|
|
|
91,796
|
|
Depreciation and amortization
|
|
|
16,340
|
|
|
|
15,712
|
|
|
|
15,253
|
|
|
|
14,865
|
|
|
|
10,403
|
|
Employee severance and office consolidation costs
|
|
|
4,522
|
|
|
|
10,157
|
|
|
|
|
|
|
|
|
|
|
|
236
|
|
Intangible impairment charge
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,200
|
|
Goodwill impairment charge
|
|
|
7,263
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses
|
|
|
449,457
|
|
|
|
516,338
|
|
|
|
621,755
|
|
|
|
516,004
|
|
|
|
353,926
|
|
Income (loss) from operations
|
|
|
(1,198
|
)
|
|
|
35,574
|
|
|
|
56,826
|
|
|
|
52,814
|
|
|
|
20,010
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
144
|
|
|
|
579
|
|
|
|
760
|
|
|
|
1,466
|
|
|
|
1,939
|
|
Interest expense
|
|
|
(11,949
|
)
|
|
|
(14,403
|
)
|
|
|
(15,891
|
)
|
|
|
(17,547
|
)
|
|
|
(6,781
|
)
|
Write-off of deferred financing costs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4,152
|
)
|
|
|
|
|
Other
|
|
|
7,770
|
|
|
|
4,034
|
|
|
|
(2,043
|
)
|
|
|
(4,816
|
)
|
|
|
(1,795
|
)
|
Gain on debt extinguishment
|
|
|
|
|
|
|
2,887
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income (expenses)
|
|
|
(4,035
|
)
|
|
|
(6,903
|
)
|
|
|
(17,174
|
)
|
|
|
(25,049
|
)
|
|
|
(6,637
|
)
|
Income (loss) before income taxes
|
|
|
(5,233
|
)
|
|
|
28,671
|
|
|
|
39,652
|
|
|
|
27,765
|
|
|
|
13,373
|
|
Income tax provision (benefit)
|
|
|
(674
|
)
|
|
|
13,434
|
|
|
|
16,509
|
|
|
|
11,755
|
|
|
|
4,843
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income
|
|
$
|
(4,559
|
)
|
|
$
|
15,237
|
|
|
$
|
23,143
|
|
|
$
|
16,010
|
|
|
$
|
8,530
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INCOME (LOSS) PER SHARE DATA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share
|
|
$
|
(0.31
|
)
|
|
$
|
1.03
|
|
|
$
|
1.57
|
|
|
$
|
1.10
|
|
|
$
|
0.60
|
|
Weighted average shares
|
|
|
14,907
|
|
|
|
14,862
|
|
|
|
14,751
|
|
|
|
14,520
|
|
|
|
14,323
|
|
Diluted:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share
|
|
$
|
(0.31
|
)
|
|
$
|
1.02
|
|
|
$
|
1.54
|
|
|
$
|
1.08
|
|
|
$
|
0.58
|
|
Weighted average shares
|
|
|
14,907
|
|
|
|
14,992
|
|
|
|
14,993
|
|
|
|
14,889
|
|
|
|
14,762
|
|
CONSOLIDATED
BALANCE SHEET DATA(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
Working capital
|
|
$
|
42,214
|
|
|
$
|
56,476
|
|
|
$
|
68,595
|
|
|
$
|
60,084
|
|
|
$
|
56,404
|
|
Total assets
|
|
|
489,911
|
|
|
|
539,723
|
|
|
|
554,888
|
|
|
|
498,675
|
|
|
|
455,072
|
|
Total short and long-term debt, including capital leases
|
|
|
133,116
|
|
|
|
138,394
|
|
|
|
172,159
|
|
|
|
165,673
|
|
|
|
200,099
|
|
Total shareholders equity
|
|
|
230,847
|
|
|
|
236,047
|
|
|
|
212,624
|
|
|
|
175,257
|
|
|
|
140,112
|
|
|
|
|
(1) |
|
Includes the effects of the January 1, 2007 adoption of
FASB Interpretation No. 48, Accounting for Uncertainty in
Income Taxes. |
|
(2) |
|
From 2006 to 2008, the Company made three acquisitions. See the
Acquisitions section of Managements Discussion and
Analysis of Financial Condition and Results of Operations. |
16
|
|
ITEM 7.
|
MANAGEMENTS
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
Refer
to Risk Factors previously discussed in Part 1 Item 1A
and the Cautionary Statement for
Forward-Looking
Information later in this section.
Managements
Discussion and Analysis of Financial Condition and Results of
Operations
The information set forth and discussed below in
Managements Discussion and Analysis of Financial Condition
and Results of Operations (MD&A) is derived from the
Companys Consolidated Financial Statements and the related
notes thereto, which are included herein, and should be read in
conjunction therewith.
Company
Overview
Kendle International Inc. (the Company or Kendle) is a global
clinical research organization (CRO) that delivers integrated
clinical development services, including clinical trial
management, clinical data management, statistical analysis,
medical writing, regulatory consulting and organizational
meeting management and publications services, among other
things, on a contract basis to the biopharmaceutical industry.
The Company operates in North America, Europe, Asia/Pacific,
Latin America and Africa. The Company operates its business in
two reportable operating segments, Early Stage and Late Stage.
The Early Stage business currently focuses on the Companys
Phase I operations while Late Stage is comprised of clinical
development services related to Phase II through III
clinical trials conducted worldwide, late phase clinical
development services related to Phase IIIB and IV clinical
trials conducted worldwide, regulatory affairs and biometrics
offerings. The Company aggregates its clinical and data
monitoring reporting unit, project management and late phase
reporting unit, regulatory, site and medical affairs reporting
unit, and biostatistics and statistical programming reporting
unit into the Late Stage segment under the aggregation criteria
in accounting guidance related to segments. The aggregation
criteria met includes a similar nature of services provided, a
similar type of customer, similar methods used to distribute
services, similar economic characteristics and a similar
regulatory environment. In addition, the Company reports support
functions primarily composed of Human Resources, Information
Technology, Sales and Marketing and Finance under the Support
and Other category for purposes of segment reporting. A portion
of the costs incurred from the support units are allocated to
the Early and Late Stage reportable operating segments.
The Companys revenue recognition process is described
later in this MD&A under Critical Accounting Policies
and Estimates.
Late
Stage Segment Contracts
The Company provides services to its customers primarily under
full-service contracts that include a broad range of
services in support of all aspects of a customers clinical
trial. These services typically include biostatistics, clinical
development services for Phase II through IV clinical
trials and regulatory affairs. The Company from time to time
provides a select number of these services under more narrow
contracts focusing on one or more specialty areas, referred to
as Functional Service Awards. The Company usually competes for
business awards in a competitive bidding process. In the bidding
process, the Company submits a bid that includes a price based
upon hourly billing rates for billable employees multiplied by
task hours the Company estimates will be necessary to achieve
the service assumptions. Upon receiving a business award, the
Company and its customer negotiate a contract to memorialize
these assumptions and the related price.
Service contracts usually are long-term arrangements that
require Company performance over several years. A contract
usually requires a portion of the contract fee to be paid at the
time of contract execution, and the balance is received in
specified installments or milestones over the contracts
duration. Other methods for receiving payment include units
achieved and time and materials incurred. During performance of
the services, any of the following events may occur and impact
the contract price:
|
|
|
|
|
The customer may request a change in the assumptions;
|
|
|
|
The customer may increase or decrease the scope of services,
which requires a change to the service assumptions; and
|
|
|
|
The Company may discover that, for a particular contract, the
assumptions are incorrect or insufficient to permit completion
of the contract.
|
17
In each of the foregoing situations, the Company enters into
negotiations for a contract amendment to reflect the change in
scope or assumptions and the related price. Depending on the
complexity of the amendment, the amendment process can take from
a few weeks for a simple adjustment, such as a timeline
extension, to several months for a complex amendment, such as a
change in patient enrollment strategy. Under the Companys
policy, project teams are not authorized to engage in tasks
outside the scope of the contract without prior management
approval. In limited situations, management may authorize the
project team to commence work on activities outside the contract
scope while the Company and its customer negotiate and finalize
the contract amendment.
Contract amendments are commonplace within the industry and
occur on the majority of the Companys contracts. At any
point in time, the Company will be in the process of discussing
numerous proposed amendments, the scope and value of which can
change significantly between time of proposal and final
agreement. The total value of these amendments primarily
represents future work and revenues.
In addition to full-service and functional service arrangements
described above, the Company provides consulting services to its
customers under contracts that generally are shorter-term in
nature than full-service contracts. Net service revenues from
these contracts are not material to the Companys
consolidated net service revenues.
In connection with providing services, the Company incurs
pass-through costs, which include travel-related expenses for
Company employees performing services and fees payable to
third-party investigators or labs participating in, or
supporting, the customers clinical trial. The customer
agrees to reimburse the Company on a
dollar-for-dollar
basis for the costs incurred by the Company in accordance with
contractually specified parameters. The revenues and costs from
these pass-through and third-party costs are reflected in the
Companys Consolidated Statements of Operations under the
line items titled Reimbursable
out-of-pocket
revenues and Reimbursable
out-of-pocket
costs, respectively.
The customer may terminate the contract at any time with little
or no advance notice to the Company. Customers, in particular,
may terminate a contract immediately for concerns related to the
efficacy or safety of a particular drug. Upon termination, the
customer is required to pay the Company for the value of work
completed up to termination as well as reimburse the Company for
its
out-of-pocket
costs incurred in accordance with the contract.
Historically the majority of the Companys contracts were
fixed-price in nature and net service revenues were calculated
on a proportional performance or percentage of completion
methodology. However over the recent history the Company and its
customers have moved toward a units-based contract methodology
in new contracts. It is the Companys intent to continue to
structure its contracts under a units-based methodology.
Therefore, the Company expects the percentage of contracts under
which net service revenues are recognized using units-based
methodology to continue to increase in future periods. Under a
units-based contract methodology, amounts recognized as net
service revenues are calculated based on units completed in the
period multiplied by a unit value or selling price that is
outlined in the contract.
A contract amendment, which results in revisions to net service
revenues and cost estimates, is recognized in revenue
calculations beginning in the period in which the parties reach
written agreement to the amendment.
Early
Stage Segment Contracts
Early Stage segment business awards are also subject to a
competitive bidding process and, upon award, are memorialized in
a contract that includes terms and conditions that are
substantially similar to the Companys contracts with its
Late Stage segment customers. Most of the revenue for the Early
Stage segment is recognized under units-based contracts by
multiplying units completed by the applicable contract
per-unit
price. In general, the Early Stage segment contract duration is
substantially less than that of the Late Stage segment. Because
the Early Stage business is also subject to the same
cancellation risk as the Late Stage contracts, the Company
attempts to require the customer to pay a cancellation fee if
the customer cancels a project award. Net service revenues from
these Early Stage contracts generally represent less than 10% of
the Companys consolidated net service revenues.
18
Acquisitions
In June 2008, the Company completed its acquisition of
DecisionLine Clinical Research Corporation (DecisionLine) and
its related company. DecisionLine (now Kendle Toronto) is a
clinical research organization located in Toronto, Ontario
specializing in the conduct of early phase studies.
The results of operations for acquisitions are included in the
Companys Consolidated Statements of Operations from the
dates of acquisition.
Recent
Developments and CRO Marketplace
The CRO industry in general continues to be dependent on the
research and development efforts of the principal pharmaceutical
and biotechnology companies as major customers, and the Company
believes this dependence will continue. The loss of business
from any of its major customers could have a material adverse
effect on the Company. The economic conditions have created a
very challenging climate causing the Company to rapidly adjust
its strategies and align the workforce to match the demand for
its services. The business climate has caused customers to
re-evaluate priorities resulting in increases in contracts for
the more promising projects, scaling back
and/or
canceling other projects and delaying decisions on others. The
biopharmaceutical industry is reducing costs and, often, their
workforce. The Company may benefit from increased outsourcing on
the part of its customers or it may be harmed by a reduction in
spending. The Company views the current conditions as an
opportunity to attract well qualified candidates to strengthen
and improve its operations and gain penetration and increase
market share as less research and development is done in-house
by our customers. Another industry trend is the rapidly
approaching patent cliff for a number of blockbuster
drugs within the biopharmaceutical industry and the significant
loss of industry revenue from these drugs. The Companys
customers are addressing this situation in two ways: (1) by
exploring ways to capture the revenue from these drugs once they
move to the generic category, and (2) by
continuing to identify new uses for the existing drugs which may
increase its value by lengthening its patent life, or developing
new compounds. This is both an opportunity and a challenge for
the Company, as its customers will need to find less costly,
more efficient research options often through the establishment
of strategic alliances or partnerships. The Company believes it
is well positioned for this development.
In addition, the volatility of currency exchange rate
fluctuations may have a significant impact on the Company as
more of its business is earned outside the United States.
Fluctuations in exchange rates are not predictable, with any
degree of accuracy, or foreseeable.
Results
of Operations
Year
Ended December 31, 2010 (2010) Compared with Year
Ended December 31, 2009 (2009)
Net
Service Revenues
Information to be discussed regarding segment net service
revenues is outlined in the following table:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
|
|
|
|
|
|
Increase
|
|
|
% Increase
|
|
|
|
2010
|
|
|
2009
|
|
|
(Decrease)
|
|
|
(Decrease)
|
|
|
|
(In thousands)
|
|
|
Net service revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Late stage
|
|
$
|
305,872
|
|
|
$
|
370,178
|
|
|
$
|
(64,306
|
)
|
|
|
(17.4
|
)%
|
Early stage
|
|
|
25,888
|
|
|
|
37,473
|
|
|
|
(11,585
|
)
|
|
|
(30.9
|
)%
|
Support & other(a)
|
|
|
2,006
|
|
|
|
9,037
|
|
|
|
(7,031
|
)
|
|
|
(77.8
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total net service revenues
|
|
|
333,766
|
|
|
|
416,688
|
|
|
|
(82,922
|
)
|
|
|
(19.9
|
)%
|
Reimbursable
out-of-pocket
revenues(b)
|
|
|
114,493
|
|
|
|
135,224
|
|
|
|
(20,731
|
)
|
|
|
(15.3
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
$
|
448,259
|
|
|
$
|
551,912
|
|
|
$
|
(103,653
|
)
|
|
|
(18.8
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a) |
|
Support & Other consists of revenues performed for
administrative services. |
|
(b) |
|
Reimbursable
out-of-pocket
revenues and expenses fluctuate from period to period, primarily
due to the level of investigator activity in a particular period. |
19
Net service revenues decreased 19.9% to $333.8 million for
2010 from $416.7 million in 2009.
Net service revenues in the Late Stage segment decreased 17.4%
to $305.9 million in 2010 compared to $370.2 million
in 2009. The declines were driven primarily by low new business
awards throughout 2009 and the first half of 2010, reductions in
the scope of existing projects, cancellations of existing
projects and continued delays in the selling cycle, more
specifically, advancing contracts from the awarded status to the
signed contract status, which prevented the Company from
commencing work and revenue generating activities. Additionally,
pharmaceutical company mergers as well as uncertainty in the
global economy delayed customer decisions on previously awarded
contracts and slowed the contract signature process as
pharmaceutical companies re-evaluate their pipelines and their
plans for future development of products. The Company also
experienced a significantly higher than normal cancellation rate
on previously awarded studies in 2009 and for at least the first
quarter of 2010. In the second quarter of 2010, the Company
began to see this rate moderate and in the third and fourth
quarters cancellations were lower than the first half of 2010.
Net service revenues in the Early Stage segment decreased
approximately 30.9%, to approximately $25.9 million in 2010
compared to $37.5 million in 2009, primarily due to lower
sales volumes and continued project delays similar to those
discussed in the Late Stage segment. Due to the trend of
decreased net service revenues at the Phase I unit in the
Netherlands, the Company made a decision (in the fourth quarter)
to close the Early Stage operations at this location. Please see
Note 9 to the financial statements for further details.
A summary of net service revenues by geographic region for 2010
and 2009 is presented below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31,
|
|
|
|
|
|
|
|
|
|
$ Increase
|
|
|
% Increase
|
|
|
|
2010
|
|
|
2009
|
|
|
(Decrease)
|
|
|
(Decrease)
|
|
|
|
(In thousands)
|
|
|
North America
|
|
$
|
154,090
|
|
|
$
|
200,866
|
|
|
$
|
(46,776
|
)
|
|
|
(23.3
|
)%
|
Europe
|
|
|
130,767
|
|
|
|
157,628
|
|
|
|
(26,861
|
)
|
|
|
(17.0
|
)%
|
Latin America
|
|
|
36,215
|
|
|
|
40,830
|
|
|
|
(4,615
|
)
|
|
|
(11.3
|
)%
|
Asia-Pacific
|
|
|
12,694
|
|
|
|
17,364
|
|
|
|
(4,670
|
)
|
|
|
(26.9
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total net service revenues
|
|
$
|
333,766
|
|
|
$
|
416,688
|
|
|
$
|
(82,922
|
)
|
|
|
(19.9
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In 2010 revenues decreased in all regions from the prior year.
This is the result of the same factors as previously mentioned
in the analysis of Late Stage and Early Stage revenues. The
Company experienced a decline in both demand and volume in all
regions, however the decrease in Latin America was not as great
as that of the other regions as the Companys customers
continue to look toward accessing the patient populations in
lower cost, emerging regions to conduct clinical trials.
Net service revenues from the Companys top five customers
accounted for approximately 26% and 27% of net service revenues
in 2010 and 2009, respectively. No customer accounted for more
than 10% of total net service revenues for 2010 or 2009.
Reimbursable
Out-of-Pocket
Revenues/Expenses
Reimbursable
out-of-pocket
revenues and expenses fluctuate from period to period due
primarily to the level of investigator activity in a particular
period. Reimbursable
out-of-pocket
revenues and expenses decreased 15.3% to $114.5 million in
2010 from $135.2 million in 2009. The decrease is due
primarily to a decrease in the number of studies in which the
Company is procuring investigator services.
20
Operating
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31,
|
|
|
|
|
|
|
|
|
|
$ Increase
|
|
|
% Increase
|
|
|
|
2010
|
|
|
2009
|
|
|
(Decrease)
|
|
|
(Decrease)
|
|
|
|
(In thousands)
|
|
|
Direct costs
|
|
|
171,600
|
|
|
|
210,586
|
|
|
|
(38,986
|
)
|
|
|
(18.5
|
)%
|
Reimbursable
out-of-pocket
costs
|
|
|
114,493
|
|
|
|
135,224
|
|
|
|
(20,731
|
)
|
|
|
(15.3
|
)%
|
SG&A expenses
|
|
|
135,239
|
|
|
|
144,659
|
|
|
|
(9,420
|
)
|
|
|
(6.5
|
)%
|
Restructuring expenses
|
|
|
4,522
|
|
|
|
10,157
|
|
|
|
(5,635
|
)
|
|
|
(55.5
|
)%
|
Depreciation and amortization
|
|
|
16,340
|
|
|
|
15,712
|
|
|
|
628
|
|
|
|
4.0
|
%
|
Goodwill impairment
|
|
|
7,263
|
|
|
|
|
|
|
|
7,263
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
449,457
|
|
|
|
516,338
|
|
|
|
(66,881
|
)
|
|
|
(13.0
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct costs decreased in 2010 from 2009 by approximately
$39.0 million, or 18.5%. The decrease in direct costs is
attributable to a full year of cost savings initiatives (that
began in the second quarter of 2009) and reduced work
volumes as a result of the decline in net service revenues
experienced by the Company.
Direct costs expressed as a percentage of net service revenues
were 51.4% in 2010 compared to 50.5% in 2009. In 2009, direct
costs benefitted from insurance proceeds received against an
accrual for rework that was originally absorbed by the Company.
Selling, general and administrative (SG&A) expenses
decreased in 2010 from 2009 by approximately $9.4 million,
or 6.5%. The primary reason for the decrease in SG&A costs
relates to the full year benefit of the cost savings initiatives
undertaken in the second quarter of 2009, which are discussed in
detail below along with restructuring expenses, as well as
strict cost control measures put into place in 2009 and 2010.
Selling, general and administrative expenses expressed as a
percentage of net service revenues were 40.5% in 2010 compared
to 34.7% in 2009. SG&A as a percent of revenues has
increased when compared to the previous period as a significant
portion of these costs are more fixed in nature and do not
decrease in proportion with net service revenues. Additionally,
in the second quarter of 2010, the Company awarded annual salary
merit increases to its employees for the first time since 2008,
reinstated certain benefits that had previously been suspended,
continued on its path to implement its new ERP system, and
continued to invest in its new business development and global
sales organization, which partially offset the benefits of our
cost savings efforts.
Beginning in the second quarter of 2009, the Company commenced
several initiatives to optimize its workforce, match capacity
with demand, and reduce operating expenses. The Company recorded
restructuring charges totaling $4.5 million in 2010 and
$10.2 million in 2009, for severance-related and other
expenses (primarily related to facility closures). These
measures resulted in lower costs in 2010 as compared to 2009.
Severance charges have been primarily related to the Late Stage
and Support and Other reportable segments, with the exception of
a $3.0 million severance reserve recorded in the fourth
quarter of 2010 related to the announced closing of Early Stage
operations at the Companys Utrecht, Netherlands facility.
Depreciation and amortization expense increased by
$0.6 million, from $15.7 million in 2009 to
$16.3 million in 2010.
Due to the inconsistent nature of the Early Stage business, both
within the Company and the industry, during the third quarter of
2010 the Company commenced an evaluation of strategic
alternatives for the Early Stage segment. Based upon this review
and other triggering events, the Company began, but was unable
to complete its goodwill impairment analysis, which was
completed during the fourth quarter. Also during the fourth
quarter, in addition to conducting its annual impairment
analysis for both the Early and Late Stage segments, the Company
made a decision to close the Early Stage portion of its
operations in Utrecht, The Netherlands. As a result of the above
events the Company recorded a goodwill impairment charge of
$7.3 million for its Early Stage segment in the fourth
quarter of 2010. At December 31, 2009, the fair value of
the Early Stage segment exceeded the carrying value, resulting
in no goodwill impairment charge. At December 31, 2010 and
2009, the fair value of all Late Stage reporting units exceeded
the carrying value, resulting in no goodwill impairment charge.
21
Information to be discussed regarding segment operating income
is outlined in the below table:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31,
|
|
|
|
|
|
|
|
|
|
Increase
|
|
|
% Increase
|
|
|
|
2010
|
|
|
2009
|
|
|
(Decrease)
|
|
|
(Decrease)
|
|
|
|
(In thousands)
|
|
|
Operating income (loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Late stage
|
|
$
|
63,575
|
|
|
$
|
81,109
|
|
|
|
(17,534
|
)
|
|
|
(21.6
|
)%
|
Early stage
|
|
|
(11,455
|
)
|
|
|
4,187
|
|
|
|
(15,642
|
)
|
|
|
(373.6
|
)%
|
Support & other
|
|
|
(53,318
|
)
|
|
|
(49,722
|
)
|
|
|
(3,596
|
)
|
|
|
7.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating income (loss)
|
|
$
|
(1,198
|
)
|
|
$
|
35,574
|
|
|
$
|
(36,772
|
)
|
|
|
(103.4
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Company experienced a loss from operations in 2010 of
$1.2 million, or (0.4%) of net service revenues compared to
income from operations of $35.6 million, or 8.5% of net
service revenues in 2009. The overall decline in operating
income and operating income as a percentage of net service
revenues was primarily due to items discussed in more detail in
the preceding paragraphs, primarily the reduction in net service
revenues, goodwill impairment and restructuring items. Please
see section titled Non-GAAP Operating Income and EPS for
further discussion.
Income from operations from Kendles Late Stage segment in
2010 was $63.6 million or 20.8% of net service revenues
compared to Late Stage income from operations of
$81.1 million, or 21.9% of net service revenues in 2009.
The decline in the Late Stage operating margin was due primarily
to a decline in net service revenues, felt most heavily in the
North American, European and Asia Pacific regions, which was
driven by a decline in new business awards and new contracts,
increased cancellations and delays in existing studies leading
to decreased utilization of billable associates and excess
capacity which the Company was able to partially offset by its
restructuring efforts.
Early Stage operating results declined in 2010 from the same
periods in 2009 as a result of the decline in net service
revenues, as well as the restructuring costs and goodwill
impairment recorded in connection with the closure of Early
Stage operations at its Utrecht, The Netherlands facility. Early
Stage operations generally have higher fixed costs making a
decline in revenues more difficult to absorb. The Early Stage
operations for 2010 resulted in operating losses, largely driven
by the results of the Utrecht closure. The Early Stage segment
incurred net operating loss of $11.5 million or (44.2%) of
net service revenues in 2010 compared to Early Stage income from
operations of $4.2 million, or 11.2% of net service
revenues in 2009.
Other
Income/(Expense)
Total other income (expense) was a net expense of
$4.0 million in 2010 compared to expense of
$6.9 million in 2009.
The components of Other Income/Expense were as follows for the
periods presented:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31,
|
|
|
|
|
|
|
|
|
|
Increase
|
|
|
|
2010
|
|
|
2009
|
|
|
(Decrease)
|
|
|
|
(In thousands)
|
|
|
Other income (expense)
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
$
|
144
|
|
|
$
|
579
|
|
|
$
|
(435
|
)
|
Interest expense
|
|
|
(11,949
|
)
|
|
|
(14,403
|
)
|
|
|
2,454
|
|
Gain (loss) on extinguishment of debt
|
|
|
(71
|
)
|
|
|
2,887
|
|
|
|
(2,958
|
)
|
Foreign currency gains
|
|
|
8,665
|
|
|
|
5,350
|
|
|
|
3,315
|
|
Other expenses
|
|
|
(824
|
)
|
|
|
(1,316
|
)
|
|
|
492
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income (expense)
|
|
$
|
(4,035
|
)
|
|
$
|
(6,903
|
)
|
|
$
|
2,868
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22
Interest
Income
Interest income decreased by approximately $435,000 in 2010
which is the result of both a decrease in average cash balance
and lower returns on invested cash.
Interest
Expense
The primary component of interest expense is related to the
Companys 3.375% Convertible Notes issued in June
2007. For 2010, the amount of interest expense recognized for
the contractual interest rate was $5.0 million and the
amount recognized for discount amortization was
$5.6 million for a total of approximately
$10.6 million. Additionally, approximately
$1.6 million of interest expense was recognized for
amortization of deferred issuance costs related to the
Companys Convertible Notes, the new credit Facility and
termination of the Old Facility (as defined in Liquidity and
Capital Resources). For 2009, the amount of interest expense
recognized for the contractual interest rate was
$6.1 million and the amount recognized for discount
amortization was $6.5 million for a total of
$12.6 million. Additionally, $1.3 million of interest
expense was recognized for amortization of deferred issuance
costs related to the Convertible Notes and the Companys
credit facility. The decline in interest expense in 2010 is due
to a full year of lower outstanding principle on the Convertible
Notes purchased by the Company on the open market in 2009 as
well as an additional open market purchase in the second quarter
of 2010.
Gain
on Extinguishment of Debt
In 2010, the Company repurchased in the open market
$12.0 million in par value of its outstanding Convertible
Notes for cash in the amount of $11.1 million. The amortized
book value of the debt was $10.8 million and a pre-tax net
loss of approximately $71,000 was recorded. Debt issuance costs
with a carrying value of $154,000 were written off in
conjunction with the transaction and were included in the
determination of net loss. During 2009, the Company repurchased
in several transactions on the open market $45.5 million in
par value of Convertible Notes for cash in the amount of
$36.5 million. The carrying value of these Convertible
Notes at the time of repurchase was approximately
$40.0 million and a pre-tax gain on extinguishment of debt
of approximately $2.9 million was recorded. As part of the
repurchase transaction, the proportionate share of debt issuance
costs ($840,000) were included in the determination of the gain
amount and were written off.
See also the Liquidity and Capital Resources section.
Foreign
Currency
The exchange rate transaction gains and losses typically occur
when the Company holds assets
and/or
liabilities in a currency other than the functional currency of
the reporting location. Due to uncertainties regarding the
timing of and currencies involved in the majority of the
Companys foreign exchange rate transactions, it is
impracticable to implement hedging instruments to match the
Companys foreign currency inflows and outflows. In 2009,
the Company implemented procedures intended to mitigate the
impact of foreign currency exchange rate fluctuations including
an intercompany procedure to allow for regular settlement of
intercompany balances. The Company will continue to evaluate
ways to mitigate the risk of this impact in the future.
For the year ended December 31, 2010, the Company recorded
foreign exchange rate gains of $8.7 million dollars,
related primarily to strengthening of most currencies against
the Euro.
In the first quarter of 2009, the Company eliminated a
substantial portion of its foreign currency denominated
intercompany notes payable between the U.S. subsidiary and
the U.K. subsidiary and between the U.S. subsidiary and
German subsidiary. The Company maintained foreign currency
arrangements in connection with these transactions. The Company
also terminated its foreign currency hedge arrangements that
were in place to hedge this currency exposure. As a result the
Company incurred losses related to the exchange rate
fluctuations on the intercompany notes and related derivative
instruments (pre-settlement) of approximately $1.0 million
for the year ended December 31, 2009. In addition to the
losses on the intercompany notes and foreign currency hedge
arrangements discussed above, the Company recorded foreign
exchange rate gains of approximately $6.3 million in 2009.
The foreign exchange gain in 2009 mostly occurred in the first
six months of 2009 and was primarily due to
23
the strengthening of the British pound against the Euro and the
strengthening of the U.S. dollar against both the British
pound and the Euro during that time period.
Income
Taxes
The Company recorded a tax benefit at an effective rate of
approximately 12.9% in 2010 compared to tax expense at an
effective rate of approximately 46.8% in 2009. The tax benefit
of $674,000 for 2010 includes approximately $90,000 of tax
benefit related to the impairment of approximately
$7.3 million of goodwill. Additionally, tax benefits were
recorded during the year related to the recognition of tax
benefits that were previously unrecognized. The tax expense of
$13.4 million for 2009 includes $4.4 million in tax
expense for the settlement of foreign currency hedges and
related intercompany notes and a $1.0 million item for the
tax related to the taxable gain from the extinguishment of debt
in connection with the open market repurchases. These items are
partially offset by a tax benefit recorded in the third quarter
of 2009 related to revisions in estimates for certain items
related to the Companys 2008 U.S. federal tax return
and an additional tax benefit of approximately $1.0 million
recorded during 2009 related to the usage of certain deferred
tax assets for which a valuation allowance had been previously
recorded.
Net
Income (Loss)
Net loss for 2010 was approximately $4.6 million, or $0.31
per diluted share and basic share, compared with net income of
approximately $15.2 million, or $1.02 per diluted share and
$1.03 per basic share in 2009.
Non-GAAP Operating
Income, Net Income and EPS
Non-GAAP operating income, non-GAAP net income and
non-GAAP EPS are alternative views of the Companys
performance used by management that the Company is providing
because management believes this information enhances
investors understanding of the Companys results.
Non-GAAP measures exclude certain items because of the nature of
these items and the impact that they have on the analysis of
underlying business performance and trends. The excluded items
are restructuring charges and goodwill impairment. The excluded
items are significant components in understanding and assessing
financial performance. Therefore, the information on non-GAAP
operating income, net income and EPS should be considered in
addition to, but not in lieu of, operating income, net income
and earnings per share prepared in accordance with generally
accepted accounting principles in the United States
(GAAP). Additionally, since non-GAAP measures are
not determined in accordance with GAAP, they have no
standardized meaning prescribed by GAAP and, therefore, may not
be comparable to the calculation of similar measures of other
companies.
24
A reconciliation between GAAP financial measures and non-GAAP
financial measures is as follows:
|
|
|
|
|
|
|
|
|
|
|
For the Years Ended
|
|
|
|
December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
|
(In thousands except per share data)
|
|
|
Reconciliation of
non-GAAP
income (loss) from operations:
|
|
|
|
|
|
|
|
|
Income (loss) from operations, as reported
|
|
$
|
(1,198
|
)
|
|
$
|
35,574
|
|
Restructuring expense
|
|
|
4,522
|
|
|
|
10,157
|
|
Goodwill impairment
|
|
|
7,263
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP income from operations
|
|
$
|
10,587
|
|
|
$
|
45,731
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of
non-GAAP net
income (loss):
|
|
|
|
|
|
|
|
|
Net income (loss), as reported
|
|
$
|
(4,559
|
)
|
|
$
|
15,237
|
|
Restructuring expense, net of tax
|
|
|
3,349
|
|
|
|
6,799
|
|
Goodwill impairment, net of tax
|
|
|
7,173
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP net income
|
|
$
|
5,963
|
|
|
$
|
22,036
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of
non-GAAP
diluted net income (loss) per share:
|
|
|
|
|
|
|
|
|
Net income (loss) per share, as reported
|
|
$
|
(0.31
|
)
|
|
$
|
1.02
|
|
Restructuring expense, net of tax
|
|
|
0.22
|
|
|
|
0.45
|
|
Goodwill impairment, net of tax
|
|
|
0.48
|
|
|
|
|
|
Rounding
|
|
|
0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP net income per share
|
|
$
|
0.40
|
|
|
$
|
1.47
|
|
|
|
|
|
|
|
|
|
|
Restructuring
Expenses
Non-GAAP operating income and non-GAAP net income and EPS
exclude restructuring costs, primarily costs related to facility
closures and employee severance costs. Restructuring costs have
occurred in past periods and may occur in future periods, and
therefore should not be considered to be non-recurring. However,
management excludes these amounts from non-GAAP operating income
and non-GAAP net income and EPS because it believes it is
helpful for understanding the Companys performance.
Goodwill
Impairment
For the year ended December 31, 2010, the Company recorded
an impairment loss of $7.3 million in connection with the
finalization of the third quarter goodwill impairment analysis,
the Companys annual impairment testing in the fourth
quarter and the decision to close the Early Stage operations of
its Utrecht, The Netherlands facility. Subsequent to the
impairment charge, the Companys Early Stage segment
maintains approximately $11.7 million of goodwill.
25
Year
Ended December 31, 2009 (2009) Compared with Year
Ended December 31, 2008 (2008)
Net
Service Revenues
Information to be discussed regarding segment net service
revenues is outlined in the following table:
Revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
|
|
|
|
|
|
$ Increase
|
|
|
% Increase
|
|
|
|
2009
|
|
|
2008
|
|
|
(Decrease)
|
|
|
(Decrease)
|
|
|
Net service revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Late stage
|
|
$
|
370,178
|
|
|
$
|
430,317
|
|
|
$
|
(60,139
|
)
|
|
|
(14.0
|
)%
|
Early stage(a)
|
|
|
37,473
|
|
|
|
35,199
|
|
|
|
2,274
|
|
|
|
6.5
|
%
|
Support & other(b)
|
|
|
9,037
|
|
|
|
9,576
|
|
|
|
(539
|
)
|
|
|
(5.6
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total net service revenues
|
|
$
|
416,688
|
|
|
$
|
475,092
|
|
|
$
|
(58,404
|
)
|
|
|
(12.3
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a) |
|
The Early Stage segment results for the twelve months ended
December 31, 2008 include the June (acquisition date)
through December operating results of DecisionLine. |
|
(b) |
|
Support and Other consists of revenues performed for
administrative services. |
Net service revenues decreased 12% to $416.7 million for
2009 from $475.1 million in 2008. The changes in currency
rates reduced net service revenues by approximately 6% for the
year 2009.
Net service revenues in the Late Stage segment decreased
approximately 14% to $370.2 million in 2009 compared to
$430.3 million in 2008. The declines were driven primarily
by changes in foreign currency exchange rates, reductions in the
scope of existing projects, cancellations of existing projects
and continued delays in the selling cycle, more specifically,
advancing contracts from the awarded status to the signed
contract status, which prevented the Company from commencing
work and revenue generating activities. As mentioned, the
Company also experienced a significantly higher than normal
cancellation rate on previously awarded studies. The Company
believes this situation is the result of biopharmaceutical
industry merger and acquisition activity, weakness in the
current global economy and reduced access to capital, among
other things. Additionally, recent pharmaceutical company
mergers as well as reduced prescription drug sales and
uncertainty in the global economy delayed customer decisions on
previously awarded contracts and slowed the contract signature
process as pharmaceutical companies re-evaluated their pipelines
and, in the case of newly merged customers, focused on
integration efforts rather than future development of products.
Net service revenues in the Early Stage segment increased
approximately 6.5%, or $2.3 million to approximately
$37.5 million in 2009 compared to $35.2 million in
2008. The majority of this increase is attributable to the
Kendle Toronto acquisition as 2009 results contain
12 months of net service revenues from Kendle Toronto
compared to 7 months of net service revenues in 2008. This
increase was partially offset by the impact of currency rate
fluctuations and decreased net service revenues at the Phase I
unit in the Netherlands as a result of the previously mentioned
project delays and cancellations.
A summary of net service revenues by geographic region for 2009
and 2008 is presented below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31
|
|
|
|
|
|
|
|
|
|
$ Increase
|
|
|
% Increase
|
|
|
|
2009
|
|
|
2008
|
|
|
(Decrease)
|
|
|
(Decrease)
|
|
|
North America
|
|
$
|
200,866
|
|
|
$
|
229,346
|
|
|
$
|
(28,480
|
)
|
|
|
(12.4
|
)%
|
Europe
|
|
|
157,628
|
|
|
|
189,528
|
|
|
|
(31,900
|
)
|
|
|
(16.8
|
)%
|
Latin America
|
|
|
40,830
|
|
|
|
38,996
|
|
|
|
1,834
|
|
|
|
4.7
|
%
|
Asia-Pacific
|
|
|
17,364
|
|
|
|
17,222
|
|
|
|
142
|
|
|
|
0.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total net service revenues
|
|
$
|
416,688
|
|
|
$
|
475,092
|
|
|
$
|
(58,404
|
)
|
|
|
(12.3
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26
In 2009, the Company experienced a decline in both demand and
volume in North America and Europe as the Companys
customers continue to look toward accessing the patient
populations in Latin America, Asia-Pacific and other lower cost
emerging regions to conduct clinical trials.
Net service revenues from the Companys top five customers
accounted for approximately 27% of net service revenues in both
2009 and 2008. No customer accounted for more than 10% of total
net service revenues for 2009 or 2008.
Reimbursable
Out-of-Pocket
Revenues/Expenses
Reimbursable
out-of-pocket
revenues and expenses fluctuate from period to period due
primarily to the level of investigator activity in a particular
period. Reimbursable
out-of-pocket
revenues and expenses decreased 33% to $135.2 million in
2009 from $203.5 million in 2008. The decrease is due
primarily to a decrease in the number of studies in which the
Company is procuring investigator services.
Operating
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31,
|
|
|
|
|
|
|
|
|
|
$ Increase
|
|
|
% Increase
|
|
|
|
2009
|
|
|
2008
|
|
|
(Decrease)
|
|
|
(Decrease)
|
|
|
Direct costs
|
|
$
|
210,586
|
|
|
$
|
247,436
|
|
|
$
|
(36,850
|
)
|
|
|
(14.9
|
)%
|
Reimbursable
out-of-pocket
costs
|
|
|
135,224
|
|
|
|
203,489
|
|
|
|
(68,265
|
)
|
|
|
(33.5
|
)%
|
SG&A expenses
|
|
|
144,659
|
|
|
|
155,577
|
|
|
|
(10,918
|
)
|
|
|
(7.0
|
)%
|
Restructuring expenses
|
|
|
10,157
|
|
|
|
|
|
|
|
10,157
|
|
|
|
|
|
Depreciation and amortization
|
|
|
15,712
|
|
|
|
15,253
|
|
|
|
459
|
|
|
|
3.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
$
|
516,338
|
|
|
$
|
621,755
|
|
|
$
|
(105,417
|
)
|
|
|
(17.0
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct costs decreased in 2009 from 2008 by approximately
$36.9 million, or 15%. The decrease in direct costs in 2009
is attributable to the decline in net service revenues and
headcount reductions and other cost savings initiatives
initiated in the second quarter of 2009 as discussed in more
detail below.
Additionally, in the fourth quarter of 2008, the Company
identified a programming issue unique to one study and one
customer that required the Company to rework a large portion of
the project and additionally, to bear costs that would, under
normal circumstances, be absorbed by the customer. The Company
accrued $4.9 million related to these costs in the fourth
quarter of 2008. In 2009, as a result of ongoing discussions
with the customer and the insurance provider, the Company
increased the accrual for direct costs by $2.2 million to a
total of $7.1 million and received the insurance claim
recovery of $5.0 million. The net reduction in direct costs
in 2009 related to this programming issue and the insurance
claim recovery was approximately $2.8 million.
Direct costs expressed as a percentage of net service revenues
were 50.5% in 2009 compared to 52.1% in 2008. The decrease in
direct costs as a percentage of net service revenues in 2009 is
due in large part to the fluctuations in the accrual for rework
discussed in the preceding paragraph.
Selling, general and administrative (SG&A) expenses
decreased in 2009 from 2008 by approximately $10.9 million,
or 7%. The primary reason for the decrease in SG&A costs
relates to the cost savings initiatives undertaken in 2009, as
discussed in more detail below. Selling, general and
administrative expenses expressed as a percentage of net service
revenues were 34.7% in 2009 compared to 32.7% in 2008.
In the second quarter of 2009, the Company commenced several
initiatives to optimize its workforce and capacity and to reduce
operating expenses. These activities included a reduction of
discretionary spending, limiting previously planned headcount
additions, delay or elimination of salary merit increases,
reduction or elimination of certain other benefits, workforce
reductions or furloughs, and other cost savings in an attempt to
reduce expenses. The Company recorded a charge in the second
quarter of 2009 for severance-related and other expenses
(primarily related to facility closures), of approximately
$6.0 million. In the third quarter of 2009, the Company
revised its estimate of severance costs and expensed an
additional $380,000. As a result of these initiatives, the
Company realized savings of approximately $20 million in
2009.
27
In the fourth quarter of 2009, due to continued weakness in new
business awards and future net service revenue projections and
higher than historical cancellations, the Company committed to
additional headcount reductions expected to be initiated during
the first quarter of 2010 and recorded a charge in the fourth
quarter of 2009 for severance-related expenses of approximately
$3.8 million. Because the bulk of the Companys
expenses are typically incurred in the Late Stage and Support
and Other reportable segments, the majority of the costs removed
from the business also affect those two segments. Headcount was
reduced from approximately 4,275 associates at the end of 2008
to 3,640 associates at the end of 2009. This reduction was
primarily in the U.S. and Western Europe and is expected to
result in savings of approximately $16 to $18 million in
2010. When customer demand increases, the Company will be
required to increase staffing to deliver services and all of the
estimated savings may not materialize.
Depreciation and amortization expense increased by
$0.4 million, from $15.3 million in 2008 to
$15.7 million in 2009. The increase is primarily due to a
full year of amortization expense in 2009 on a customer
relationship asset from the Kendle Toronto acquisition versus
seven months in 2008.
Information to be discussed regarding segment operating income
is outlined in the below table:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
|
|
|
|
|
|
Increase
|
|
|
% Increase
|
|
|
|
2009
|
|
|
2008
|
|
|
(Decrease)
|
|
|
(Decrease)
|
|
|
Operating Income/(Loss):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Late stage
|
|
$
|
81,109
|
|
|
$
|
105,140
|
|
|
$
|
(24,031
|
)
|
|
|
(22.9
|
)%
|
Early stage(a)
|
|
|
4,187
|
|
|
|
6,177
|
|
|
|
(1,990
|
)
|
|
|
(32.2
|
)%
|
Support & other(b)
|
|
|
(49,722
|
)
|
|
|
(54,491
|
)
|
|
|
4,769
|
|
|
|
8.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating income
|
|
$
|
35,574
|
|
|
$
|
56,826
|
|
|
$
|
(21,252
|
)
|
|
|
(37.4
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a) |
|
The Early Stage segment results for the twelve months ended
December 31, 2008 include the June (acquisition date)
through December operating results of DecisionLine. |
|
(b) |
|
Support and Other consists of unallocated corporate expenses,
primarily information technology, marketing and communications,
human resources, finance and legal, net of revenues earned. |
Income from operations in 2009 declined to $35.6 million,
or 8.5% of net service revenues, compared to $56.8 million,
or 12.0% of net service revenues in 2008. The overall decline in
operating income and operating income as a percentage of net
service revenues was primarily due to items discussed in more
detail in the preceding paragraphs, including the reduction in
net service revenues and the restructuring expense. Please see
section titled Non-GAAP Operating Income, Net Income and
EPS for further discussion.
Income from operations from Kendles Late Stage segment in
2009 was $81.1 million or 21.9% of net service revenues
compared to Late Stage income from operations of
$105.1 million, or 24.4% of net service revenues in 2008.
The decline in the Late Stage operating margin was due primarily
to a decline in net service revenues, primarily in the North
American and European regions, driven by the decline in new
business awards and new contracts, increased cancellations and
delays in existing studies leading to decreased utilization of
billable associates and excess capacity. Additionally, in 2009
the decline in Late Stage operating margin was due to the
accrual of costs related to the workforce capacity optimization
as discussed above.
Income from operations from Kendles Early Stage segment in
2009 was $4.2 million, or 11.2% of net service revenues
compared to Early Stage income from operations of
$6.2 million, or 17.5% of net service revenues in 2008. The
primary reason for the decline in operating income as a
percentage of net service revenues was due to low demand, for
reasons previously cited, at the Companys Phase I unit in
the Netherlands.
Other
Income/(Expense)
Total other income (expense) was expense of $6.9 million in
2009 compared to expense of $17.2 million in 2008.
28
The components of Other Income/Expense were as follows for the
periods presented:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
Change
|
|
|
Other income (expense)
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
$
|
579
|
|
|
$
|
760
|
|
|
$
|
(181
|
)
|
Interest expense
|
|
|
(14,403
|
)
|
|
|
(15,891
|
)
|
|
|
1,488
|
|
Gain on extinguishment of debt
|
|
|
2,887
|
|
|
|
|
|
|
|
2,887
|
|
Foreign currency gains / (losses)
|
|
|
5,350
|
|
|
|
(1,006
|
)
|
|
|
6,356
|
|
Other expenses
|
|
|
(1,316
|
)
|
|
|
(1,037
|
)
|
|
|
(279
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income (expense)
|
|
$
|
(6,903
|
)
|
|
$
|
(17,174
|
)
|
|
$
|
10,271
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
Income
Interest income decreased by approximately $181,000 in 2009 due
to lower returns on the invested cash.
Interest
Expense
The primary component of interest expense is related to the
Companys 3.375% Convertible Notes issued in June
2007. The Company adopted new accounting guidance related to
convertible debt effective January 1, 2009 as it relates to
this issuance and as required by the new guidance has
retrospectively adjusted the prior periods for the effects of
the new guidance.
For 2009, the amount of interest expense recognized for the
contractual interest rate was $6.1 million and the amount
recognized for discount amortization was $6.5 million for a
total of $12.6 million. Additionally, $1.3 million of
interest expense was recognized for amortization of deferred
issuance costs related to the Convertible Notes and the
Companys credit facility. For 2008, the amount of interest
expense recognized for the contractual interest rate was
$6.8 million and the amount recognized for discount
amortization was $6.6 million for a total of
$13.4 million. Additionally, $1.2 million of interest
expense was recognized for amortization of deferred issuance
costs related to the Convertible Notes and the Companys
credit facility. The decline in interest expense in 2009 is due
to the open market repurchases during the year of a portion of
the convertible notes outstanding.
Gain
on Extinguishment of Debt
During 2009, the Company repurchased in several transactions on
the open market $45.5 million in par value of Convertible
Notes for cash in the amount of $36.5 million. The carrying
value of these Convertible Notes at the time of repurchase was
approximately $40.0 million and a pretax gain on
extinguishment of debt of approximately $2.9 million was
recorded. As part of the repurchase transactions, the
proportionate share of debt issuance costs in the amount of
$840,000 was included in the determination of the gain amount
and was written off.
See also the Liquidity and Capital Resources section.
Foreign
Currency
In the first quarter of 2007, the Company entered into foreign
currency hedge arrangements to hedge foreign currency exposure
related to intercompany notes outstanding. The hedging
transactions were designed to mitigate the Companys
exposure related to two intercompany notes between the
Companys U.S. subsidiary, as lender, and the
Companys subsidiary in each of the United Kingdom and
Germany. The derivative arrangements were not designated for
hedge accounting treatment and mark to market adjustments on
these arrangements were recorded in the Companys
Consolidated Statements of Operations.
In the first quarter of 2009, the Company eliminated a
substantial portion of the note payable between the
U.S. subsidiary and the U.K. subsidiary, referenced above,
and the entire amount of the note payable between the
U.S. subsidiary and German subsidiary. In connection with
these transactions, the Company also terminated its foreign
currency hedge arrangements referenced in the preceding
paragraph.
29
In 2009, losses related to the exchange rate fluctuations on the
intercompany notes and related derivative instruments
(pre-settlement) were approximately $1.0 million compared
to gains of approximately $2.4 million in 2008 on the
intercompany notes and derivatives instruments.
In addition to the gains on the intercompany notes and foreign
currency hedge arrangements discussed above, the Company
recorded foreign exchange rate gains of approximately
$6.3 million in 2009 compared to losses of approximately
$3.4 million in 2008. The foreign exchange gain in 2009
mostly occurred in the first six months of 2009 and was
primarily due to the strengthening of the British pound against
the Euro and the strengthening of the U.S. dollar against
both the British pound and the Euro during that time period. As
mentioned below, the Company has implemented procedures intended
to mitigate the impact of foreign currency exchange rate
fluctuations and those procedures have helped to reduce the
impact in the second half of 2009. The foreign exchange losses
in 2008 were due primarily to the weakening of the British pound
against the Euro as the Company had a large amount of euro
denominated payables in countries that have a functional
currency of the British pound.
The exchange rate transaction gains and losses typically occur
when the Company holds assets
and/or
liabilities in a currency other than the functional currency of
the reporting location. Due to uncertainties regarding the
timing of and currencies involved in the majority of the
Companys foreign exchange rate transactions, it is
impracticable to implement hedging instruments to match the
Companys foreign currency inflows and outflows. In 2009,
the Company implemented procedures intended to mitigate the
impact of foreign currency exchange rate fluctuations including
an intercompany procedure to allow for regular settlement of
intercompany balances. The Company will continue to evaluate
ways to mitigate the risk of this impact in the future.
Income
Taxes
The Company recorded tax expense at an effective rate of
approximately 46.8% in 2009 compared to approximately 41.6% in
2008. The tax expense of $13.4 million for 2009 includes
$4.4 million in tax expense for the settlement of foreign
currency hedges and related intercompany notes and a
$1.0 million item for the tax related to the taxable gain
from the extinguishment of debt in connection with the open
market repurchases. These items are partially offset by a tax
benefit recorded in the third quarter of 2009 related to
revisions in estimates for certain items related to the
Companys 2008 U.S. federal tax return and an
additional tax benefit of approximately $1.0 million
recorded during 2009 related to the usage of certain deferred
tax assets for which a valuation allowance had been previously
recorded. In 2008, the Company recorded an additional tax
benefit of approximately $3.3 million related to the
recognition of tax benefits that were previously unrecognized in
accordance with accounting guidance related to accounting for
uncertainty in income taxes.
Net
Income
The net income for 2009 was approximately $15.2 million, or
$1.02 per diluted share and $1.03 per basic share.
The net income for 2008 was approximately $23.1 million, or
$1.54 per diluted share and $1.57 per basic share.
Liquidity
and Capital Resources
The Company had cash and cash equivalents of approximately
$21.2 million at December 31, 2010 compared to
approximately $52.1 million at December 31, 2009. In
2010, cash and cash equivalents decreased by $30.9 million
primarily as a result of cash used in investing and financing
activities of $19.6 million and $11.8 million,
respectively, offset slightly by cash provided from operating
activities. Foreign exchange rates negatively impacted cash and
cash equivalents by approximately $0.4 million. In
addition, the Company has restricted cash of approximately
$0.9 million at December 31, 2010 compared with
$1.1 million at December 31, 2009, which represents
cash received from customers that is held in a separate Company
bank account and available for use only for specific
project-related expenses, primarily investigator fees, upon
authorization from the customer. Because this restricted cash is
directly related to operation of the Companys business,
the activity is included in operating cash flows as opposed to
financing cash flows.
Net cash provided by operating activities for the year consisted
primarily of a net loss of $4.6 million adjusted for
noncash expenses of $20.6 million primarily related to
depreciation and amortization, debt issuance cost
30
amortization, and goodwill impairment charges, partially offset
by the noncash changes in deferred income taxes and unrealized
gains in foreign exchange for the year ended December 31,
2010. Additional uses of operating cash resulted from decreases
in advanced billings and accrued liabilities primarily as a
result of lower revenue volumes in 2010, offset partially by the
net collections of accounts receivable. In 2009, changes in
operating assets and liabilities provided net cash in the amount
of $10.5 million, driven by collections of accounts
receivable as well as receipt of cash payments totaling
$4.5 million for tenant improvement allowances as per the
terms of the lease for the Companys headquarters.
Fluctuations in accounts receivable and advance billings occur
on a regular basis as services are performed, milestones or
other billing criteria are achieved, invoices are sent to
customers and payments for outstanding accounts receivable are
collected from customers. Accounts receivable, net of advance
billings, decreased from $49.1 million at December 31,
2009, to $48.1 million at December 31, 2010.
Cash flows used for investing activities for the year ended
December 31, 2010 included the use of approximately
$17.3 million for property and equipment additions and
$2.4 million for the final payment on a prior acquisition.
Cash flows used for investing activities for the year ended
December 31, 2009 included the use of $19.0 million
for property and equipment additions and $2.9 million for
acquisition of businesses (primarily partial payment of accrued
contingent consideration) combined with the receipt of
$17.3 million from the termination of the existing hedge
agreements.
Cash flows used in financing activities for the year ended
December 31, 2010 were $11.8 million, of which
$11.1 million was used to repurchase $12.0 million in
par value of the Companys Convertible Notes on the open
market. Cash flows used in financing activities for the year
ended December 31, 2009 were $36.9 million, of which
$36.5 million was used to repurchase $45.5 million in
par value of the Companys Convertible Notes on the open
market.
Cash used for capital expenditures of $17.3 million,
$19.0 million, $27.1 million in 2010, 2009, and 2008,
respectively was primarily related to information technology
initiatives.
In March 2010, the Company terminated its prior credit agreement
and entered into a new credit agreement (the
Facility). The Facility is comprised of a
$35 million revolving loan commitment, with up to
$10 million of such commitment available for issuance of
letters of credit and up to $5 million of such commitment
available for
same-day
swing line loans. At the Companys request and with the
consent of the current lender or additional lenders, the total
commitment may be increased by, or incremental term loans be
obtained for, up to an additional $15 million. At the
Companys election, loans under the Facility are available
either at (i) an adjusted base rate plus an applicable
margin; or (ii) an adjusted LIBOR rate plus an applicable
margin. The applicable margin for each interest rate is
calculated in accordance with the terms of the Facility.
The Facility, as amended on April 27, 2010, matures on
March 31, 2015. Before this amendment, the Facility had the
potential for accelerated maturity on January 15, 2012 in
the event that five percent (5%) or more of the currently
outstanding principal amount of the Convertible Notes discussed
below had not been redeemed or repaid in full on or prior to
January 15, 2012. The Facility was amended again on
January 21, 2011 (Amendment No. 2) to increase
the Total Leverage Ratio for certain periods and
also contemplates certain additional add-backs to
Consolidated EBITDA for certain cash and non-cash
charges.
Borrowings under the Facility are collateralized by
substantially all of the Companys assets pursuant to the
terms of a Pledge and Security Agreement. The Facility contains
various affirmative and negative covenants including those
regarding limitations on the Companys ability to incur
certain indebtedness, limitations on certain investments,
limitations on capital expenditures in any fiscal year and
limitations on certain acquisitions and asset sales outside the
ordinary course of business as well as financial covenants
regarding limitations on the Companys total leverage
ratio, senior secured leverage ratio and interest coverage
ratio. The Company is in compliance with the covenants as of
December 31, 2010.
The Company also maintains an existing $5.0 million
Multicurrency Facility that is renewable annually and is used in
connection with the Companys European operations.
In July, 2007, the Company issued $200 million of five-year
Convertible Notes with a maturity date of July 15, 2012.
The Convertible Notes bear interest at an annual rate of 3.375%,
payable semi-annually in arrears on January 15 and July 15 of
each year. The Convertible Notes are convertible at the option
of the holder into cash and, if
31
applicable, shares of the Companys common stock at an
initial conversion price of $47.71 per share (approximating
20.9585 shares per $1,000 principal amount of the
Convertible Notes), upon the occurrence of certain events. In
addition, upon events defined as a fundamental
change under the Convertible Note Indenture, holders of
the Convertible Notes may require the Company to repurchase the
Convertible Notes. If upon the occurrence of such events in
which the holders of the Convertible Notes exercise the
conversion provisions of the Convertible Notes, the Company will
need to remit the principal balance of the Convertible Notes to
the holders in cash. As such, the Company would be required to
classify the entire amount outstanding of the Convertible Notes
as a current liability in the following quarter. The evaluation
of the classification of amounts outstanding associated with the
Convertible Notes occurs every quarter. As of December 31,
2010 and 2009, the Convertible Notes are classified as long-term
in the accompanying Consolidated Balance Sheets.
Concurrent with the sale of the Convertible Notes, the Company
purchased convertible bond hedges from two counterparties which
are designed to mitigate potential dilution from the conversion
of the Convertible Notes in the event that the market value per
share of the Companys common stock at the time of exercise
is greater than approximately $47.71. In addition, the Company
issued warrants to the counterparties that could require the
Company to issue shares of the Companys common stock at a
strike price of $61.22 per share. The Convertible Note hedge and
warrant transactions generally have the effect of increasing the
conversion price of the Convertible Notes to approximately
$61.22 per share of Kendle common stock, representing
approximately a 70% premium based on the closing sale price as
reported on The NASDAQ Global Market on July 10, 2007, of
$36.01 per share.
In 2010, the Company repurchased $12.0 million in par value
of its Convertible Notes on the open market for cash of
$11.1 million. The amortized carrying value of these
repurchased notes was $10.8 million and a non-cash net loss
of $71,000 was recorded. As part of the repurchase transaction,
the proportionate share of debt issuance costs in the amount of
$154,000 was written off. This transaction is expected to result
in reduced cash interest expense and non-cash discount
amortization of $2.0 million over the remaining term of the
Convertible Notes. Of the consideration paid to repurchase the
Convertible Notes, $348,000 was allocated to the equity
component. This is considered to be a reacquisition of a portion
of the equity component of the Convertible Notes and as such is
recorded as a reduction of additional paid in capital.
As of December 31, 2010, $142.5 million in par value
was outstanding under the Convertible Notes, no amounts were
outstanding under the revolving credit portion of the Facility
that the Company maintained and no amounts were outstanding
under the Multicurrency Facility. The Company did draw on the
Facility for short periods of time in the third and fourth
quarters of 2010 to cover operational cash flow needs resulting
primarily from temporary billing delays related to the ERP
implementation, promptly repaying each advance. The maximum
amount outstanding at any point was $3 million and the
average daily amount outstanding for the second half of 2010 was
$250,000. The weighted average interest rate paid on these
advances was 5.76%.
The Companys primary cash needs on both a short-term and
long-term basis are for the payment of salaries and fringe
benefits, hiring and recruiting expenses, business development
costs, capital expenditures, acquisitions and facility-related
expenses. The Company believes that its existing capital
resources, together with cash flows from operations and
borrowing capacity under the Facility and the Multicurrency
Facility, will be sufficient to meet its foreseeable cash needs
for both the short and long term.
The Company has not historically experienced regular liquidity
or collections issues with the large majority of its customers.
However, the Company does have contracts with biotechnology and
small pharmaceutical companies, some of which are dependent upon
external financing to fund their contractual commitments. The
Company is continuing to monitor the financial status of its
customers.
As more of the Companys revenues are generated in
locations other than the U.S., repatriation of those cash flows
in a tax efficient manner is increasingly challenging. The
Company is in the process of revising its internal transfer
pricing methodologies to align with its current operational
model with the goal of future tax savings as a result of
increased utilization of existing tax attributes.
In the future, the Company will continue to consider the
acquisition of businesses to enhance its service offerings,
therapeutic base and global presence. Any such acquisitions may
require additional external financings
32
and the Company may from time to time seek to obtain funds from
public or private issuances of equity or debt securities. There
can be no assurance that such financings will be available on
terms acceptable to the Company.
Contractual
Obligations
Future minimum payments for all contractual obligations for
years subsequent to December 31, 2010 are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year
|
|
|
Years
|
|
|
Years
|
|
|
Years
|
|
|
|
|
|
|
2011
|
|
|
2012-2013
|
|
|
2014-2015
|
|
|
After 2016
|
|
|
Total
|
|
|
|
(In thousands)
|
|
|
Capital lease obligations (including interest)
|
|
$
|
35
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
35
|
|
Operating Leases
|
|
|
17,127
|
|
|
|
26,195
|
|
|
|
17,136
|
|
|
|
17,974
|
|
|
|
78,432
|
|
Debt payments(1)
|
|
|
|
|
|
|
142,500
|
|
|
|
|
|
|
|
|
|
|
|
142,500
|
|
Interest on debt(2)
|
|
|
4,809
|
|
|
|
2,605
|
|
|
|
|
|
|
|
|
|
|
|
7,414
|
|
FIN 48 obligation, including interest and penalties(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
21,971
|
|
|
$
|
171,300
|
|
|
$
|
17,136
|
|
|
$
|
17,974
|
|
|
$
|
228,381
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term obligations arising in the ordinary course of
business are excluded from the above table.
|
|
|
(1) |
|
Under the terms of the Convertible Notes, the Convertible Notes
are convertible into shares of the Common Stock upon the
occurrence of various factors described in the Liquidity and
Capital Resources section of Managements Discussion and
Analysis. The above table assumes no conversion with the
remaining principal amount of the Convertible Notes paid at the
maturity date of July 15, 2012. |
|
(2) |
|
The interest rate used in the calculation of interest was 3.375%
which represents the cash coupon obligation. |
|
(3) |
|
FIN 48 obligations of $1.1 million (including
interest) have not been reflected in the above table due to the
inherent uncertainty as to the amount and timing of settlement,
which is contingent upon the occurrence of possible future
events, such as examinations and determinations by various tax
authorities. |
Critical
Accounting Policies and Estimates
The preparation of financial statements in conformity with
accounting principles generally accepted in the United States of
America requires management to make significant estimates and
assumptions that affect the reported Consolidated Financial
Statements for a particular period. Actual results could differ
from those estimates.
Revenue
Recognition
A portion of the Companys net service revenues are based
on fixed-price contracts calculated on a proportional
performance basis (also referred to herein as
percentage-of-completion)
based upon assumptions regarding the estimated total costs for
each contract. The Company also recognizes revenue under
units-based contracts by multiplying units completed by the
applicable contract
per-unit
price. Additionally, work is performed under
time-and-materials
contracts, recognizing revenue as hours are worked based on the
hourly billing rate for each contract.
Percentage-of-Completion
With respect to certain fixed price contracts, costs are
incurred for performance of each contract and compared to the
estimated budgeted costs for that contract to determine a
percentage of completion on the contract. The percentage of
completion is then multiplied by the contract value to determine
the amount of revenue recognized. The contract value equals the
value of the services to be performed under the contract as
determined by aggregating the labor hours estimated to be
incurred to perform the tasks in the contract at the agreed
rates. Contract value excludes the value of third-party and
other pass-through costs. As the work progresses, original
estimates might be changed as a result of managements
regular contract review process.
33
Management regularly reviews the budget on each contract to
determine if the budgeted costs accurately reflect the costs
that the Company will incur for contract performance. The
Company reviews each contracts performance to date,
current cost trends and circumstances specific to each contract.
The Company estimates its remaining costs to complete the
contract based on a variety of factors, including:
|
|
|
|
|
Actual costs incurred to date and the work completed as a result
of incurring the actual costs;
|
|
|
|
The remaining work to be completed based on the timeline of the
contract as well as the number of incomplete tasks in the
contract; and
|
|
|
|
Factors that could change the rate of progress of future
contract performance.
|
Examples of factors included in the review process that could
change the rate of progress of future contract performance are:
patient enrollment rate, changes in the composition of staff on
the project or other customer requirements, among other things.
Based on these contract reviews, the Company adjusts its cost
estimates. Adjustments to net service revenue resulting from
changes in cost estimates are recorded on a cumulative basis in
the period in which the revisions are made. When estimates
indicate a loss, such loss is provided in the current period in
its entirety. While the Company routinely adjusts cost estimates
on individual contracts, the Companys estimates and
assumptions historically have been accurate in all material
respects in the aggregate. The Company expects the estimates and
assumptions to remain accurate in all material respects in the
aggregate in future periods.
A contract amendment, which results in revisions to net service
revenues and cost estimates, is recognized in the
percentage-of-completion
calculations beginning in the period in which the parties reach
written agreement to the amendment (see also Company Overview
section of MD&A for a description of the contract amendment
process). Historically, the aggregate value of contract
amendments signed in any year represents approximately 15% to
20% of annual sales. Although the majority of the Companys
contract amendments relate to future services, the Company and
its customers may execute contract amendments for services that
the Company already has performed. In these circumstances, net
service revenue from past services performed is recognized in
the current period. Historically, the impact of such amendments
on results of operations has not been material.
Under the Companys policy, project teams are not
authorized to engage in tasks outside the scope of the contract
without prior management approval. In limited situations,
management may authorize the project team to commence work on
activities outside the contract scope while the Company and its
customer negotiate and finalize the contract amendment. When
work progresses on unsigned, unprocessed contract amendments,
the Company reviews the direct costs incurred, and, where
significant defers such costs on the balance sheet. In addition,
the impact of such costs on the estimates to complete is
considered and, where material, the estimates are adjusted.
Historically, neither the deferred costs nor the impact on
estimates have been material.
The Company believes that total costs constitute the most
appropriate indicator of the performance of fixed price
contracts because the costs relate primarily to the amount of
labor hours incurred to perform the contract. The customer
receives the benefit of the work performed throughout the
contract term and is obligated to pay for services once
performed. Accordingly, the Company believes that an input
measure of cost is a reasonable surrogate for an output measure
under the proportional performance model and is consistent with
the revenue recognition concepts issued by the SEC.
Units-Based
The Company has seen increasing demand from its customers to
move to a units-based contract methodology in new contracts and
a majority of the Companys net service revenues are based
on a units methodology. It is the Companys intent to
structure more of its contracts under a units-based methodology
for calculating net service revenues so the Company expects the
percentage of contracts under which net service revenues are
recognized using units-based methodology to continue to increase
in future periods. Under a units-based contract methodology,
amounts recognized as net service revenues are calculated based
on units completed in the period multiplied by a unit value or
selling price that is outlined in the contract.
34
For a units-based contract, a typical unit could include such
things as completion of a monitoring visit, monthly site
management units or case report form pages entered. The Company
tracks the units completed for each unit category included in
the contract. Net service revenue is recognized monthly based on
the units actually completed in the period at the agreed upon
unit value or selling price. Net service revenue is recognized
only up to the number of units contained in each contract. If
the Company completes or expects to complete units over and
above the number of units initially estimated and contained in
the contract, a contract amendment is generated to reflect the
additional units needed.
A contract amendment, which results in revisions to net service
revenues and expected units or unit values, is recognized in the
unit-based net service revenue calculations beginning in the
period in which the parties agree to the amendment (see also
Company Overview section of MD&A for a description of the
contract amendment process).
The Company believes that under certain types of contracts the
value of the work performed is best captured by calculating net
service revenues using the value of units completed. The Company
believes that units-based revenue recognition is consistent with
the revenue recognition concepts issued by the SEC.
As the Company provides services on projects, it also incurs
third-party and other pass-through costs, which are reimbursable
by its customers pursuant to the contract. The revenues and
costs from these third-party and other pass-through costs are
reflected in the Companys Consolidated Statements of
Operations under the line items titled Reimbursable
out-of-pocket
revenues and Reimbursable
out-of-pocket
costs, respectively.
Direct
Costs
Direct costs consist of compensation and related fringe benefits
for project-related associates, unreimbursed project-related
costs and an allocated portion of indirect costs, which
primarily includes facilities-related costs and information
systems costs. Labor costs represent over 80% of total direct
costs with the allocated portion of indirect costs and other
expenses representing the remainder. To determine the allocated
portion of indirect costs, the Company calculates an allocation
percentage based on the relationship between billable associate
salaries and total salaries. The remaining indirect costs are
allocated to SG&A.
Because the Companys business is labor intensive, direct
costs historically have increased with an increase in net
service revenues. The Company, however, has not experienced any
material variations in the relationship between direct costs and
net service revenues for the fiscal years ended 2010, 2009, and
2008. The following factors, among others, may cause direct
costs to decrease as a percentage of net service revenues:
|
|
|
|
|
Higher utilization rates for billable employees; and
|
|
|
|
The ability to complete contracted work more efficiently than
estimated by the Company.
|
The following factors, among others, will cause direct costs to
increase as a percentage of net service revenues:
|
|
|
|
|
The occurrence of cost overruns from increased time to complete
contract performance;
|
|
|
|
Lower utilization rates for billable employees;
|
|
|
|
Increased costs due to higher-paid employees or contractors
performing contract services; and
|
|
|
|
Pricing pressure from increased competition.
|
Other
Costs
Selling, general and administrative expenses consist of
compensation and related fringe benefits for sales and
administrative employees and professional services, as well as
unallocated costs related to facilities, information systems and
other costs.
Depreciation and amortization expenses consist of depreciation
and amortization costs recorded on a straight-line method over
the estimated useful life of the property or equipment and
internally developed software. Finite-lived intangible assets
are generally amortized on an accelerated basis based on the
discounted cash flow calculations used in the valuation of the
asset.
35
Accounts
Receivable/Allowance for Doubtful Accounts
Billed accounts receivable represent amounts for which invoices
have been issued to customers. Unbilled accounts receivable are
amounts recognized as revenue for which invoices have not yet
been issued to customers. Advance billings represent amounts
billed or payment received for which revenues have not yet been
earned. The Company maintains an allowance for doubtful accounts
receivable based on historical evidence of accounts receivable
collections and specific identification of accounts receivable
that might pose collection problems. The bad debt reserve is
monitored on a regular basis and adjusted as circumstances
warrant. The Companys allowance for doubtful accounts has
been sufficient to cover any bad debt write-offs. The Company
will continue to monitor its bad debt exposure and adjust bad
debt reserves as necessary.
If the Company is unable to collect all or part of its
outstanding receivables, there could be a material impact to the
Companys Consolidated Statements of Operations or
financial position.
Goodwill
and Intangible Assets
The Company analyzes goodwill and other finite-lived intangible
assets to determine any potential impairment loss annually in
the fourth quarter, unless conditions exist that require an
updated analysis on an interim basis. A fair value approach is
used to test goodwill for impairment. The fair value approach
compares estimates related to the fair value of the reporting
unit with the units carrying amount, including goodwill.
The fair value is determined using both the market approach and
the income approach which consists of projected discounted cash
flows. If the carrying amount of the reporting unit exceeds the
fair value, the amount of the impairment loss must be measured.
The Company has five reporting units that are tested for
impairment: Early Stage, and the four Late Stage reporting units
consisting of: Clinical and Data Monitoring; Project Management
and Late Phase Services; Regulatory, Site and Medical Affairs;
and Biostatistics and Statistical Programming. Reporting units
are defined as the components of operating segments for which
discrete financial information is available and regularly
reviewed by management.
Due to the inconsistent nature of the Early Stage business, both
within the Company and the industry, during the third quarter of
2010 the Company commenced an evaluation of strategic
alternatives for the Early Stage segment. Based upon this review
and other triggering events, the Company began, but was unable
to complete its goodwill impairment analysis, this was completed
during the fourth quarter. Also during the fourth quarter, in
addition to conducting its annual impairment analysis for both
the Early and Late Stage segments, the Company made a decision
to close the Early Stage portion of its operations in Utrecht,
The Netherlands. As a result of the above events the Company
recorded a goodwill impairment charge of $7.3 million for
its Early Stage segment in the fourth quarter of 2010. At
December 31, 2009 the fair value of the Early Stage segment
exceeded the carrying value, resulting in no goodwill impairment
charge.
At December 31, 2010 and 2009, the fair value of all Late
Stage reporting units exceeded the carrying value, resulting in
no goodwill impairment charge. At December 31, 2010 the
fair value of each Late Stage reporting unit exceeded the
carrying value by the following approximate percentages:
Regulatory, Site and Medical Affairs greater than
100%; Project Management & Late Phase 21%;
Clinical and Data Monitoring 2% and Biostatistics
and Statistical Programming 44%.
The estimate of fair value is inherently subjective and requires
the Company to make a number of assumptions and projections.
These assumptions and projections relate to revenue growth
rates, profit margin percentages, discount rates, perpetuity
growth rates, future capital expenditures and future market
conditions, among other things. The most significant assumptions
are revenue, and operating margin growth rates, as well as the
discount rate. The use of different assumptions could increase
or decrease estimated discounted future cash flows and may
affect the results of the Companys impairment analysis.
The growth rates are forward looking and by their nature are
uncertain. The Company may or may not be able to achieve the
estimated growth rates
and/or
margin rates.
Internally
Developed Software
Pursuant to the accounting guidance related to the
capitalization of software developed or obtained for internal
use, the Company capitalizes costs incurred to internally
develop software used primarily in the Companys
proprietary clinical trial and data management systems, and
amortizes these costs over the useful life of the product,
36
not to exceed five years. Internally developed software
represents software in the application development stage, and
there is no assurance that the software development process will
produce a final product for which the fair value exceeds its
carrying value. Internally developed software is an intangible
asset subject to impairment write-downs whenever events indicate
that the carrying value of the software may not be recoverable.
As with other long-lived assets, this asset is reviewed at least
annually to determine the appropriateness of the carrying value
of the asset and the estimated useful lives. Assessing the fair
value of the internally developed software requires estimates
and judgment on the part of management. As discussed in
Note 1 to the Consolidated Financial Statements, internally
developed software is amortized over its estimated useful life
of five years. The Company believes the useful life established
remains reasonable.
Tax
Valuation Allowance and Tax Liabilities
The Company follows the guidance related to accounting for
uncertainties in income taxes. This guidance requires
significant judgment in determining what constitutes an
individual tax position as well as assessing the outcome of each
tax position. Changes in judgments as to recognition or
measurement of tax positions can materially affect the estimate
of the effective tax rate, and, consequently, the Companys
operating results. The Company considers many factors when
evaluating and estimating tax positions and tax benefits, which
may require periodic adjustments and which may not accurately
anticipate actual outcomes. In addition, the calculation of tax
liabilities involves dealing with uncertainties in the
application of complex tax regulations in a multitude of
jurisdictions. At December 31, 2010, the Company has
recorded a gross liability for uncertain income tax positions of
$1.1 million (including interest). If events occur and the
payment of these amounts ultimately proves to be unnecessary,
the reversal of liabilities would result in tax benefits being
recognized in the period when it is determined the liabilities
are no longer necessary. If the calculation of liability related
to uncertain tax positions proves to be more or less than the
ultimate assessment, a tax expense or benefit to expense,
respectively, would result.
The Company provides for income taxes on all transactions that
have been recognized in the Consolidated Financial Statements in
accordance with accounting guidance related to accounting for
income taxes. Specifically, the Company estimates its tax
liability based on current tax laws in the statutory
jurisdictions in which it operates. Because the Company conducts
business on a global basis, its effective tax rate has and will
continue to depend upon the geographic distribution of its
pre-tax earnings (losses) among jurisdictions with varying tax
rates. These estimates include judgments about deferred tax
assets and liabilities resulting from temporary differences
between assets and liabilities recognized for financial
reporting purposes and such amounts recognized for tax purposes.
The Company has assessed the realization of deferred tax assets
and a valuation allowance has been established based on an
assessment that it is more likely than not, that realization
cannot be assured. The ultimate realization of this tax benefit
is dependent upon the generation of sufficient pretax income in
the respective tax jurisdictions. If estimates prove inaccurate
or if the tax laws change unfavorably, significant revisions in
the valuation allowance may be required in the future.
Stock-based
Compensation
The Company follows the guidance related to accounting for
share-based payments. The Company generally uses the
straight-line method of recording compensation expense relative
to share-based payment, unless awards have graded vesting
features and the expense recorded under the straight-line method
is not adequate. In those situations, compensation cost is
recognized separately over each tranche. Stock-based
compensation expense is recorded primarily in general and
administrative expenses in the Companys Consolidated
Statements of Operations as the majority of the stock option
expense relates to options granted to executives.
If factors change and the Company employs different assumptions
in the calculation of stock-based compensation in future
periods, the compensation expense that the Company records may
differ significantly from the expense recorded in the current
period.
New
Accounting Pronouncements
For a discussion of New Accounting Pronouncements, see
Note 1 to the Companys Consolidated Financial
Statements.
37
Cautionary
Statement for Forward-Looking Information
Certain statements contained in this Annual Report on
Form 10-K
that are not historical facts constitute forward-looking
statements within the meaning of the Private Securities
Litigation Reform Act of 1995 and are intended to be covered by
the safe harbors created by that Act. Reliance should not be
placed on forward-looking statements because they involve known
and unknown risks, uncertainties and other factors that may
cause actual results, performance or achievements to differ
materially from those expressed or implied. Any forward-looking
statement speaks only as of the date made. The Company
undertakes no obligation to update any forward-looking
statements to reflect events or circumstances arising after the
date on which they are made.
Statements concerning expected financial performance, on-going
business strategies and possible future action which the Company
intends to pursue to achieve strategic objectives constitute
forward-looking information. Implementation of these strategies
and the achievement of such financial performance are each
subject to numerous conditions, uncertainties and risk factors.
Factors that could cause actual performance to differ materially
from these forward-looking statements include those Risk Factors
set forth in Item 1A of this Annual Report on
Form 10-K.
|
|
ITEM 7A.
|
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
Interest
Rates
The Company is exposed to changes in interest rates on any
amounts outstanding under the Facility and Multicurrency
Facility. At December 31, 2010, no amounts were outstanding
under the Facility or the Multicurrency Facility.
Foreign
Currency
The Company operates on a global basis and is therefore exposed
to various types of currency risks. Two specific transaction
risks arise from the nature of the contracts the Company
executes with its customers. From time to time contracts are
denominated in a currency different than the particular local
currency. This contract currency denomination issue is
applicable only to a portion of the contracts executed by the
Company. The first risk occurs as revenue recognized for
services rendered is denominated in a currency different from
the currency in which the subsidiarys expenses are
incurred. As a result, the subsidiarys net service
revenues and resultant net income or loss can be affected by
fluctuations in exchange rates.
The second risk results from the passage of time between the
invoicing of customers under these contracts and the ultimate
collection of customer payments against such invoices. Because
the contract is denominated in a currency other than the
subsidiarys local currency, the Company recognizes a
receivable at the time of invoicing at the local currency
equivalent of the foreign currency invoice amount. Changes in
exchange rates from the time the invoice is prepared until the
payment from the customer is received will result in the Company
receiving either more or less in local currency than the local
currency equivalent of the invoice amount at the time the
invoice was prepared and the receivable established. This
difference is recognized by the Company as a foreign currency
transaction gain or loss, as applicable, and is reported in
Other income (expense) in the Consolidated Statements of
Operations.
A third type of transaction risk arises from transactions
denominated in multiple currencies between any two of the
Companys various subsidiary locations. For each
subsidiary, the Company maintains an intercompany receivable and
payable, which is denominated in multiple currencies. Changes in
exchange rates from the time the intercompany receivable/payable
balance arises until the balance is settled or measured for
reporting purposes, results in exchange rate gains and losses.
This intercompany receivable/payable arises when work is
performed by a Kendle location in one country on behalf of a
Kendle location in a different country under contract with the
customer. Additionally, there are occasions when funds are
transferred between subsidiaries for working capital purposes.
Where possible, the Company settles these intercompany balances
frequently to reduce this exposure. The foreign currency
transaction gain or loss is reported in Other Income (Expense)
in the Consolidated Statements of Operations.
In 2010, the Company recorded total foreign exchange gains of
$8.9 million compared to gains of approximately
$6.3 million in 2009 related to the risks described above.
38
The Companys Consolidated Financial Statements are
denominated in U.S. dollars. Accordingly, changes in
exchange rates between the applicable foreign currency and the
U.S. dollar will affect the translation of each foreign
subsidiarys financial results into U.S. dollars for
purposes of reporting the Consolidated Financial Statements. The
Companys foreign subsidiaries functional currency is
the local currency, accordingly those subsidiaries translate
their financial results from local currency into
U.S. dollars as follows: income statement accounts are
translated at average exchange rates for the period; balance
sheet asset and liability accounts are translated at end of
period exchange rates; and equity accounts are translated at
historical exchange rates. Translation of the balance sheet in
this manner affects the shareholders equity account
referred to as the foreign currency translation adjustment
account. This account exists only in the foreign
subsidiaries U.S. dollar balance sheet and is
necessary to keep the foreign subsidiaries balance sheet
stated in U.S. dollars in balance. Cumulative foreign
currency translation adjustments, which are reported as a
separate component of Shareholders Equity, were
approximately $20.8 million and $22.2 million at
December 31, 2010 and 2009, respectively.
Foreign
Currency Hedges
In 2007, the Company entered into foreign currency hedging
transactions to mitigate exposure in movements between the
U.S. dollar and British Pounds Sterling and U.S dollar and
Euro. The hedging transactions were designed to mitigate the
Companys exposure related to two intercompany notes
between the Companys U.S. subsidiary, as lender, and
the Companys subsidiaries in each of the United Kingdom
and Germany. The hedge agreements were not designated for hedge
accounting treatment under accounting guidance related to
derivatives and all changes in the fair market value of the
hedge were recorded in the Companys Consolidated
Statements of Operations.
The note between the Companys U.S. subsidiary and
United Kingdom subsidiary is denominated in Pounds Sterling and
was substantially settled in January 2009, at this time the
hedge agreement related to this loan was terminated resulting in
$17.3 million of cash proceeds. The Company recorded
foreign exchange gains of $997,000 related to the Pound Sterling
loan in 2009. Prior to the termination of the Pound Sterling
hedge in January 2009, the Company recorded foreign exchange
losses of $1.3 million.
The note between the Companys U.S. subsidiary and
German subsidiary was denominated in Euros and repaid in full in
March 2009, and the related hedge agreement was terminated at
the same time. Foreign exchange losses of $1.5 million and
gains of $741,000 were recorded related to the Euro note and the
Euro hedge agreement, respectively, prior to their repayment and
termination in March 2009.
|
|
ITEM 8.
|
FINANCIAL
STATEMENTS AND SUPPLEMENTARY DATA
|
The Financial Statements and Supplementary Data called for by
this Item are set forth in pages F-1 to F-32, which are
incorporated herein by reference.
|
|
ITEM 9.
|
CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
|
None to report.
|
|
ITEM 9A.
|
CONTROLS
AND PROCEDURES
|
Managements
Evaluation of Disclosure Controls and Procedures
Based on the Companys most recent evaluation, which was
completed as of the end of the period covered by this Annual
Report on
Form 10-K,
our CEO/Chairman (principal executive officer) and Chief
Financial Officer (principal financial and accounting officer)
concluded that the Companys disclosure controls and
procedures (as defined in
Rules 13a-15(e)
and
15d-15(e) of
the Securities Exchange Act of 1934, as amended) are effective.
(a) Managements
Report on Internal Control over Financial
Reporting
The Companys management is responsible for establishing
and maintaining adequate internal controls designed to provide
reasonable assurance regarding the reliability of financial
reporting and the preparation of
39
financial statements for external purposes in accordance with
accounting principles generally accepted in the United States of
America (GAAP). The Companys internal control
over financial reporting includes those policies and procedures
that:
1. pertain to the maintenance of records that, in
reasonable detail, accurately and fairly reflect the
transactions and dispositions of assets of the Company;
2. provide reasonable assurance that transactions are
recorded as necessary to permit preparation of consolidated
financial statements in accordance with GAAP and that receipts
and expenditures of the Company are being made only in
accordance with the authorizations of management and the
Directors of the Company; and
3. provide reasonable assurance regarding prevention or
timely detection of unauthorized acquisition, use or disposition
of the Companys assets that could have a material effect
on the Consolidated Financial Statements.
All internal control systems, no matter how well designed, have
inherent limitations, including the possibility of human error,
collusion and the improper overriding of controls by management.
Accordingly, even those systems determined to be effective can
provide only reasonable, but not absolute assurance with respect
to financial statement preparation and presentation. Further,
because of changes in conditions, the effectiveness of internal
control may vary over time.
As required by Section 404 of the Sarbanes Oxley Act of
2002, management assessed the effectiveness of the
Companys internal control over financial reporting as of
December 31, 2010. Managements assessment is based on
the criteria established in the Internal Control
Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission. Based upon our
assessment, management concludes that the Company maintained
effective internal control over financial reporting as of
December 31, 2010. Deloitte and Touche LLP, the
Companys independent registered public accounting firm,
has issued an attestation report on the Companys internal
control over financial reporting as of December 31, 2010.
This report appears below.
(b) Changes
in Internal Control Over Financial Reporting
During the third quarter of 2010, the Company implemented a new
enterprise resource planning (ERP) system for a large portion of
North America and Latin America. This implementation included
modules primarily for general ledger, accounts payable, accounts
receivable and revenue recognition. During the fourth quarter of
2010, the Company revised certain internal controls over
financial reporting to utilize the new ERP system.
The Companys management, including the Companys
Chief Executive Officer and Chief Financial Officer, has
determined that these revised internal controls over financial
reporting provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial
statements for external reporting purposes in accordance with
generally accepted accounting principles during the period
covered by this report. Management has also determined that
there were no changes in the Companys internal controls
over financial reporting related to legacy systems that have
materially affected, or are reasonably likely to materially
affect, the internal controls over financial reporting for the
quarter-ended December 31, 2010.
The Company expects the transition from legacy systems to the
new ERP system to continue into 2011. The Company will continue
to evaluate the impact of the implementation on its internal
controls over financial reporting. At this time, the Company
does not anticipate any adverse impact from the conversion.
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Candace
Kendle
Candace
Kendle, PharmD
|
|
Chairman of the Board of Directors, Chief Executive Officer and
Principal Executive Officer
|
|
March 16, 2011
|
|
|
|
|
|
/s/ Keith
A. Cheesman
Keith
A. Cheesman
|
|
Senior Vice President, Chief Financial Officer and Principal
Financial Accounting Officer
|
|
March 16, 2011
|
40
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Shareholders of
Kendle International Inc.
Cincinnati, Ohio
We have audited the internal control over financial reporting of
Kendle International Inc. and subsidiaries (the
Company) as of December 31, 2010, based on
criteria established in Internal Control Integrated
Framework issued by the Committee of Sponsoring Organizations of
the Treadway Commission. The Companys management is
responsible for maintaining effective internal control over
financial reporting and for its assessment of the effectiveness
of internal control over financial reporting, included in the
accompanying Managements Report on Internal Control over
Financial Reporting. Our responsibility is to express an opinion
on the Companys internal control over financial reporting
based on our audit.
We conducted our audit in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether effective internal control
over financial reporting was maintained in all material
respects. Our audit included obtaining an understanding of
internal control over financial reporting, assessing the risk
that a material weakness exists, testing and evaluating the
design and operating effectiveness of internal control based on
the assessed risk, and performing such other procedures as we
considered necessary in the circumstances. We believe that our
audit provides a reasonable basis for our opinion.
A companys internal control over financial reporting is a
process designed by, or under the supervision of, the
companys principal executive and principal financial
officers, or persons performing similar functions, and effected
by the companys board of directors, management, and other
personnel to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with
generally accepted accounting principles. A companys
internal control over financial reporting includes those
policies and procedures that (1) pertain to the maintenance
of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of the assets of the
company; (2) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the company
are being made only in accordance with authorizations of
management and directors of the company; and (3) provide
reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of the
companys assets that could have a material effect on the
financial statements.
Because of the inherent limitations of internal control over
financial reporting, including the possibility of collusion or
improper management override of controls, material misstatements
due to error or fraud may not be prevented or detected on a
timely basis. Also, projections of any evaluation of the
effectiveness of the internal control over financial reporting
to future periods are subject to the risk that the controls may
become inadequate because of changes in conditions, or that the
degree of compliance with the policies or procedures may
deteriorate.
In our opinion, the Company maintained, in all material
respects, effective internal control over financial reporting as
of December 31, 2010, based on the criteria established in
Internal Control Integrated Framework issued by the
Committee of Sponsoring Organizations of the Treadway Commission.
We have also audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States), the
consolidated financial statements as of and for the year ended
December 31, 2010 of the Company and our report dated
March 16, 2011 expressed an unqualified opinion on those
financial statements.
/s/ DELOITTE &
TOUCHE LLP
Cincinnati, Ohio
March 16, 2011
41
|
|
ITEM 9B
|
OTHER
INFORMATION
|
Nothing to report.
PART III
ITEM 10.
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE
GOVERNANCE
DIRECTORS
OF THE COMPANY
The name, age and background information for each of the
Companys Directors is set forth in the section titled
Election of Directors contained in the
Companys definitive Proxy Statement to be filed with the
SEC and is incorporated herein by reference.
AUDIT
COMMITTEE
Information regarding the members of the audit committee and the
audit committee financial expert is set forth in the sections
titled Board of Directors and Audit
Committee under the heading Governance of the
Company in the Companys definitive Proxy Statement
to be filed with the SEC. The information in these sections is
incorporated herein by reference.
EXECUTIVE
OFFICERS OF THE COMPANY
The Executive Officers of the Company at March 1, 2011,
were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
Executive
|
Name
|
|
Age
|
|
Position
|
|
Officer Since
|
|
Candace Kendle, PharmD
|
|
64
|
|
Chief Executive Officer and Chairman of the Board of Directors
|
|
1989
|
Christopher C. Bergen
|
|
60
|
|
Executive Vice President and Chief Administrative Officer
|
|
1989
|
Keith A. Cheesman
|
|
51
|
|
Senior Vice President and Chief Financial Officer
|
|
2009
|
Mark J. Roseman, D.Sc
|
|
50
|
|
Senior Vice President and Chief Marketing Officer
|
|
2010
|
Stephen A. Cutler, PhD
|
|
51
|
|
Senior Vice President and Chief Operating Officer
|
|
2009
|
Background information regarding Dr. Kendle and
Mr. Bergen is set forth in the sections titled
Election of Directors and Securities Ownership
of Management in the Companys definitive Proxy
Statement to be filed with the SEC. Background information
regarding Mr. Cheesman, Dr. Roseman and
Dr. Cutler is set forth in the notes to the table within
the section titled Securities Ownership of
Management contained in the Companys definitive
Proxy Statement to be filed with the SEC. This information is
incorporated herein by reference.
SECTION 16(A)
BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Information on compliance with Section 16(a) of the
Exchange Act is set forth in the section titled
Section 16(a) Beneficial Ownership Reporting
Compliance under the heading entitled Securities
Ownership in the Companys definitive Proxy Statement
to be filed with the SEC and is incorporated herein by reference.
CODE OF
ETHICS
The Company has adopted a Code of Ethics and Conduct, which
applies to the Companys employees, including its Chief
Executive Officer and its principal financial and accounting
officer. The Code of Ethics and Conduct is available on the
Companys web site at www.kendle.com. Amendments to
the Code of Ethics and Conduct will be posted to the
Companys web site. In addition, the Company will make
available, free of charge, to
42
any person, a copy of its Code of Ethics and Conduct upon
written request submitted to the Company. This written request
should be addressed to the Companys Secretary at the
Companys principal executive offices.
|
|
ITEM 11.
|
EXECUTIVE
COMPENSATION
|
Information required by this report is set forth in the
following sections under the heading titled Governance of
the Company in the Companys definitive Proxy
Statement to be filed with the SEC, which information is
incorporated herein by reference:
|
|
|
|
|
Compensation Committee Interlocks and Insider
Participation; and
|
|
|
|
Directors Compensation and Equity Holding
Requirements.
|
Information required by this report is set forth in the
Executive Compensation section in the Companys
definitive Proxy Statement to be filed with the SEC. The
Executive Compensation section includes information
under the following headings, which information is incorporated
herein by reference.
|
|
|
|
|
Compensation Discussion and Analysis:;
|
|
|
|
Compensation Committee Report;
|
|
|
|
Summary Compensation Table;
|
|
|
|
Grants of Plan-Based Awards;
|
|
|
|
Outstanding Equity Awards at Fiscal Year End;
|
|
|
|
Option Exercises and Stock Vested;
|
|
|
|
Nonqualified Deferred Compensation; and
|
|
|
|
Potential Payments Upon Termination or
Change-in-Control.
|
|
|
ITEM 12.
|
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS
|
Information on the number of shares beneficially owned by each
Director and executive officer, and by all Directors and
executive officers as a group is set forth in the section titled
Securities Ownership of Management under the heading
titled Securities Ownership in the Companys
definitive Proxy Statement to be filed with the SEC. The
information set forth in such section is incorporated herein by
reference.
Information on the number of shares beneficially owned by any
person who is known to the Company to be the beneficial owner of
more than five percent of the Companys Common Stock is set
forth in the section titled Principal Shareholders
under the heading titled Securities Ownership in the
Companys definitive Proxy Statement to be filed with the
SEC. The information set forth in such section is incorporated
herein by reference.
43
The following table presents summary information at
December 31, 2010, with respect to all of the
Companys equity compensation plans.
Equity
Compensation Plan Information
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(c)
|
|
|
|
|
|
|
|
|
|
Number of Securities
|
|
|
|
(a)
|
|
|
|
|
|
Remaining Available
|
|
|
|
Number of
|
|
|
|
|
|
for Future Issuance
|
|
|
|
Securities to be
|
|
|
(b)
|
|
|
Under Equity
|
|
|
|
Issued upon
|
|
|
Weighted-Average
|
|
|
Compensation Plans
|
|
|
|
Exercise of
|
|
|
Exercise Price
|
|
|
(Excluding
|
|
|
|
Outstanding
|
|
|
of Outstanding
|
|
|
Securities
|
|
|
|
Options, Warrants
|
|
|
Options, Warrants
|
|
|
Reflected in Column
|
|
Plan Category
|
|
and Rights(1)
|
|
|
and Rights(1)
|
|
|
(a))(2)
|
|
|
Equity compensation plans approved by security holders
|
|
|
397,150
|
|
|
$
|
15.60
|
|
|
|
590,430
|
|
Equity compensation plans not approved by security holders
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
397,150
|
|
|
$
|
15.60
|
|
|
|
590,430
|
|
|
|
|
(1) |
|
Excludes the 2003 Directors Compensation Plan under
which no options, warrants or rights are granted. This plan has
been approved by shareholders for up to 75,000 shares. |
|
(2) |
|
Represents shares available for issuance under the 2007 Stock
Incentive Plan. |
|
|
ITEM 13.
|
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE
|
TRANSACTIONS
WITH RELATED PERSONS
Information with respect to transactions with related persons,
if any, is contained under the caption Review and Approval
of Transactions with Related Persons under the heading
titled Governance of the Company in the
Companys definitive Proxy Statement to be filed with the
SEC. The information set forth in such section is incorporated
herein by reference.
REVIEW,
APPROVAL OR RATIFICATION OF TRANSACTIONS WITH RELATED
PERSONS
Information with respect to the review, approval or ratification
of transactions with related persons is contained under the
caption Review and Approval of Transactions with Related
Persons under the heading titled Governance of the
Company in the Companys definitive Proxy Statement
to be filed with the SEC. The information set forth in such
section is incorporated herein by reference.
PROMOTERS
AND CERTAIN CONTROL PERSONS
Not applicable.
DIRECTOR
INDEPENDENCE
The name of each Director who is independent is contained in the
section titled Director Independence under the
heading titled Governance of the Company in the
Companys definitive Proxy Statement to be filed with the
SEC. The information set forth in such section is incorporated
herein by reference.
|
|
ITEM 14.
|
PRINCIPAL
ACCOUNTANT FEES AND SERVICES
|
Information required by this Item is contained in the sections
titled Audit Committees Pre-Approval Policies and
Procedures and Fees Paid to Registered Public
Accounting Firm under the heading titled
Ratification of Appointment of Registered Public
Accounting Firm in the Companys definitive Proxy
Statement to be filed with the SEC and is incorporated herein by
reference.
44
PART IV
|
|
ITEM 15.
|
EXHIBITS AND
FINANCIAL STATEMENT SCHEDULES
|
(a) (1) and (2) All financial statements
and schedules required to be filed by Item 8 of this Annual
Report on
Form 10-K
and included in this report are listed beginning on
page F-1.
No additional financial statements or schedules are being filed
as the required information is not applicable or because the
information is required and is included in the respective
financial statements or notes thereto.
(3) Exhibits Exhibits set forth below that are
on file with the SEC are incorporated by reference as exhibits
hereto.
|
|
|
|
|
Exhibit
|
|
|
Number
|
|
Description of Exhibit
|
|
|
2
|
.1
|
|
Stock Purchase Agreement between the Company and Charles River
Laboratories International, Inc. dated as of May 9, 2006
(Incorporated by reference to the
Form 8-K
filed with the Commission on May 12, 2006)
|
|
2
|
.2
|
|
First Amendment to the Stock Purchase Agreement dated as of
August 16, 2006 between the Company and Charles River
Laboratories, Inc. (Incorporated by reference to the
Companys Current Report on
Form 8-K
filed with the Commission on August 18, 2006)
|
|
3
|
.1
|
|
Restated and Amended Articles of Incorporation. Incorporated by
reference to the Companys Registration Statement
No. 333-30581
filed under the Securities Act of 1933.
|
|
3
|
.2
|
|
Amended and Restated Code of Regulations (Incorporated by
reference to the Companys Current Report on
Form 8-K
filed with the Commission on November 16, 2009)
|
|
3
|
.3
|
|
Amendment of the Restated and Amended Articles of Incorporation
to Increase the Authorized Shares (Incorporated by reference to
the Companys definitive Proxy Statement on
Schedule 14A filed with the Commission on April 14,
1999)
|
|
4
|
|
|
Specimen Common Stock Certificate (Incorporated by reference to
the Companys Registration Statement
No. 333-30581
filed under the Securities Act of 1933)
|
|
4
|
.1
|
|
Shareholder Rights Agreement dated August 14, 2009 between
the Company and American Stock Transfer &
Trust Company LLC, as Rights Agent (Incorporated by
reference to the Companys filing on
Form 8-A
filed with the Commission on August 20, 2009)
|
|
4
|
.2
|
|
Indenture dated March 31, 2007 between the Company and
LaSalle Bank National Association (Incorporated by reference to
the Companys
Form S-3
filed with the Commission on April 9, 2007)
|
|
4
|
.3
|
|
Supplemental Indenture No. 1 dated July 16, 2007
between the Company and LaSalle Bank National Association
(Incorporated by reference to the Companys Current Report
on
Form 8-K
filed with the Commission on July 16, 2007)
|
|
10
|
.1
|
|
Indemnity Agreement dated June 21, 1996 by and between the
Company and Candace Kendle Bryan (Incorporated by reference to
the Companys Registration Statement
No. 333-30581
filed under the Securities Act of 1933)
|
|
10
|
.2
|
|
Indemnity Agreement dated June 21, 1996 by and between the
Company and Christopher C. Bergen (Incorporated by reference to
the Companys Registration Statement
No. 333-30581
filed under the Securities Act of 1933)
|
|
10
|
.3
|
|
Indemnity Agreement dated June 21, 1996 by and between the
Company and Timothy M. Mooney (Incorporated by reference to the
Companys Registration Statement
No. 333-30581
filed under the Securities Act of 1933)
|
|
10
|
.4
|
|
Indemnity Agreement dated May 14, 1997 by and between the
Company and Charles A. Sanders (Incorporated by reference to the
Companys Annual Report on
Form 10-K
for the year ended December 31, 1997)
|
|
10
|
.5
|
|
Indemnity Agreement dated May 14, 1997 by and between the
Company and Philip E. Beekman (Incorporated by reference to the
Companys Annual Report on
Form 10-K
for the year ended December 31, 1997)
|
|
10
|
.6
|
|
Indemnity Agreement dated December 10, 1998 by and between
the Company and Robert Buck (Incorporated by reference to the
Companys Annual Report on
Form 10-K
for the year ended December 31, 1998)
|
45
|
|
|
|
|
Exhibit
|
|
|
Number
|
|
Description of Exhibit
|
|
|
10
|
.7
|
|
Indemnity Agreement dated December 10, 1998 by and between
the Company and Mary Beth Price (Incorporated by reference to
the Companys Annual Report on
Form 10-K
for the year ended December 31, 1998)
|
|
10
|
.8
|
|
Form of Indemnity Agreement by and between the Company and each
member of the Companys Board of Directors, except for
those Indemnity Agreements noted above (Incorporated by
reference to the Companys Annual Report on
Form 10-K
for the year ended December 31, 2003)
|
|
10
|
.9
|
|
Confirmation of Convertible Bond Hedge Transaction, dated
July 10, 2007, by and between the Company and UBS AG,
London Branch (Incorporated by reference to the Companys
Current Report on
Form 8-K
filed with the Commission on July 10, 2007)
|
|
10
|
.10
|
|
Confirmation of Convertible Bond Hedge Transaction, dated
July 10, 2007, by and between the Company and JPMorgan
Chase Bank, National Association, London Branch (Incorporated by
reference to the Companys Current Report on
Form 8-k
filed with the Commission on July 10, 2007)
|
|
10
|
.11
|
|
Confirmation of Issuer Warrant Transaction, dated July 10,
2007, by and between the Company and UBS AG, London Branch
(Incorporated by reference to the Companys Current Report
on
Form 8-k
filed with the Commission on July 10, 2007)
|
|
10
|
.12
|
|
Confirmation of Issuer Warrant Transaction, dated July 10,
2007, by and between the Company and JPMorgan Chase Bank,
National Association, London Branch (Incorporated by reference
to the Companys Current Report on
Form 8-k
filed with the Commission on July 10, 2007)
|
|
10
|
.13
|
|
Lease Agreement dated February 27, 2008 by and between the
Company and Carew Realty, Inc. (Incorporated by reference to the
Companys Quarterly Report on
Form 10-Q
for the quarterly period ended March 31, 2008)
|
|
10
|
.14
|
|
Credit Agreement dated as of March 15, 2010 by and among
the Company , various Lenders and JPMorgan Chase Bank, N.A., as
Administrative Agent (Incorporated by reference to the
Companys Annual Report on
Form 10-K
for the year ended December 31, 2009)
|
|
10
|
.15
|
|
Guaranty dated as of March 15, 2010 by and among various
Subsidiaries of the Company in favor of JPMorgan Chase Bank,
N.A., as Administrative Agent (Incorporated by reference to the
Companys Annual Report on
Form 10-K
for the year ended December 31, 2009)
|
|
10
|
.16
|
|
Pledge and Security Agreement dated as of March 15, 2010 by
and among the Company, various Subsidiaries of the Company and
JPMorgan Chase Bank, N.A., as Administrative Agent (Incorporated
by reference to the Companys Annual Report on
Form 10-K
for the year ended December 31, 2009)
|
|
10
|
.17
|
|
Amendment No. 1 to Credit Agreement with various lenders
and JPMorgan Chase Bank, N.A., as Administrative Agent dated as
of April 27, 2010 (Incorporated by reference to the
Companys Quarterly Report on
Form 10-Q
for the quarterly period ended March 31, 2010)
|
|
10
|
.18
|
|
Amendment No. 2 to Credit Agreement with various lenders
and JPMorgan Chase Bank, N.A., as Administrative Agent dated as
of January 21, 2011 (Filed herewith)
|
|
10
|
.19
|
|
MANAGEMENT CONTRACTS AND COMPENSATION PLANS
|
|
|
|
|
(a) 1995 Stock Option and Stock Incentive Plan
(Incorporated by reference to the Companys Registration
Statement
No. 333-30581
filed under the Securities Act of 1933)
|
|
|
|
|
(b) 1995 Stock Option and Stock Incentive Plan
Individual Stock Option Agreement for Incentive Stock Option
(contained in Exhibit 10.20(a)) (Incorporated by reference
to the Companys Registration Statement
No. 333-30581
filed under the Securities Act of 1933)
|
|
|
|
|
(c) 1997 Stock Option and Stock Incentive Plan
(Incorporated by reference to the Companys Registration
Statement
No. 333-30581
filed under the Securities Act of 1933)
|
|
|
|
|
(c)(1) Amendment No. 1 to 1997 Stock Option and Stock
Incentive Plan (Incorporated by reference to the Companys
Annual Report on
Form 10-K
for the year ended December 31, 2002)
|
|
|
|
|
(c)(2) Amendment No. 2 to 1997 Stock Option and Stock
Incentive Plan (Incorporated by reference to the Companys
definitive Proxy Statement on Schedule 14A filed with the
Commission on April 12, 2000)
|
|
|
|
|
(c)(3) Amendment No. 3 to 1997 Stock Option and Stock
Incentive Plan (Incorporated by reference to the Companys
Annual Report on
Form 10-K
for the year ended December 31, 2002)
|
46
|
|
|
|
|
Exhibit
|
|
|
Number
|
|
Description of Exhibit
|
|
|
|
|
|
(c)(4) Form of Restricted Stock Award Agreement (Incorporated by
reference to the Companys Annual Report on
Form 10-K
for the year ended December 31, 2004)
|
|
|
|
|
(d) Form of Protective Compensation and Benefit Agreement.
Incorporated by reference to the Companys Registration
Statement
No. 333-30581
filed under the Securities Act of 1933)
|
|
|
|
|
(e) 2007 Stock Incentive Plan (Incorporated by reference to
the Companys definitive Proxy Statement on
Schedule 14A filed with the Commission on April 9,
2007)
|
|
|
|
|
(e)(1) Form of Performance Based Stock Unit Agreement
(Incorporated by reference to the Companys Quarterly
Report on
Form 10-Q
for the quarterly period ended March 31, 2008)
|
|
|
|
|
(f) Annual Incentive Plan (Incorporated by reference to the
Companys Current Report on
Form 8-K
filed with the Commission on May 20, 2008)
|
|
|
|
|
(g) Nonqualified Deferred Compensation Plan (Incorporated
by reference to the Companys Current Report on
Form 8-K
filed with the Commission on May 20, 2008)
|
|
|
|
|
(h) 2003 Directors Compensation Plan (Incorporated by
reference to the Companys Quarterly Report on
Form 10-Q
for the quarterly period ended June 30, 2003)
|
|
12
|
.1
|
|
Computation of Ratio of Earnings to Fixed Charges (Filed
herewith)
|
|
14
|
|
|
Code of Ethics (Available on the Companys Web site at
www.kendle.com)
|
|
21
|
|
|
List of Subsidiaries (Filed herewith)
|
|
23
|
.1
|
|
Consent of Deloitte & Touche LLP (Filed herewith)
|
|
24
|
|
|
Powers of Attorney (Filed herewith)
|
|
31
|
.1
|
|
Certification of the Chief Executive Officer pursuant to
Rule 13a-14(a)
(Filed herewith)
|
|
31
|
.2
|
|
Certification of the Chief Financial Officer pursuant to
Rule 13a-14(a)
(Filed herewith)
|
|
32
|
.1
|
|
Certification Pursuant to 18 U.S.C Section 1350 as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of
2002 Chief Executive Office (Filed herewith)
|
|
32
|
.2
|
|
Certification Pursuant to 18 U.S.C Section 1350 as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of
2002 Chief Financial Officer (Filed herewith)
|
47
Kendle
International Inc.
Index to
Consolidated Financial Statements
|
|
|
|
|
|
|
Page
|
|
|
|
|
F-2
|
|
|
|
|
F-3
|
|
|
|
|
F-4
|
|
|
|
|
F-5
|
|
|
|
|
F-6
|
|
|
|
|
F-7
|
|
F-1
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Shareholders of
Kendle International Inc.
Cincinnati, Ohio
We have audited the accompanying consolidated balance sheets of
Kendle International Inc. and subsidiaries (the
Company) as of December 31, 2010 and 2009, and
the related consolidated statements of operations,
shareholders equity, and cash flows for each of the three
years in the period ended December 31, 2010. These
financial statements are the responsibility of the
Companys management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are
free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by
management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, such consolidated financial statements present
fairly, in all material respects, the financial position of
Kendle International Inc. and subsidiaries as of
December 31, 2010 and 2009, and the results of their
operations and their cash flows for each of the three years in
the period ended December 31, 2010, in conformity with
accounting principles generally accepted in the United States of
America.
We have also audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States), the
Companys internal control over financial reporting as of
December 31, 2010, based on the criteria established in
Internal Control Integrated Framework issued by the
Committee of Sponsoring Organizations of the Treadway Commission
and our report dated March 16, 2011 expressed an
unqualified opinion on the Companys internal control over
financial reporting.
/s/ DELOITTE &
TOUCHE LLP
Cincinnati, Ohio
March 16, 2011
F-2
CONSOLIDATED
STATEMENTS OF OPERATIONS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Years Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
(In thousands except per share data)
|
|
|
Net service revenues
|
|
$
|
333,766
|
|
|
$
|
416,688
|
|
|
$
|
475,092
|
|
Reimbursable
out-of-pocket
revenues
|
|
|
114,493
|
|
|
|
135,224
|
|
|
|
203,489
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
448,259
|
|
|
|
551,912
|
|
|
|
678,581
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct costs
|
|
|
171,600
|
|
|
|
210,586
|
|
|
|
247,436
|
|
Reimbursable
out-of-pocket
costs
|
|
|
114,493
|
|
|
|
135,224
|
|
|
|
203,489
|
|
Selling, general and administrative
|
|
|
135,239
|
|
|
|
144,659
|
|
|
|
155,577
|
|
Depreciation and amortization
|
|
|
16,340
|
|
|
|
15,712
|
|
|
|
15,253
|
|
Restructuring expenses
|
|
|
4,522
|
|
|
|
10,157
|
|
|
|
|
|
Goodwill impairment
|
|
|
7,263
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses
|
|
|
449,457
|
|
|
|
516,338
|
|
|
|
621,755
|
|
Income (loss) from operations
|
|
|
(1,198
|
)
|
|
|
35,574
|
|
|
|
56,826
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
144
|
|
|
|
579
|
|
|
|
760
|
|
Interest expense
|
|
|
(11,949
|
)
|
|
|
(14,403
|
)
|
|
|
(15,891
|
)
|
Gain on extinguishment of debt
|
|
|
|
|
|
|
2,887
|
|
|
|
|
|
Other
|
|
|
7,770
|
|
|
|
4,034
|
|
|
|
(2,043
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income (expense)
|
|
|
(4,035
|
)
|
|
|
(6,903
|
)
|
|
|
(17,174
|
)
|
Income (loss) before income taxes
|
|
|
(5,233
|
)
|
|
|
28,671
|
|
|
|
39,652
|
|
Income tax provision (benefit)
|
|
|
(674
|
)
|
|
|
13,434
|
|
|
|
16,509
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
(4,559
|
)
|
|
$
|
15,237
|
|
|
$
|
23,143
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) per share data:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share
|
|
$
|
(0.31
|
)
|
|
$
|
1.03
|
|
|
$
|
1.57
|
|
Weighted average shares
|
|
|
14,907
|
|
|
|
14,862
|
|
|
|
14,751
|
|
Diluted:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share
|
|
$
|
(0.31
|
)
|
|
$
|
1.02
|
|
|
$
|
1.54
|
|
Weighted average shares
|
|
|
14,907
|
|
|
|
14,992
|
|
|
|
14,993
|
|
The accompanying notes are an integral part of these
Consolidated Financial Statements.
F-3
CONSOLIDATED
BALANCE SHEETS
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
2010
|
|
|
2009
|
|
|
|
(In thousands except share data)
|
|
|
ASSETS
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
21,217
|
|
|
$
|
52,103
|
|
Restricted cash
|
|
|
881
|
|
|
|
1,112
|
|
Accounts receivable, net
|
|
|
105,586
|
|
|
|
125,287
|
|
Deferred tax asset current
|
|
|
7,876
|
|
|
|
8,147
|
|
Other current assets
|
|
|
24,665
|
|
|
|
20,676
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
160,225
|
|
|
|
207,325
|
|
Property and equipment, net
|
|
|
56,898
|
|
|
|
53,539
|
|
Goodwill
|
|
|
236,189
|
|
|
|
243,589
|
|
Other intangible assets, net
|
|
|
11,808
|
|
|
|
15,164
|
|
Long-term deferred tax asset
|
|
|
17,929
|
|
|
|
12,716
|
|
Other assets
|
|
|
6,862
|
|
|
|
7,390
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
489,911
|
|
|
$
|
539,723
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS EQUITY
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Current portion of obligations under capital leases
|
|
$
|
34
|
|
|
$
|
52
|
|
Trade payables
|
|
|
18,187
|
|
|
|
14,928
|
|
Advance billings
|
|
|
57,525
|
|
|
|
76,202
|
|
Other accrued liabilities
|
|
|
42,265
|
|
|
|
59,667
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
118,011
|
|
|
|
150,849
|
|
Obligations under capital leases, less current portion
|
|
|
|
|
|
|
34
|
|
Convertible notes, net
|
|
|
133,082
|
|
|
|
138,308
|
|
Deferred income taxes liabilities
|
|
|
2,872
|
|
|
|
7,508
|
|
Non-current income taxes payable
|
|
|
1,110
|
|
|
|
1,872
|
|
Other liabilities
|
|
|
3,989
|
|
|
|
5,105
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
259,064
|
|
|
|
303,676
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
Shareholders equity:
|
|
|
|
|
|
|
|
|
Preferred stock no par value; 100,000 shares
authorized; none issued and outstanding
|
|
|
|
|
|
|
|
|
Common stock no par value; 45,000,000 shares
authorized; 14,955,259 and 14,912,327 shares issued and
14,932,207 and 14,889,275 outstanding at December 31, 2010
and 2009, respectively
|
|
|
75
|
|
|
|
75
|
|
Additional paid-in capital
|
|
|
181,308
|
|
|
|
180,534
|
|
Retained earnings
|
|
|
29,177
|
|
|
|
33,736
|
|
Accumulated other comprehensive income:
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment
|
|
|
20,779
|
|
|
|
22,194
|
|
Less: Cost of common stock held in treasury, 23,052 shares
at December 31, 2010 and 2009, respectively
|
|
|
(492
|
)
|
|
|
(492
|
)
|
|
|
|
|
|
|
|
|
|
Total shareholders equity
|
|
|
230,847
|
|
|
|
236,047
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders equity
|
|
$
|
489,911
|
|
|
$
|
539,723
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these
Consolidated Financial Statements.
F-4
CONSOLIDATED
STATEMENTS OF SHAREHOLDERS EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
|
|
|
|
Common Stock
|
|
|
Common
|
|
|
Additional
|
|
|
|
|
|
Retained
|
|
|
Other
|
|
|
Total
|
|
|
|
|
|
|
Number of
|
|
|
Stock
|
|
|
Paid-in
|
|
|
Treasury
|
|
|
Earnings
|
|
|
Comprehensive
|
|
|
Shareholders
|
|
|
Comprehensive
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Stock
|
|
|
(Deficit)
|
|
|
Income
|
|
|
Equity
|
|
|
Income (Loss)
|
|
|
|
(In thousands except share data)
|
|
|
Balance at January 1, 2008
|
|
|
14,657,977
|
|
|
$
|
75
|
|
|
$
|
176,521
|
|
|
$
|
(492
|
)
|
|
$
|
(4,644
|
)
|
|
$
|
3,798
|
|
|
$
|
175,258
|
|
|
|
|
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23,143
|
|
|
|
|
|
|
|
23,143
|
|
|
|
23,143
|
|
Other comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,724
|
|
|
|
10,724
|
|
|
|
10,724
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
33,867
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued under stock plans
|
|
|
180,489
|
|
|
|
|
|
|
|
2,294
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,294
|
|
|
|
|
|
Stock compensation expense
|
|
|
|
|
|
|
|
|
|
|
1,030
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,030
|
|
|
|
|
|
Income tax benefit from exercise of stock options
|
|
|
|
|
|
|
|
|
|
|
175
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
175
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2008
|
|
|
14,838,466
|
|
|
$
|
75
|
|
|
$
|
180,020
|
|
|
$
|
(492
|
)
|
|
$
|
18,499
|
|
|
$
|
14,522
|
|
|
$
|
212,624
|
|
|
|
|
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,237
|
|
|
|
|
|
|
|
15,237
|
|
|
|
15,237
|
|
Other comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,672
|
|
|
|
7,672
|
|
|
|
7,672
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22,909
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share based compensation plans and other
|
|
|
50,809
|
|
|
|
|
|
|
|
815
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
815
|
|
|
|
|
|
Repurchase of equity component of convertible notes
|
|
|
|
|
|
|
|
|
|
|
(204
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(204
|
)
|
|
|
|
|
Partial retirement of note hedges and warrants
|
|
|
|
|
|
|
|
|
|
|
(97
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(97
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2009
|
|
|
14,889,275
|
|
|
$
|
75
|
|
|
$
|
180,534
|
|
|
$
|
(492
|
)
|
|
$
|
33,736
|
|
|
$
|
22,194
|
|
|
$
|
236,047
|
|
|
|
|
|
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4,559
|
)
|
|
|
|
|
|
|
(4,559
|
)
|
|
|
(4,559
|
)
|
Other comprehensive loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,415
|
)
|
|
|
(1,415
|
)
|
|
|
(1,415
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(5,974
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share based compensation plans and other
|
|
|
42,932
|
|
|
|
|
|
|
|
1,125
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,125
|
|
|
|
|
|
Repurchase of equity component of convertible notes
|
|
|
|
|
|
|
|
|
|
|
(348
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(348
|
)
|
|
|
|
|
Partial retirement of note hedges and warrants
|
|
|
|
|
|
|
|
|
|
|
(3
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2010
|
|
|
14,932,207
|
|
|
$
|
75
|
|
|
$
|
181,308
|
|
|
$
|
(492
|
)
|
|
$
|
29,177
|
|
|
$
|
20,779
|
|
|
$
|
230,847
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these
Consolidated Financial Statements.
F-5
CONSOLIDATED
STATEMENTS OF CASH FLOWS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Years Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
(In thousands)
|
|
|
Cash flows from operating activities
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
(4,559
|
)
|
|
$
|
15,237
|
|
|
$
|
23,143
|
|
Adjustments to reconcile net income to cash provided by
operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
16,340
|
|
|
|
15,712
|
|
|
|
15,253
|
|
Goodwill impairment charge
|
|
|
7,263
|
|
|
|
|
|
|
|
|
|
Deferred income taxes
|
|
|
(9,605
|
)
|
|
|
4,138
|
|
|
|
(6,745
|
)
|
Income tax benefit from stock option exercises
|
|
|
(11
|
)
|
|
|
(2
|
)
|
|
|
(175
|
)
|
Compensation expense on stock grants
|
|
|
914
|
|
|
|
679
|
|
|
|
1,030
|
|
Debt issue cost amortization
|
|
|
7,197
|
|
|
|
7,729
|
|
|
|
7,783
|
|
Foreign currency exchange (gain) loss
|
|
|
(1,905
|
)
|
|
|
(2,691
|
)
|
|
|
4,321
|
|
Gain on extinguishment of debt
|
|
|
|
|
|
|
(2,887
|
)
|
|
|
|
|
Other
|
|
|
459
|
|
|
|
1,333
|
|
|
|
(1,564
|
)
|
Changes in operating assets and liabilities, net of effects from
acquisitions:
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted cash
|
|
|
206
|
|
|
|
(82
|
)
|
|
|
(85
|
)
|
Accounts receivable
|
|
|
13,995
|
|
|
|
37,786
|
|
|
|
(28,036
|
)
|
Other current assets
|
|
|
(3,254
|
)
|
|
|
(1,344
|
)
|
|
|
(3,493
|
)
|
Other assets
|
|
|
579
|
|
|
|
(31
|
)
|
|
|
(317
|
)
|
Trade payables
|
|
|
5,111
|
|
|
|
(4,395
|
)
|
|
|
1,010
|
|
Advance billings
|
|
|
(13,154
|
)
|
|
|
(22,401
|
)
|
|
|
19,613
|
|
Accrued liabilities and other
|
|
|
(18,646
|
)
|
|
|
5,508
|
|
|
|
5,318
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
930
|
|
|
|
54,289
|
|
|
|
37,056
|
|
Cash flows from investing activities
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from termination of foreign currency hedges
|
|
|
|
|
|
|
17,312
|
|
|
|
|
|
Acquisitions of property and equipment
|
|
|
(17,043
|
)
|
|
|
(18,431
|
)
|
|
|
(25,911
|
)
|
Additions to internally developed software
|
|
|
(249
|
)
|
|
|
(535
|
)
|
|
|
(1,186
|
)
|
Acquisitions of businesses, less cash acquired
|
|
|
(2,400
|
)
|
|
|
(2,875
|
)
|
|
|
(18,053
|
)
|
Other
|
|
|
62
|
|
|
|
32
|
|
|
|
(1,143
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities
|
|
|
(19,630
|
)
|
|
|
(4,497
|
)
|
|
|
(46,293
|
)
|
Cash flows from financing activities
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of long-term debt
|
|
|
10,000
|
|
|
|
|
|
|
|
37,500
|
|
Payments of long-term debt
|
|
|
(10,000
|
)
|
|
|
|
|
|
|
(37,500
|
)
|
Repurchase of convertible notes
|
|
|
(11,145
|
)
|
|
|
(36,463
|
)
|
|
|
|
|
Purchase of note hedges and warrants
|
|
|
(3
|
)
|
|
|
(97
|
)
|
|
|
|
|
Proceeds from issuance of common stock
|
|
|
160
|
|
|
|
247
|
|
|
|
2,241
|
|
Income tax benefit from stock option exercises
|
|
|
11
|
|
|
|
2
|
|
|
|
175
|
|
Amounts payable book overdraft
|
|
|
(281
|
)
|
|
|
133
|
|
|
|
465
|
|
Payments on capital lease obligations
|
|
|
(52
|
)
|
|
|
(228
|
)
|
|
|
(234
|
)
|
Debt issue costs
|
|
|
(470
|
)
|
|
|
(482
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by financing activities
|
|
|
(11,780
|
)
|
|
|
(36,888
|
)
|
|
|
2,647
|
|
Effects of exchange rates on cash and cash equivalents
|
|
|
(406
|
)
|
|
|
4,030
|
|
|
|
(3,753
|
)
|
Net increase (decrease) in cash and cash equivalents
|
|
|
(30,886
|
)
|
|
|
16,934
|
|
|
|
(10,343
|
)
|
Cash and cash equivalents
|
|
|
|
|
|
|
|
|
|
|
|
|
Beginning of year
|
|
|
52,103
|
|
|
|
35,169
|
|
|
|
45,512
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
End of year
|
|
$
|
21,217
|
|
|
$
|
52,103
|
|
|
$
|
35,169
|
|
Supplemental disclosure of cash flow information
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid during the year for interest
|
|
$
|
5,436
|
|
|
$
|
7,312
|
|
|
$
|
8,087
|
|
Cash paid during the year for income taxes
|
|
$
|
14,106
|
|
|
$
|
14,382
|
|
|
$
|
25,931
|
|
Supplemental schedule of noncash investing and financing
activities
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued equipment purchases
|
|
$
|
(117
|
)
|
|
$
|
(1,307
|
)
|
|
$
|
(1,090
|
)
|
Acquisitions of businesses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value of assets acquired via cash
|
|
$
|
|
|
|
$
|
5,039
|
|
|
$
|
25,432
|
|
Fair value of liabilities assumed or incurred
|
|
$
|
2,400
|
|
|
$
|
(2,164
|
)
|
|
$
|
(7,379
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash payments
|
|
$
|
2,400
|
|
|
$
|
2,875
|
|
|
$
|
18,053
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these
Consolidated Financial Statements.
F-6
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
|
|
1.
|
NATURE OF
BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES
|
Nature
of Business
Kendle International Inc. (the Company or Kendle), an Ohio
corporation established in 1989, is a global clinical research
organization (CRO) that provides a broad range of Phase I-IV
global clinical development services to the biopharmaceutical
industry. The Company has operations in North America, Europe,
Asia/Pacific, Latin America and Africa.
Principles
of Consolidation and Organization
The Consolidated Financial Statements include the financial
information of Kendle International Inc. and its wholly-owned
subsidiaries. Investments in companies or joint ventures in
which the Company is a partial owner are carried at cost plus
equity in undistributed earnings since acquisition, but would be
consolidated if the Company has both the power to direct
significant activities and the obligation to absorb losses or
rights to receive benefits. Investments in unconsolidated
companies that are less than 20% owned and in which the Company
cannot exercise significant influence are carried at cost. There
are no significant amounts on the Consolidated Balance Sheets
related to investments in unconsolidated companies.
All intercompany accounts and transactions have been eliminated.
The results of operations of the Companys wholly-owned
subsidiaries have been included in the Consolidated Financial
Statements of the Company from the respective dates of
acquisition.
Business
Combinations
Accounting guidance related to business combinations requires
assets acquired and liabilities assumed in a business
combination to be recorded at fair value. Fair values are
generally determined by using comparisons to market value
transactions and present value techniques. The use of a
discounted cash flow technique requires significant judgments
with respect to expected cash flows to be derived from the
assets, the estimated period of time the assets will produce
those cash flows and the selection of an appropriate discount
rate. Changes in such estimates could change the amounts
allocated to individual identifiable assets, the lives over
which the assigned values are amortized and the amounts
allocated to goodwill. While the Company believes its
assumptions are reasonable, if different assumptions were made,
the purchase price allocation and the estimated useful lives of
amortizable assets could differ substantially from the reported
amounts.
Foreign
Currency Translation
Assets and liabilities of the Companys wholly-owned
subsidiaries are translated into U.S. dollars at year-end
exchange rates. Income statement accounts are translated at
average exchange rates for the period. These translation
adjustments are recorded as a separate component of
Shareholders Equity. Foreign currency transaction gains
(losses) were $8.7 million in 2010, $5.4 million in
2009 and ($1.0) million in 2008, and are included in the
Consolidated Statements of Operations in Other income (expense).
Cash
and Cash Equivalents, Including Restricted Cash
Cash and cash equivalents consist of demand deposits and money
market funds held with financial institutions, with an initial
maturity of three months or less.
The Company maintains its demand deposits with certain financial
institutions. The balance of one account from
time-to-time
exceeds the maximum U.S. federally insured amount.
Additionally, there is no state insurance coverage on bank
balances held in The Netherlands.
At December 31, 2010, the Company held cash of
approximately $881,000 that is restricted as to its use as
compared to approximately $1,112,000 at December 31, 2009.
The restricted cash represents cash received from
F-7
customers that is segregated in a separate Company bank account
and available for use only for specific project-related
expenses, primarily investigator fees, upon authorization from
the customer.
Revenue
Recognition
The Company recognizes revenue on a majority of its contracts
using a units-based methodology whereby units completed are
multiplied by the applicable contract
per-unit
price. A portion of the Companys net service revenues are
based on fixed-price contracts calculated on a proportional
performance basis (also referred to herein as
percentage-of-completion)
based upon assumptions regarding the estimated total costs for
each contract. Additionally, work is performed under
time-and-materials
contracts, recognizing revenue as hours are worked based on the
hourly billing rate for each contract.
Percentage-of-Completion
With respect to fixed price contracts, costs are incurred for
performance of each contract and compared to the estimated
budgeted costs for that contract to determine a percentage of
completion on the contract. The percentage of completion is then
multiplied by the contract value to determine the amount of
revenue recognized. The contract value equals the value of the
services to be performed under the contract as determined by
aggregating the labor hours estimated to be incurred to perform
the tasks in the contract at the agreed rates. Contract value
excludes the value of third-party and other pass-through costs.
As the work progresses, original estimates might be changed as a
result of managements regular contract review process.
Management regularly reviews the budget on each contract to
determine if the budgeted costs accurately reflect the costs
that the Company will incur for contract performance. The
Company reviews each contracts performance to date,
current cost trends and circumstances specific to each contract.
The Company estimates its remaining costs to complete the
contract based on a variety of factors, including:
|
|
|
|
|
Actual costs incurred to date and the work completed as a result
of incurring the actual costs;
|
|
|
|
The remaining work to be completed based on the timeline of the
contract as well as the number of incomplete tasks in the
contract; and
|
|
|
|
Factors that could change the rate of progress of future
contract performance.
|
Examples of factors included in the review process that could
change the rate of progress of future contract performance are
patient enrollment rate, changes in the composition of staff on
the project or other customer requirements, among other things.
Based on these contract reviews, the Company adjusts its cost
estimates. Adjustments to net service revenue resulting from
changes in cost estimates are recorded on a cumulative basis in
the period in which the revisions are made. When estimates
indicate a loss, such loss is provided in the current period in
its entirety. While the Company routinely adjusts cost estimates
on individual contracts, the Companys estimates and
assumptions historically have been accurate in all material
respects in the aggregate. The Company expects the estimates and
assumptions to remain accurate in all material respects in the
aggregate in future periods.
A contract amendment, which results in revisions to net service
revenues and cost estimates, is recognized in the
percentage-of-completion
calculations beginning in the period in which the parties reach
written agreement to the amendment. Historically the aggregate
value of contract amendments signed in any year represents
approximately 15% to 20% of annual sales, and, like sales,
represents future net service revenues. Although the majority of
the Companys contract amendments relate to future
services, the Company and its customers may execute contract
amendments for services that the Company already has performed.
In these circumstances, net service revenue from these services
is recognized in the current period. Historically, the impact of
such amendments on results of operations has not been material.
Under the Companys policy, project teams are not
authorized to engage in tasks outside the scope of the contract
without prior management approval. In limited situations,
management may authorize the project team to commence work on
activities outside the contract scope while the Company and its
customer negotiate and finalize the contract amendment. When
work progresses on unsigned, unprocessed contract amendments,
the Company
F-8
reviews the direct costs incurred, and, where significant,
defers such costs on the balance sheet. In addition, the impact
of such costs on the estimates to complete is considered and,
where material, the estimates are adjusted. Historically,
neither the deferred costs nor the impact on estimates have been
material.
The Company believes that total costs are an appropriate
indicator of the performance of fixed price contracts because
the costs relate primarily to the amount of labor hours incurred
to perform the contract. The customer receives the benefit of
the work performed throughout the contract term and is obligated
to pay for services once performed. Accordingly, the Company
believes that an input measure of cost is a reasonable surrogate
for an output measure under the proportional performance model
and is consistent with the revenue recognition concepts issued
by the Securities and Exchange Commission.
Units-Based
The Company has seen increasing demand from its customers to
move toward a units-based contract methodology in new contracts.
The Company has structured more of its contracts under a
units-based methodology for calculating net service revenues so
the percentage of contracts under which net service revenues are
recognized using units-based methodology has increased and is
expected to continue to increase in future periods. Under a
units-based contract methodology, amounts recognized as net
service revenues are calculated based on units completed in the
period multiplied by a unit value or selling price that is
outlined in the contract.
For a units-based contract, a typical unit could include such
things as completion of a monitoring visit, monthly site
management units or case report form pages entered. The Company
tracks the units completed for each unit category included in
the contract. Net service revenue is recognized monthly based on
the units actually completed in the period at the agreed upon
unit value or selling price. Net service revenue is recognized
only up to the number of units contained in each contract. If
the Company completes or expects to complete units over and
above the number of units initially estimated and contained in
the contract, a contract amendment is generated to reflect the
additional units needed.
A contract amendment, which results in revisions to net service
revenues and cost estimates, is recognized in the unit-based net
service revenue calculations beginning in the period in which
the parties agree to the amendment.
The Company believes that under certain types of contracts the
value of the work performed is best captured by calculating net
service revenues using the value of units completed. The Company
believes that units-based revenue recognition is consistent with
the revenue recognition concepts issued by the Securities and
Exchange Commission.
Reimbursable
Out of Pocket Revenues/Costs
As the Company provides services on projects, it also incurs
third-party and other pass-through costs, which are reimbursable
by its customers pursuant to the contract. The revenues and
costs from these third-party and other pass-through costs are
reflected in the Companys Consolidated Statements of
Operations under the line items titled Reimbursable
out-of-pocket
revenues and Reimbursable
out-of-pocket
costs, respectively.
Concentration
of Credit Risk
Accounts receivable represent amounts due from customers that
are concentrated mainly in the biopharmaceutical industry. The
concentration of credit risk is subject to the financial and
industry conditions of the Companys customers. The Company
does not require collateral or other securities to support
customer receivables. The Company regularly monitors the
creditworthiness of its customers. Refer to Note 13,
Segment Information for additional information regarding revenue
concentration.
Long-Lived
Assets
Property and equipment are stated at cost, net of accumulated
depreciation. Depreciation is computed over the estimated useful
lives, ranging from five to fifty years using the straight-line
method. Leasehold improvements are amortized over the lesser of
the estimated useful life of the improvement or the remaining
term of the underlying lease. Repairs and maintenance are
charged to expense as incurred. Upon disposition, the asset and
the related
F-9
accumulated depreciation are relieved and any gains or losses
are reflected in the Consolidated Statements of Operations.
Useful lives by asset category can vary based on the nature of
the asset purchased. The following represents the maximum
estimated useful lives for the below categories of assets:
|
|
|
Furniture and Fixtures
|
|
10 years
|
Computer and Software
|
|
5 years
|
Leasehold Improvements
|
|
Lesser of estimated life of asset or lease term
|
Buildings
|
|
50 years
|
Capital Lease Assets
|
|
Lesser of estimated life of asset or lease term
|
Equipment under capital leases is recorded at the present value
of future minimum lease payments and is amortized over the
estimated useful lives of the assets, not to exceed the terms of
the related leases. Accumulated amortization on equipment under
capital leases was approximately $272,000 at December 31,
2010 compared to $399,000 at December 31, 2009.
The Company capitalizes costs such as design, configuration
activities, coding and testing activities incurred internally to
develop software used primarily in the Companys
proprietary clinical trial and data management systems, and
amortizes these costs on a straight-line basis over the
estimated useful life of the product, not to exceed five years.
The Company does not capitalize costs that are precluded from
capitalization in the authoritative guidance such as preliminary
project phase costs, planning, oversight, process re-engineering
costs, training costs, or data conversion costs. Internally
developed software costs included in the Consolidated Balance
Sheets at December 31, 2010, and 2009 were
$18.2 million and $18.0 million, respectively. The
related accumulated amortization at December 31, 2010, and
2009 was $16.7 million and $16.2 million, respectively.
In accordance with guidance related to accounting for impairment
or disposal of long-lived assets, long-lived assets such as
property, plant and equipment, and software are reviewed for
impairment whenever facts and circumstances indicate that the
carrying value may not be recoverable. When required, impairment
losses on assets to be held and used are recognized based on the
fair value of the asset. The fair value is determined based on
estimates of future cash flows, market value of similar assets,
if available, or independent appraisals, if required. If the
carrying amount of the long-lived asset is not recoverable from
its undiscounted cash flows, an impairment loss is recognized
for the difference between the carrying amount and fair value of
the asset.
Goodwill
and Intangible Assets
The Company does not amortize goodwill and other identifiable
intangible assets that have indefinite useful lives. Intangible
assets that have finite useful lives are amortized over their
estimated useful lives.
The Company analyzes goodwill and other finite-lived intangible
assets to determine any potential impairment loss annually in
the fourth quarter, unless conditions exist that require an
updated analysis on an interim basis. A fair value approach is
used to test goodwill for impairment. The fair value approach
compares estimates related to the fair value of the reporting
unit with the units carrying amount, including goodwill.
The fair value is determined using both the market approach and
the income approach which consists of projected discounted cash
flows. If the carrying amount of the reporting unit exceeds the
fair value, the amount of the impairment loss must be measured.
The Company has five reporting units that are tested for
impairment: Early Stage, and the four Late Stage reporting units
consisting of: Clinical and Data Monitoring; Project Management
and Late Phase Services; Regulatory, Site and Medical Affairs;
and Biostatistics and Statistical Programming. Reporting units
are defined as the components of operating segments for which
discrete financial information is available and regularly
reviewed by management.
Due to the inconsistent nature of the Early Stage business, both
within the Company and the industry, during the third quarter of
2010 the Company commenced an evaluation of strategic
alternatives for the Early Stage segment. Based upon this review
and other triggering events, the Company began, but was unable
to complete its goodwill impairment analysis, which was
completed during the fourth quarter of 2010. Also during the
fourth quarter of 2010, in addition to conducting its annual
impairment analysis for both the Early and Late Stage segments,
the Company made a decision to close the Early Stage portion of
its operations in Utrecht, The
F-10
Netherlands. As a result of the above events the Company
recorded a goodwill impairment charge of $7.3 million for
its Early Stage segment in the fourth quarter of 2010. At
December 31, 2009 the fair value of the Early Stage segment
exceeded the carrying value, resulting in no goodwill impairment
charge.
At December 31, 2010 and 2009, the fair value of all Late
Stage reporting units exceeded their respective carrying values,
resulting in no goodwill impairment charge.
Derivatives
From time to time, the Company may use derivative instruments to
manage exposure to interest rates and foreign currency.
Derivatives meeting the hedge criteria established in guidance
related to accounting for derivative instruments and hedging
activities, are recorded in the Consolidated Balance Sheets at
fair value at each balance sheet date. When the derivative is
entered into, the Company designates whether or not the
derivative instrument is an effective hedge of an asset,
liability or firm commitment and classifies the hedge as a cash
flow hedge or a fair value hedge. If the hedge is determined to
be an effective cash flow hedge, changes in the fair value of
the derivative instrument are recorded as a component of other
comprehensive income (loss). Changes in the value of fair value
hedges are recorded in results of operations.
Throughout 2010 and at December 31, 2010 the Company was
not a party to any hedge transactions. For parts of 2009 the
Company participated in foreign currency hedge agreements to
mitigate exposure on two intercompany notes denominated in
foreign currencies. The notes were either repaid in full or
significantly reduced in 2009. Due to the reduced exposure the
hedge agreements were terminated. The Company recorded losses of
$2.0 million related to the hedge agreements in 2009. The
hedge agreements were not designated for hedge accounting
treatment under accounting guidance related to derivatives and
all changes in the fair market value of the hedge were recorded
in the Companys Consolidated Statements of Operations.
Marketing
and Advertising Costs
Marketing and advertising costs include costs incurred to
promote the Companys business. Marketing and advertising
costs are expensed as incurred. Advertising expense incurred by
the Company was $1.6 million for the year ended
December 31, 2010 and $2.1 million for each of the
years ended December 31, 2009 and 2008.
Investigator
and Project Costs
In addition to various contract costs previously described, the
Company incurs costs, in excess of contract amounts, which are
reimbursable by its customers. Accounting guidance related to
income statement characterization of reimbursements received for
out-of-pocket
expenses incurred requires the Company to include amounts paid
to investigators and other
out-of-pocket
costs as reimbursable
out-of-pocket
revenues and reimbursable
out-of-pocket
expenses in the Consolidated Statements of Operations. In
certain contracts, these costs are fixed by the contract terms.
Accordingly, the Company recognizes these costs as part of net
service revenues and direct costs.
Net
Income (Loss) Per Share Data
Net income (loss) per basic share is computed using the weighted
average common shares outstanding. Net income per diluted share
is computed using the weighted average common shares and
potential common shares outstanding.
F-11
The weighted average shares used in computing net income (loss)
per diluted share have been calculated as follows:
Net
Income (Loss) Per Share Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
(In thousands)
|
|
|
Weighted average common shares outstanding
|
|
|
14,907
|
|
|
|
14,862
|
|
|
|
14,751
|
|
Stock options and non-vested restricted shares
|
|
|
|
|
|
|
130
|
|
|
|
242
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares
|
|
|
14,907
|
|
|
|
14,992
|
|
|
|
14,993
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options to purchase approximately 165,000 and
149,000 shares of common stock were outstanding during 2010
and 2009, respectively, but were not included in the computation
of earnings per diluted share because the effect would be
antidilutive. No options were antidilutive in 2008.
Under accounting guidance related to contingently convertible
instruments effect on diluted earnings per share because of the
Companys obligation to settle the par value of its
Convertible Notes (defined in Note 7, Debt) in cash, the
Company is not required to include any shares underlying the
Convertible Notes in its weighted average shares outstanding
used in calculating diluted earnings per share until the average
stock price per share for the quarter exceeds the $47.71
conversion price and only to the extent of the additional shares
that the Company may be required to issue in the event that the
Companys conversion obligation exceeds the principal
amount of the Convertible Notes converted. These conditions have
not been met as of December 31, 2010. At any such time in
the future that these conditions are met, only the number of
shares that would be issuable (under the treasury
method of accounting for the share dilution) will be included,
which is based upon the amount by which the average stock price
exceeds the conversion price. The following table provides
examples of how changes in the Companys stock price will
require the inclusion of additional shares in the denominator of
the weighted average shares outstanding assuming
dilution calculation. The table also reflects the impact on the
number of shares that the Company would expect to issue upon
concurrent settlement of the Convertible Notes and the bond
hedges and warrants mentioned below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incremental Shares
|
|
|
|
|
|
|
|
|
|
Total Treasury
|
|
|
Shares Due to the
|
|
|
Issued by the
|
|
|
|
Convertible Notes
|
|
|
|
|
|
Method Incremental
|
|
|
Company under Note
|
|
|
Company Upon
|
|
Share Price
|
|
Shares
|
|
|
Warrant Shares
|
|
|
Shares(1)
|
|
|
Hedges
|
|
|
Conversion(2)
|
|
|
$40.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$45.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$50.00
|
|
|
136,592
|
|
|
|
|
|
|
|
136,592
|
|
|
|
(136,592
|
)
|
|
|
|
|
$55.00
|
|
|
395,683
|
|
|
|
|
|
|
|
395,683
|
|
|
|
(395,683
|
)
|
|
|
|
|
$60.00
|
|
|
611,592
|
|
|
|
|
|
|
|
611,592
|
|
|
|
(611,592
|
)
|
|
|
|
|
$65.00
|
|
|
794,284
|
|
|
|
173,820
|
|
|
|
968,104
|
|
|
|
(794,284
|
)
|
|
|
173,820
|
|
$70.00
|
|
|
950,877
|
|
|
|
374,732
|
|
|
|
1,325,609
|
|
|
|
(950,877
|
)
|
|
|
374,732
|
|
|
|
|
(1) |
|
Represents the number of incremental shares that must be
included in the calculation of fully diluted shares under U.S.
Generally Accepted Accounting Principles. |
|
(2) |
|
Represents the number of incremental shares to be issued by the
Company upon conversion of the Convertible Notes, assuming
concurrent settlement of the bond hedges and warrants. |
Income
Taxes
The Company and its U.S. subsidiaries file a consolidated
U.S. federal income tax return. Other subsidiaries of the
Company file tax returns in their local jurisdictions.
The Company provides for income taxes on all transactions that
have been recognized in the Consolidated Financial Statements in
accordance with accounting guidance related to income taxes.
Accordingly, the impact of
F-12
changes in income tax laws on deferred tax assets and deferred
tax liabilities are recognized in net earnings in the period
during which such changes are enacted.
The Company records deferred tax assets and liabilities based on
temporary differences between the financial statement and tax
bases of assets and liabilities and for tax benefit
carryforwards using enacted tax rates in effect in the year in
which the differences are expected to reverse. Management
provides valuation allowances against deferred tax assets for
amounts that are not considered more likely than not to be
realized. The valuation of the deferred tax asset is dependent
on, among other things, the ability of the Company to generate a
sufficient level of future taxable income. In estimating future
taxable income, the Company has considered both positive and
negative evidence, such as historical and forecasted results of
operations, and has considered the implementation of prudent and
feasible tax planning strategies.
The Company follows accounting guidance related to accounting
for uncertainty in income taxes which requires significant
judgment in determining what constitutes an individual tax
position as well as assessing the outcome of each tax position.
Changes in judgments as to recognition or measurement of tax
positions can materially affect the estimate of the effective
tax rate, and, consequently, the Companys operating
results. The Company considers many factors when evaluating and
estimating tax positions and tax benefits, which may require
periodic adjustments and which may not accurately anticipate
actual outcomes. In addition, the calculation of tax liabilities
involves dealing with uncertainties in the application of
complex tax regulations in a multitude of jurisdictions. The
Company determines its liability for uncertain tax positions
globally. At December 31, 2010, the Company has recorded a
gross liability for uncertain tax positions of $1.1 million
(including interest). If events occur and the payment of these
amounts ultimately proves to be unnecessary, the reversal of
liabilities would result in tax benefits being recognized in the
period when it is determined the liabilities are no longer
necessary. If the calculation of liability related to uncertain
tax positions proves to be more or less than the ultimate
assessment, a tax expense or benefit to expense, respectively,
would result.
Stock
Options
The Company follows the accounting guidance related to
accounting for share-based payments. The Company generally uses
the straight-line method of recording compensation expense
relative to share-based payment, unless awards have graded
vesting features and the expense recorded under the
straight-line method is not adequate. In those situations,
compensation cost is recognized separately over each tranche.
Stock-based compensation expense is recorded primarily in
general and administrative expenses in the Companys
Consolidated Statements of Operations as the majority of the
stock option expense related to options granted to executives.
Restricted/Unrestricted
Stock
Non-vested stock (referred to as restricted stock in
the 1997 Plan) may also be granted pursuant to the 2007 Plan,
which replaced the 1997 Plan (defined in Note 8).
Non-vested shares typically vest ratably over a three-year
period, with shares restricted from transfer until vesting. In
2010, the Company granted 105,370 shares of restricted
stock compared to 86,250 shares in 2009 and
24,200 shares in 2008. If a participant ceases to be an
eligible employee prior to the lapsing of transfer restrictions,
such shares return to the Company without consideration.
Unrestricted stock also may be granted to key employees under
the 2007 Plan, which replaced the 1997 Plan. Unrestricted shares
vest immediately. The Company granted 3,000 shares of
unrestricted Common Stock in 2009. No shares of unrestricted
stock were granted in 2010 or 2008.
Use of
Estimates
The preparation of Consolidated Financial Statements in
conformity with accounting principles generally accepted in the
United States requires management to make estimates and
assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities
at the date of the Consolidated Financial Statements and the
reported amounts of revenues and expenses during the reporting
period. Actual results could differ from those estimates.
F-13
Subsequent
Events
The Company evaluates events or transactions occurring after the
balance sheet date through the date of issuance of the
Consolidated Financial Statements to determine whether events
require recognition or nonrecognition and disclosure.
Recognition is required for the effects of all subsequent events
that provide additional evidence about conditions that existed
at the date of the balance sheet, including estimates inherent
in the process of preparing financial statements. Nonrecognized
subsequent events may require disclosure. The Company has
evaluated subsequent events through the issuance date.
New
Accounting Pronouncements
In October 2009, the Financial Accounting Standards Board (FASB)
issued FASB ASU
2009-13,
Revenue Recognition (Topic 605) related to revenue
recognition for multiple deliverable revenue arrangements. The
guidance will be adopted as of the first fiscal year beginning
after June 15, 2010 (January 1, 2011 for the Company)
and is not expected to have a material impact on the
Companys consolidated financial statements.
In December 2009, the FASB issued FASB ASU
2009-17,
Consolidations (Topic 810), which codifies guidance related to
former Statement 167 and revises guidance issued under former
FIN46(R). This guidance changes the process for determining
which reporting entity, if any, has a controlling financial
interest that would require consolidation. The guidance is
effective at the start of the fiscal year beginning after
November 15, 2009 (January 1, 2010 for the Company).
The Company has adopted the guidance with no impact to its
consolidated financial statements.
In December 2010, the FASB issued FASB ASU
2010-28,
When to Perform Step 2 of the Goodwill Impairment Test for
Reporting Units With Zero or Negative Carrying Amounts. This
guidance requires, in cases where the carrying amount of a
reporting unit is zero or negative, to perform the second step
of impairment testing to measure any impairment loss when it is
more likely than not that an impairment exists. This ASU is
effective for impairment tests performed in fiscal years
beginning after December 15, 2010 (January 1, 2011 for
the Company).
|
|
2.
|
FAIR
VALUE OF FINANCIAL INSTRUMENTS
|
The Company follows accounting guidance related to fair value
measurements which defines fair value and requires that assets
and liabilities carried at fair value be classified and
disclosed in one of the following three categories:
Level 1: Quoted market prices in active
markets for identical assets or liabilities.
Level 2: Observable market based inputs
or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs that are not
corroborated by market data.
The Company generally applies fair value techniques on a
non-recurring basis associated with valuing potential impairment
loss related to goodwill and other long-lived assets. The
Company recorded an impairment loss of $7.3 million related
to its Early Stage goodwill (see Note 1 for further
discussion). The fair value measurement for the goodwill
impairment test considered significant unobservable inputs
(Level 3), consisting of both market approaches and an
income approach. The market approaches involved the use of;
market multiples of revenues and earnings before interest,
taxes, depreciation and amortization (EBITDA) for comparable
public companies or comparable company transactions; and a
market capitalization method. The income approach consisted of
projected discounted cash flows and was developed using
managements assumptions and projections of future revenue
growth, profit margins, discount rates, perpetuity growth rates
and capital expenditures. Assumptions used by management were
similar to those that would be used by market participants
performing valuations of this reporting unit.
F-14
The following table summarizes the carrying amounts and fair
values of certain financial assets and liabilities at
December 31, 2010:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Active Markets for
|
|
Significant Other
|
|
Significant
|
|
|
Carrying
|
|
Identical Assets
|
|
Observable Inputs
|
|
Unobservable Inputs
|
|
|
Amount
|
|
(Level 1)
|
|
(Level 2)
|
|
(Level 3)
|
|
|
(In thousands)
|
|
Money Market Accounts
|
|
$
|
6,509
|
|
|
$
|
6,509
|
|
|
$
|
|
|
|
$
|
|
|
The following table summarizes the carrying amounts and fair
values of certain financial assets and liabilities at
December 31, 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quoted Prices in
|
|
|
|
|
|
|
|
|
Active Markets for
|
|
Significant Other
|
|
Significant
|
|
|
Carrying
|
|
Identical Assets
|
|
Observable Inputs
|
|
Unobservable Inputs
|
|
|
Amount
|
|
(Level 1)
|
|
(Level 2)
|
|
(Level 3)
|
|
|
(In thousands)
|
|
Money Market Accounts
|
|
$
|
16,627
|
|
|
$
|
16,627
|
|
|
$
|
|
|
|
$
|
|
|
The Company adopted accounting guidance related to fair value
option for financial assets and liabilities and elected not to
apply the fair value option to any eligible financial
instruments. The carrying amounts of cash, accounts receivable,
accounts payable and accruals approximate fair value. The fair
value of the Companys Convertible Notes was approximately
94% and 89% of the par value at December 31, 2010 and 2009,
respectively. The bond hedges and warrants associated with the
Convertible Notes currently have no value.
Accounts receivable are billed according to terms defined in our
customer contracts. All unbilled accounts receivable are
expected to be collected within one year.
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
|
(In thousands)
|
|
|
Billed (net of allowance)
|
|
$
|
58,926
|
|
|
$
|
79,207
|
|
Unbilled
|
|
|
46,660
|
|
|
|
46,080
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
105,586
|
|
|
$
|
125,287
|
|
|
|
|
|
|
|
|
|
|
The Company maintains an allowance for doubtful accounts
receivable based on historical evidence of accounts receivable
collections and specific identification of accounts receivable
that might cause collection problems. The balance in allowance
for doubtful accounts receivable was as follows:
|
|
|
|
|
|
|
(In thousands)
|
|
|
Balance at December 31, 2007
|
|
$
|
954
|
|
Write-offs
|
|
|
(896
|
)
|
Expense
|
|
|
3,150
|
|
Foreign currency translation
|
|
|
(141
|
)
|
|
|
|
|
|
Balance at December 31, 2008
|
|
$
|
3,067
|
|
Write-offs
|
|
|
(1,317
|
)
|
Expense
|
|
|
847
|
|
Foreign currency translation
|
|
|
86
|
|
|
|
|
|
|
Balance at December 31, 2009
|
|
$
|
2,683
|
|
Write-offs
|
|
|
(997
|
)
|
Expense
|
|
|
1,230
|
|
Foreign currency translation
|
|
|
(32
|
)
|
|
|
|
|
|
Balance at December 31, 2010
|
|
$
|
2,884
|
|
|
|
|
|
|
F-15
|
|
4.
|
PROPERTY
AND EQUIPMENT
|
Property and equipment consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
|
(In thousands)
|
|
|
Furnishings, equipment and other
|
|
$
|
116,544
|
|
|
$
|
95,786
|
|
Construction in process
|
|
|
11,086
|
|
|
|
18,395
|
|
Equipment under capital leases
|
|
|
303
|
|
|
|
467
|
|
Less: accumulated depreciation and amortization
|
|
|
(71,035
|
)
|
|
|
(61,109
|
)
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
$
|
56,898
|
|
|
$
|
53,539
|
|
|
|
|
|
|
|
|
|
|
Depreciation expense for the years ended December 31, 2010,
2009 and 2008 was $12.3 million, $10.5 million and
$9.8 million, respectively.
|
|
5.
|
GOODWILL
AND AMORTIZABLE INTANGIBLE ASSETS
|
Goodwill consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Early Stage
|
|
|
Late Stage
|
|
|
Total
|
|
|
|
(In thousands)
|
|
|
Balance at December 31, 2008
|
|
$
|
11,547
|
|
|
$
|
224,782
|
|
|
$
|
236,329
|
|
Contingent consideration paid
|
|
|
5,039
|
|
|
|
|
|
|
|
5,039
|
|
Foreign currency fluctuations
|
|
|
1,727
|
|
|
|
494
|
|
|
|
2,221
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2009
|
|
$
|
18,313
|
|
|
$
|
225,276
|
|
|
$
|
243,589
|
|
Impairment charge
|
|
|
(7,263
|
)
|
|
|
|
|
|
|
(7,263
|
)
|
Foreign currency fluctuations
|
|
|
680
|
|
|
|
(817
|
)
|
|
|
(137
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2010
|
|
$
|
11,730
|
|
|
$
|
224,459
|
|
|
$
|
236,189
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The goodwill balances presented above are net of accumulated
amortization taken prior to the change in accounting guidance
related to goodwill and include impairment charges of
$7.3 million recorded in 2010 (see further details in
Note 1) and $78 million recorded in 2002.
F-16
Amortizable intangible assets consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
|
(In thousands)
|
|
|
Carrying amount:
|
|
|
|
|
|
|
|
|
Customer relationships
|
|
$
|
22,407
|
|
|
$
|
22,169
|
|
Completed technology
|
|
|
2,600
|
|
|
|
2,600
|
|
Backlog
|
|
|
6,200
|
|
|
|
6,200
|
|
Internally developed software(a)
|
|
|
18,212
|
|
|
|
17,963
|
|
|
|
|
|
|
|
|
|
|
Total carrying amount
|
|
$
|
49,419
|
|
|
$
|
48,932
|
|
Accumulated Amortization:
|
|
|
|
|
|
|
|
|
Customer relationships
|
|
$
|
(11,018
|
)
|
|
$
|
(8,098
|
)
|
Completed technology
|
|
|
(2,292
|
)
|
|
|
(1,771
|
)
|
Backlog
|
|
|
(6,089
|
)
|
|
|
(5,936
|
)
|
Internally developed software(a)
|
|
|
(16,711
|
)
|
|
|
(16,187
|
)
|
|
|
|
|
|
|
|
|
|
Total accumulated amortization
|
|
$
|
(36,110
|
)
|
|
$
|
(31,992
|
)
|
|
|
|
|
|
|
|
|
|
Net amortizable intangible assets
|
|
$
|
13,309
|
|
|
$
|
16,940
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a) |
|
Internally developed software is included in Other Assets in the
Companys Consolidated Balance Sheets. |
Amortizable intangible assets consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Internally
|
|
|
|
Customer
|
|
|
Completed
|
|
|
|
|
|
Developed
|
|
|
|
Relationships
|
|
|
Technology
|
|
|
Backlog
|
|
|
Software(a)
|
|
|
|
(In thousands)
|
|
|
Balance at December 31, 2008
|
|
$
|
17,004
|
|
|
$
|
1,348
|
|
|
$
|
679
|
|
|
$
|
1,858
|
|
Additional amounts acquired
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
536
|
|
Foreign currency fluctuations
|
|
|
662
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2009 amortization
|
|
|
(3,595
|
)
|
|
|
(519
|
)
|
|
|
(415
|
)
|
|
|
(618
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2009
|
|
$
|
14,071
|
|
|
$
|
829
|
|
|
$
|
264
|
|
|
$
|
1,776
|
|
Additional amounts acquired
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
249
|
|
Foreign currency fluctuations
|
|
|
238
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010 amortization
|
|
|
(2,920
|
)
|
|
|
(521
|
)
|
|
|
(153
|
)
|
|
|
(524
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2010
|
|
$
|
11,389
|
|
|
$
|
308
|
|
|
$
|
111
|
|
|
$
|
1,501
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average useful lives
|
|
|
13 years
|
|
|
|
5 years
|
|
|
|
7 years
|
|
|
|
5 years
|
|
Amortization expense is determined on a straight line basis for
internally developed software and an accelerated method for
remaining amortizable intangible assets.
F-17
Amortization expense for the next five years relating to these
amortizable intangible assets is estimated to be as follows:
|
|
|
|
|
|
|
(In thousands)
|
|
|
2011:
|
|
$
|
3,426
|
|
2012:
|
|
|
2,326
|
|
2013:
|
|
|
1,503
|
|
2014:
|
|
|
951
|
|
2015
|
|
|
720
|
|
Thereafter:
|
|
|
4,383
|
|
|
|
|
|
|
Total
|
|
$
|
13,309
|
|
|
|
|
|
|
|
|
6.
|
OTHER
ACCRUED LIABILITIES
|
Other accrued liabilities consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
|
(In thousands)
|
|
|
Accrued compensation and related payroll withholdings and taxes
|
|
$
|
18,427
|
|
|
$
|
22,428
|
|
Income tax payable
|
|
|
590
|
|
|
|
4,369
|
|
Interest payable
|
|
|
2,204
|
|
|
|
2,390
|
|
Other
|
|
|
21,044
|
|
|
|
30,480
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
42,265
|
|
|
$
|
59,667
|
|
|
|
|
|
|
|
|
|
|
Through March 2010, the Company was party to a credit agreement
(including all amendments, the Old Facility). The
Old Facility was comprised of a revolving loan commitment with a
maximum borrowing capacity of $53.5 million that would have
expired in August 2011. The Old Facility contained various
affirmative and negative covenants including financial covenants
regarding maximum leverage ratio, minimum interest coverage
ratio and limitations on capital expenditures.
In March 2010, the Company terminated the Old Facility and
entered into a new credit agreement (the Facility).
The Facility is comprised of a $35 million revolving loan
commitment, with up to $10 million of such commitment
available for issuance of letters of credit and up to
$5 million of such commitment available for
same-day
swing line loans. At the Companys request and with the
consent of the current lender or additional lenders, the total
commitment may be increased by, or incremental term loans may be
obtained for, up to an additional $15 million. At the
Companys election, loans under the Facility are available
either at (i) an adjusted base rate plus an applicable
margin or (ii) an adjusted LIBOR rate plus an applicable
margin. The applicable margin for each interest rate is
calculated in accordance with the terms of the Facility.
The Facility, as amended on April 27, 2010, matures on
March 31, 2015. Before this amendment, the Facility had the
potential for accelerated maturity on January 15, 2012 in
the event that five percent (5%) or more of the currently
outstanding principal amount of the Convertible Notes discussed
below had not been redeemed or repaid in full on or prior to
January 15, 2012. The Facility was amended again on
January 21, 2011 (Amendment No. 2) to increase
the Total Leverage Ratio for certain periods and
also contemplates certain additional add-backs to
Consolidated EBITDA for certain cash and non-cash
charges.
Borrowings under the Facility are collateralized by
substantially all of the Companys assets pursuant to the
terms of a Pledge and Security Agreement. The Facility contains
various affirmative and negative covenants including those
regarding limitations on the Companys ability to incur
certain indebtedness, limitations on certain investments,
limitations on capital expenditures in any fiscal year and
limitations on certain acquisitions and asset sales outside the
ordinary course of business as well as financial covenants
regarding limitations on the Companys
F-18
total leverage ratio, senior secured leverage ratio and interest
coverage ratio. The Company is in compliance with the covenants
as of December 31, 2010.
In connection with the termination of the Old Facility, the
Company wrote off approximately $665,000 in unamortized fees
during the first quarter of 2010.
The Company also maintains an existing $5.0 million
Multicurrency Facility that is renewable annually and is used in
connection with the Companys European operations.
No amounts were outstanding under the revolving credit loan
portion of the Facility, the Old Facility or the Multicurrency
Facility at December 31, 2010 and 2009.
In July 2007, the Company entered into a Purchase Agreement with
UBS Securities LLC (the Underwriter) for the issuance and sale
by the Company of $200 million, including a
$25 million over-allotment of the Companys
3.375% Convertible Notes (Convertible Notes). The
Convertible Notes have a maturity date of July 15, 2012 and
were sold to the Underwriters at a price of $1,000 per
Convertible Note, less an underwriting discount of 3% per
Convertible Note. In connection with this issuance, the Company
entered into convertible note hedge transactions with the
participating Underwriter and JP Morgan Chase (collectively, the
counterparties). The convertible note hedge transactions are
comprised of purchased call options and sold warrants. The
purchased call options are expected to reduce exposure to
potential dilution upon the conversion of the Convertible Notes.
The Company also entered into warrant transactions with such
counterparties. The sold warrants have an exercise price that is
approximately 70% higher than the closing price of the
Companys common stock on the date the Convertible Notes
were priced. The warrants are expected to provide the Company
with some protection against increases in our stock price over
the conversion price per share.
The discount on the Convertible Notes and the adjusted debt
issuance costs are being amortized into interest expense over
the term of the Convertible Notes using the effective interest
rate method. Application of accounting guidance for convertible
debt instruments resulted in an adjusted liability amount of
$162.3 million as of July 16, 2007 (issuance date) and
an increase to additional paid in capital for the conversion
option, net of equity issuance costs, of $36.4 million.
Subsequent to issuance, the Company has repurchased in the open
market a portion of its outstanding Convertible Notes with a par
value of $12 million and $45.5 million (respectively
in 2010 and 2009) for cash in the amount of
$11.1 million and $36.5 million, respectively. The
amortized book value of the repurchased debt was
$10.8 million in 2010 and $40.0 million in 2009,
resulting in a net loss of approximately $71,000 in 2010 and a
net gain of $2.9 million for 2009. Debt issuance costs with
a carrying value of $154,000 and $840,000 were written off in
conjunction with these transactions for 2010 and 2009
respectively. Consideration in the amount of $348,000
(2010) and $204,000 (2009) was allocated to the
retirement of the equity component and was recorded as a
reduction of paid in capital. As a result of the repurchases,
the related bond hedges and warrant agreements were
proportionately reduced at a net cost of approximately $3,000
and $97,000 in 2010 and 2009, respectively and were also
recorded as a reduction to additional paid in capital. The
Companys Convertible Notes had an outstanding par value of
$142.5 million and $154.5 million at December 31,
2010 and 2009, respectively.
The carrying amounts of the equity and debt components were as
follows:
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
|
(In thousands)
|
|
|
Equity component, carrying amount
|
|
$
|
35,860
|
|
|
$
|
36,207
|
|
|
|
|
|
|
|
|
|
|
Principal component, at par
|
|
$
|
142,500
|
|
|
$
|
154,500
|
|
Unamortized discount
|
|
|
(9,418
|
)
|
|
|
(16,192
|
)
|
|
|
|
|
|
|
|
|
|
Principal component, carrying amount
|
|
$
|
133,082
|
|
|
$
|
138,308
|
|
|
|
|
|
|
|
|
|
|
The net carrying amounts of the Convertible Notes are classified
as long-term in the accompanying Consolidated Balance Sheets.
The debt discount is being amortized, using the effective
interest rate method, over
F-19
the term of the Convertible Notes which mature on July 15,
2012. Interest expense on the 3.375% Convertible Notes has
been recorded at the effective rate of 8.02%.
Interest expense recognized related to the Convertible Notes was
as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Years Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
(In thousands)
|
|
|
Interest cost at coupon rate
|
|
$
|
4,972
|
|
|
$
|
6,096
|
|
|
$
|
6,750
|
|
Discount amortization
|
|
|
5,667
|
|
|
|
6,456
|
|
|
|
6,631
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total interest expense recognized
|
|
$
|
10,639
|
|
|
$
|
12,552
|
|
|
$
|
13,381
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Company capitalized interest of approximately $623,000 in
2010. Capitalized interest was not material in 2009 and 2008.
|
|
8.
|
EMPLOYEE
BENEFIT PLANS
|
401(k)
Plan
The Company maintains a 401(k) retirement plan covering
substantially all U.S. associates that meet minimum age
requirements. The Company historically has made a matching
contribution of 50% of each participants contribution of
up to 6% of salary. This match was temporarily suspended
beginning in July 2009 and resumed in April 2010. The
Companys matching contributions to this plan totaled
approximately $1,200,000, $1,063,000, and $1,902,000 for the
years ended December 31, 2010, 2009, and 2008, respectively.
Stock
Option and Stock Incentive Plan
In 1997, the Company established the 1997 Stock Option and Stock
Incentive Plan (including amendments, the 1997 Plan)
that, as amended, provided for the issuance of up to
3,000,000 shares of the Companys Common Stock,
including incentive and non-qualified stock options, restricted
and unrestricted shares, and stock appreciation rights. The 1997
Plan expired by its terms on August 14, 2007. See below for
a discussion of the successor plan. Participation in the 1997
Plan was at the discretion of the Board of Directors
Management Development and Compensation Committee. Prior to
August 2002, the 1997 Plan was administered by the Board of
Directors Compensation Subcommittee. The exercise price of
incentive stock options granted under the 1997 Plan must be no
less than the fair market value of the Common Stock, as
determined under the 1997 Plan provisions, at the date the
option is granted (110% of fair market value for shareholders
owning more than 10% of the Companys Common Stock). The
exercise price of non-qualified stock options must be no less
than 95% of the fair market value of the Common Stock at the
date the option is granted. The vesting provisions of the
options granted under the 1997 Plan are determined at the
discretion of the Management Development and Compensation
Committee. The options generally expire either 90 days
after termination of employment or, if earlier, ten years after
date of grant. No options under this 1997 plan could be granted
after its expiration date in August 2007.
Non-vested stock (referred to as restricted stock in
the 1997 Plan) may also be granted pursuant to the 1997 Plan.
Restricted shares typically vest ratably over a three year
period, with shares restricted from transfer until vesting. If a
participant ceases to be an eligible employee prior to the
lapsing of transfer restrictions, such shares return to the
Company without consideration. Unrestricted stock may also be
granted to key employees under the 1997 Plan. Unrestricted
shares vest immediately.
At the Annual Meeting of Shareholders on May 10, 2007,
shareholders of the Company approved the 2007 Stock Incentive
Plan (the 2007 Plan). Under the 2007 Plan, all
employees of the Company and its subsidiaries will be eligible
to receive awards. The 2007 Plan is an omnibus stock
plan that provides a variety of equity award vehicles to
maintain flexibility. The 2007 Plan will permit the grant of
stock options, stock appreciation rights, restricted stock
awards, restricted stock units and stock awards. A maximum of
one million shares will be available for grants of all equity
awards under the 2007 Plan. No shares of Common Stock were
granted in 2007 under the 2007 Plan.
F-20
In the first quarter of 2008, the Company issued
1,850 shares of non-vested stock which vests over a
12-month
period. Under the terms of the 2007 Plan, the associates that
received the 1,850 shares are considered retirement
eligible, which is defined as at least 55 years of
age and 10 years of service with the Company or
65 years of age. Therefore, the entire expense for these
shares was recorded in the first quarter of 2008. The Company
did not issue any shares of non-vested stock in 2009 or 2010.
Unrestricted stock may also be granted to key employees under
the 2007 Plan. Unrestricted shares vest immediately. In the
third quarter of 2009, the Company granted 3,000 shares of
Common Stock. The Company did not issue any shares of
unrestricted stock in 2008 or 2010.
In 2008, the Company issued 7,100 shares of time-vested
restricted stock units (RSUs) under the 2007 Plan. The RSUs vest
over a variety of periods ranging from immediate to
36 months. Of the 7,100 shares awarded, 2,400 were
issued to retirement eligible associates and resulted in
immediate vesting and expense recognition. The expense
recognition for the remaining balance of RSUs issued will be
recorded on a straight line basis over the term of the specific
vesting period. In 2009, the Company issued 53,050 shares
of time-vested RSUs. Of this award, 49,050 shares vest in
their entirety after 18 months and the remaining
4,000 shares vest in their entirety after 60 months.
Of the 53,050 shares awarded, 5,000 RSUs were issued to
retirement eligible associates and resulted in immediate vesting
and expense recognition. The expense for the remaining RSUs will
be recorded on a straight-line basis over the vesting period. In
2010, the Company issued 44,586 shares of time-vested RSUs.
Of this award, 26,853 shares vest in their entirety after
18 months, 15,233 shares split-vest over
24 months and the remaining 2,500 shares vest in their
entirety after 15 months. Of the 44,586 shares
awarded, 5,971 RSUs were issued to retirement eligible
associates and resulted in immediate vesting and expense
recognition. The expense for the remaining RSUs will be recorded
on a straight-line basis over the vesting period.
Also, in the first six months of 2008, the Company issued
15,250 shares of performance-based RSUs under the 2007
Plan. The vesting of these shares is dependent upon a
performance condition; the Company meeting a certain EPS target
for 2008, and a service condition; as 33% vest on March 15,
2009, 33% vest on January 1, 2010, and 33% vest on
January 1, 2011. If the performance condition is not met at
least at the 90% of target level, the award does not vest. If
the performance condition is met at greater than 90% of target
level but below 100% of target level, the number of shares is
adjusted to 50% of the original award. Of the total of
15,250 shares issued, 8,550 were issued in the first
quarter of 2008 to retirement eligible associates. Under the
terms of the award, regardless of whether or not the performance
condition is achieved, should an event similar to retirement
occur during the first half of 2008, one-half of the RSUs
granted would immediately vest. Similarly, should an event
similar to retirement occur during the second half of 2008, the
full amount of the RSUs granted would immediately vest. The
Company therefore recorded one-half of the expense for the
retirement eligible associates in the first quarter of 2008 and
recorded the second half of the expense in the third quarter of
2008. Expense for non retirement-eligible associates is being
recorded over the vesting period (33 months). In the fourth
quarter of 2008, the Company determined that the performance
conditions were not met and the retirement eligible associates
had not retired. Accordingly, none of the granted shares will
vest and therefore all previously recorded expense was reversed.
In 2009, the Company issued 33,200 shares of
performance-based RSUs. Of this award, the vesting of 27,200 of
these shares is dependent upon a performance condition, the
Company meeting a certain EPS target for 2009, and a service
condition, as 33% vest in March 2010, 33% vest in January 2011,
and 33% vest in January 2012. If the performance condition is
not met at least at the 90% of target level, the award does not
vest. If the performance condition is met at greater than 90% of
target level but below 100% of target level, the number of
shares is adjusted to 50% of the original award. Of the total of
33,200 shares issued, 18,000 were issued to retirement
eligible associates. Under the terms of the award, regardless of
whether or not the performance condition is achieved, should an
event similar to retirement occur during the first half of 2009,
one-half of the RSUs granted would immediately vest. Similarly,
should an event similar to retirement occur during the second
half of 2009, the full amount of the RSUs granted would
immediately vest. The Company therefore recorded one-half of the
expense for the retirement eligible associates in the first
quarter of 2009 and recorded the second half of the expense in
the third quarter of 2009. Expense for non retirement-eligible
associates is being recorded over the vesting period. In the
fourth quarter of 2009, the Company determined that the
performance conditions were not met and the retirement eligible
associates had not retired. Accordingly, none of the granted
shares will vest and therefore all previously recorded expense
was reversed.
F-21
In 2010, the Company issued 60,784 shares of
performance-based RSUs. The vesting of these shares is dependent
upon a performance condition, the Company meeting a certain EPS
target for 2010, and a service condition, as 33% vest in March
2011, 33% vest in January 2012, and 33% vest in January 2013. If
the performance condition is not met at least at the 90% of
target level, the award does not vest. If the performance
condition is met at greater than 90% of target level but below
100% of target level, the number of shares is adjusted to
between 50% and 90% of the original award based upon the target
tier level achieved. Of the total of 60,784 shares issued,
27,362 were issued to retirement eligible associates. Under the
terms of the award, regardless of whether or not the performance
condition is achieved, should an event similar to retirement
occur during the first half of 2010, one-half of the RSUs
granted would immediately vest. Similarly, should an event
similar to retirement occur during the second half of 2010, the
full amount of the RSUs granted would immediately vest. The
Company therefore recorded one-half of the expense for the
retirement eligible associates in the first quarter of 2010 and
recorded the second half of the expense in the third quarter of
2010. Expense for non retirement-eligible associates is being
recorded over the vesting period. In the fourth quarter of 2010,
the Company determined that the performance conditions were not
met and the retirement eligible associates had not retired.
Accordingly, none of the granted shares will vest and therefore
all previously recorded expense was reversed.
Stock-based compensation expense related to stock options was
approximately $358,000, $329,000 and $786,000 in 2010, 2009 and
2008, respectively. In 2010, stock-based compensation expense
caused net loss to increase by approximately $259,000.
Stock-based compensation expense in 2009 and 2008 caused net
income to decrease by approximately $256,000 and $626,000,
respectively. Stock-based compensation expense is recorded
primarily in general and administrative expenses in the
Companys Consolidated Statements of Operations as the
majority of the stock option expense relates to options granted
to executives.
The weighted average fair value of the options granted in 2010,
2009 and 2008 was estimated as $7.73, $6.03 and $18.65,
respectively, on the date of grant using the Black-Scholes
option-pricing model with the following assumptions:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
2009
|
|
2008
|
|
Expected dividend yield
|
|
|
0
|
%
|
|
|
0
|
%
|
|
|
0
|
%
|
Risk-free interest rate
|
|
|
1.8
|
%
|
|
|
2.2
|
%
|
|
|
3.6
|
%
|
Expected volatility
|
|
|
69.7
|
%
|
|
|
70.9
|
%
|
|
|
52.0
|
%
|
Expected holding period
|
|
|
3.2 years
|
|
|
|
3.2 years
|
|
|
|
5.0 years
|
|
The expected volatility is based on the Companys stock
price over a historical period which approximates the expected
term of the option as well as a comparison to volatility for
other companies in the Companys industry and expectations
of future volatility. The risk free interest rate is based on
the implied yield in U.S Treasury issues with a remaining term
approximating the expected term of the option. The expected
option term is calculated as the historic weighted average life
of similar awards.
As of December 31, 2010, there was approximately $839,000
of total unrecognized compensation cost, $408,000 of which
relates to options and $431,000 of which relates to non-vested
stock. The cost is expected to be recognized over a weighted
average period of 2.0 years for options and 1.3 years
for non-vested stock.
In addition, stock compensation accounting guidance also
requires the benefits of tax deductions in excess of recognized
compensation expense to be reported as a financing cash flow,
rather than as an operating cash flow. This requirement reduced
net operating cash flows and increased net financing cash flows
by approximately $11,000, $2,000 and $175,000 in 2010, 2009 and
2008, respectively.
F-22
Aggregate stock option activity during 2010, 2009 and 2008 was
as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
Average
|
|
|
Aggregate
|
|
|
|
|
|
|
Average
|
|
|
Remaining
|
|
|
Intrinsic
|
|
|
|
Shares
|
|
|
Exercise Price
|
|
|
Contractual Life
|
|
|
Value
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands)
|
|
|
Options outstanding at Dec. 31, 2007
|
|
|
543,007
|
|
|
$
|
13.33
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
68,000
|
|
|
|
38.32
|
|
|
|
|
|
|
|
|
|
Canceled
|
|
|
(17,290
|
)
|
|
|
24.94
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(179,040
|
)
|
|
|
12.52
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options outstanding at Dec. 31, 2008
|
|
|
414,677
|
|
|
$
|
17.35
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
54,250
|
|
|
|
12.37
|
|
|
|
|
|
|
|
|
|
Canceled
|
|
|
(53,275
|
)
|
|
|
25.79
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(35,777
|
)
|
|
|
6.95
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options outstanding at Dec. 31, 2009
|
|
|
379,875
|
|
|
$
|
16.44
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
73,500
|
|
|
|
11.36
|
|
|
|
|
|
|
|
|
|
Canceled
|
|
|
(35,290
|
)
|
|
|
20.50
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(20,935
|
)
|
|
|
7.63
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options outstanding at Dec. 31, 2010
|
|
|
397,150
|
|
|
$
|
15.60
|
|
|
$
|
5.19
|
|
|
$
|
560
|
|
Exercisable at Dec. 31, 2010
|
|
|
331,384
|
|
|
$
|
15.94
|
|
|
$
|
4.42
|
|
|
$
|
481
|
|
The intrinsic value of options exercised was approximately
$119,000 in 2010, $268,000 in 2009 and $6.2 million in 2008.
At December 31, 2009, the aggregate intrinsic value of
options outstanding was $2.3 million and the aggregate
intrinsic value of options exercisable was $2.2 million.
Intrinsic value for stock options is calculated based on the
difference between the exercise price of the underlying awards
and the quoted price of the Companys Common Stock as of
the reporting date. Substantially all of the outstanding options
are expected to vest.
Options Outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average
|
|
|
Weighted
|
|
|
|
Outstanding at
|
|
|
Remaining
|
|
|
Average
|
|
Range of Exercise Price
|
|
December 31, 2010
|
|
|
Contractual Life
|
|
|
Exercise Price
|
|
|
$ 3.46 - $ 6.92
|
|
|
40,600
|
|
|
|
2.64
|
|
|
$
|
5.90
|
|
$ 6.93 - $10.38
|
|
|
146,825
|
|
|
|
5.19
|
|
|
|
8.47
|
|
$10.39 - $13.83
|
|
|
44,750
|
|
|
|
5.64
|
|
|
|
11.85
|
|
$13.84 - $17.29
|
|
|
42,000
|
|
|
|
8.26
|
|
|
|
14.89
|
|
$17.30 - $20.75
|
|
|
37,975
|
|
|
|
0.73
|
|
|
|
19.76
|
|
$20.76 - $24.21
|
|
|
8,000
|
|
|
|
8.11
|
|
|
|
22.28
|
|
$24.22 - $27.67
|
|
|
|
|
|
|
|
|
|
|
|
|
$27.68 - $31.13
|
|
|
12,000
|
|
|
|
5.98
|
|
|
|
30.06
|
|
$31.14 - $34.59
|
|
|
35,000
|
|
|
|
5.93
|
|
|
|
32.65
|
|
$34.60 - $60.00
|
|
|
30,000
|
|
|
|
7.37
|
|
|
|
37.54
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
397,150
|
|
|
|
5.19
|
|
|
$
|
15.60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-23
Options Exercisable:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
Exercisable at
|
|
|
Average
|
|
|
|
|
Range of Exercise Price
|
|
December 31, 2010
|
|
|
Exercise Price
|
|
|
|
|
|
$ 3.46 - $ 6.92
|
|
|
40,600
|
|
|
$
|
5.90
|
|
|
|
|
|
$ 6.93 - $10.38
|
|
|
115,325
|
|
|
|
8.49
|
|
|
|
|
|
$10.39 - $13.83
|
|
|
25,750
|
|
|
|
11.63
|
|
|
|
|
|
$13.84 - $17.29
|
|
|
36,934
|
|
|
|
14.74
|
|
|
|
|
|
$17.30 - $20.75
|
|
|
37,975
|
|
|
|
19.76
|
|
|
|
|
|
$20.76 - $24.21
|
|
|
6,200
|
|
|
|
22.40
|
|
|
|
|
|
$24.22 - $27.67
|
|
|
|
|
|
|
|
|
|
|
|
|
$27.68 - $31.13
|
|
|
9,600
|
|
|
|
30.06
|
|
|
|
|
|
$31.14 - $34.59
|
|
|
35,000
|
|
|
|
32.65
|
|
|
|
|
|
$34.60 - $60.00
|
|
|
24,000
|
|
|
|
37.48
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
331,384
|
|
|
$
|
15.94
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At December 31, 2009, 336,425 options were exercisable with
a weighted-average exercise price of $15.33. At
December 31, 2008, 325,977 options were exercisable with a
weighted-average exercise price of $14.93.
Restricted/Unrestricted
Stock
The Company has granted awards of restricted shares to certain
executives pursuant to the 1997 Plan. Such shares generally vest
ratably over a three-year period, with shares restricted from
transfer until vesting. If a participant ceases to be an
eligible employee prior to the lapsing of transfer restrictions,
such shares return to the Company without consideration.
Compensation expense related to restricted and unrestricted
stock awards consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
(In thousands)
|
|
|
Restricted stock
|
|
$
|
556
|
|
|
$
|
315
|
|
|
$
|
244
|
|
Unrestricted stock
|
|
|
|
|
|
|
35
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stock based compensation
|
|
$
|
556
|
|
|
$
|
350
|
|
|
$
|
244
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-24
A summary of restricted stock activity is as follows:
|
|
|
|
|
|
|
Shares
|
|
|
Outstanding at December 31, 2007
|
|
|
125
|
|
Granted
|
|
|
24,200
|
|
Vested
|
|
|
(125
|
)
|
Canceled
|
|
|
(15,250
|
)
|
|
|
|
|
|
Outstanding at December 31, 2008
|
|
|
8,950
|
|
Granted
|
|
|
86,250
|
|
Vested
|
|
|
(6,084
|
)
|
Canceled
|
|
|
(36,800
|
)
|
|
|
|
|
|
Outstanding at December 31, 2009
|
|
|
52,316
|
|
Granted
|
|
|
105,370
|
|
Vested
|
|
|
(14,183
|
)
|
Canceled
|
|
|
(63,394
|
)
|
|
|
|
|
|
Outstanding at December 31, 2010
|
|
|
80,109
|
|
|
|
|
|
|
The weighted-average per share fair value of restricted shares
vested was $15.74 in 2010, $43.32 in 2009 and $24.47 in 2008.
The weighted-average per share fair value of restricted shares
granted was $15.54 in 2010 and $15.02 in 2009.
In 2009, the Company initiated a series of measures to achieve
operating efficiencies and reduce its cost structure. These
measures included workforce reductions, furloughs, reduction in
work week, wage and hiring freezes, elimination of a portion of
employee benefits, strict controls over discretionary spending
and facilities closures, among other items. Throughout 2009 the
Company recorded a total of $10.2 million of expense for
these restructuring efforts, of the total restructuring program
in 2009 almost 60% related to the Late Stage segment and 40%
related to the Support and Other segment. Of this amount,
approximately $3.8 million was outstanding at
December 31, 2009 and was subsequently paid in full during
2010.
In its continuing efforts to achieve operating efficiencies and
reduce its cost structure the Company has accrued approximately
$3.0 million in the fourth quarter of 2010 for anticipated
severance costs related to the closure of the Early Stage
portion of operations at its Utrecht, The Netherlands (Utrecht)
location. The Companys plan for closure has received local
statutory approval. Early Stage operations will continue to take
place at Utrecht through at least a portion of the first quarter
of 2011 as the Company works with existing customers to either
complete, or possibly transition ongoing studies to other Early
Stage locations of the Company. Due to the ongoing studies,
other costs related to the Early Stage closure cannot be
identified and estimated at this time. Late Stage operations at
the Utrecht facility are not anticipated to be materially
affected by the Early Stage closure.
F-25
|
|
10.
|
COMMITMENTS
AND CONTINGENCIES
|
Leases
The Company leases facilities, office equipment and computers
under agreements that are classified as either capital or
operating leases. The leases have initial terms that range from
two to seven years, with eight facility leases that have
provisions to extend the leases for an additional three to five
years. Future minimum payments, by year and in the aggregate,
under non-cancelable capital and operating leases with initial
or remaining terms of one year or more, are as follows at
December 31, 2010:
|
|
|
|
|
|
|
|
|
|
|
Capital
|
|
|
Operating
|
|
|
|
Leases
|
|
|
Leases
|
|
|
|
(In thousands)
|
|
|
2011
|
|
$
|
35
|
|
|
$
|
17,127
|
|
2012
|
|
|
|
|
|
|
15,303
|
|
2013
|
|
|
|
|
|
|
10,892
|
|
2014
|
|
|
|
|
|
|
8,654
|
|
2015
|
|
|
|
|
|
|
8,482
|
|
thereafter
|
|
|
|
|
|
|
17,974
|
|
|
|
|
|
|
|
|
|
|
Total minimum lease payments
|
|
|
35
|
|
|
$
|
78,432
|
|
|
|
|
|
|
|
|
|
|
Amounts representing interest
|
|
|
(1
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Present value of net minimum lease payments
|
|
|
34
|
|
|
|
|
|
Current portion
|
|
|
34
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Obligations under capital leases, less current portion
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rental expense under operating leases for 2010, 2009 and 2008
was $17.2 million, $18.7 million and
$16.9 million, respectively.
Protective
Compensation and Benefit Agreements
The Company has entered into Protective Compensation and Benefit
Agreements with certain associates, including all Executive
Officers of the Company. These Agreements, subject to annual
review by the Companys Board of Directors, expire on the
last day of the fiscal year, and are automatically extended in
one-year increments unless canceled by the Company. These
Agreements provide for specified benefits in the event of a
change in control, as defined in the Agreements. At
December 31, 2010, the maximum amount which could be
required to be paid under these Agreements, if such events
occur, is approximately $8.9 million.
Legal
Proceedings
In the normal course of business, the Company is a party to
various claims and legal proceedings. The Company records a
reserve for these matters when an adverse outcome is probable
and the amount of the potential liability is reasonably
estimable. Although the ultimate outcome of these matters is
currently not determinable, management of the Company, after
consultation with legal counsel, does not believe that the
resolution of these matters will have a material effect upon the
Companys financial condition, results of operations or
cash flows for an interim or annual period.
Anti-takeover
Provisions
The Company has adopted a shareholder rights plan that may have
anti-takeover effects which will make an acquisition of the
Company by another company more difficult. The Companys
shareholder rights plan provides that, in the event any person
or entity acquires 15% or more of the Companys outstanding
Common Stock, shareholders of the Company will be entitled to
purchase shares of Common Stock, or in certain instances shares
of the acquirer, at a discounted price. The rights are intended
to discourage a significant share acquisition, merger or tender
offer involving the Companys Common Stock by increasing
the cost of effecting any such transaction and,
F-26
accordingly, could have an adverse impact on a takeover attempt
that a shareholder might consider to be in its best interests.
The provision for income taxes (benefit) consisted of the
following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Years Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
(In thousands)
|
|
|
Current:
|
|
|
|
|
|
|
|
|
|
|
|
|
Federal
|
|
$
|
(1,084
|
)
|
|
$
|
(4,519
|
)
|
|
$
|
2,908
|
|
State and local
|
|
|
272
|
|
|
|
(586
|
)
|
|
|
324
|
|
Foreign
|
|
|
9,743
|
|
|
|
14,401
|
|
|
|
19,702
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subtotal
|
|
|
8,931
|
|
|
|
9,296
|
|
|
|
22,934
|
|
Deferred:
|
|
|
|
|
|
|
|
|
|
|
|
|
Federal
|
|
|
(6,977
|
)
|
|
|
4,131
|
|
|
|
(3,394
|
)
|
State and local
|
|
|
(777
|
)
|
|
|
164
|
|
|
|
(828
|
)
|
Foreign
|
|
|
(1,851
|
)
|
|
|
(157
|
)
|
|
|
(2,523
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subtotal
|
|
|
(9,605
|
)
|
|
|
4,138
|
|
|
|
(6,745
|
)
|
Benefit applied to reduce goodwill
|
|
|
|
|
|
|
|
|
|
|
320
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total provision (benefit)
|
|
$
|
(674
|
)
|
|
$
|
13,434
|
|
|
$
|
16,509
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The sources of income (loss) before income taxes are presented
as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
(In thousands)
|
|
|
United States
|
|
$
|
(37,878
|
)
|
|
$
|
(19,124
|
)
|
|
$
|
4,406
|
|
Foreign
|
|
|
32,645
|
|
|
|
47,795
|
|
|
|
35,246
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes
|
|
$
|
(5,233
|
)
|
|
$
|
28,671
|
|
|
$
|
39,652
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Companys consolidated effective income tax rate
differed from the U.S. Federal statutory income tax rate of
34% as set forth below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
(In thousands)
|
|
|
Income tax expense at the U.S. Federal statutory rate
|
|
|
(1,779
|
)
|
|
|
9,748
|
|
|
|
13,483
|
|
Effects of foreign taxes, net of foreign tax credits and
deductions
|
|
|
(1,562
|
)
|
|
|
(1,867
|
)
|
|
|
794
|
|
State and local income taxes, net of Federal benefit
|
|
|
179
|
|
|
|
(389
|
)
|
|
|
(713
|
)
|
Change in Valuation Allowances
|
|
|
(2,171
|
)
|
|
|
(811
|
)
|
|
|
|
|
Effects of cross currency hedge unwind
|
|
|
|
|
|
|
4,070
|
|
|
|
|
|
Non-Deductible Goodwill
|
|
|
2,380
|
|
|
|
|
|
|
|
|
|
Effects of deemed foreign dividend
|
|
|
2,431
|
|
|
|
2,244
|
|
|
|
3,292
|
|
Other
|
|
|
(152
|
)
|
|
|
439
|
|
|
|
(347
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
(674
|
)
|
|
|
13,434
|
|
|
|
16,509
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A provision has not been made for U.S. or additional
foreign taxes on the undistributed portion of earnings of
foreign subsidiaries as those earnings have been permanently
reinvested. The undistributed earnings of foreign subsidiaries
approximate $104.0 million. It is not practicable to
determine the amount of the additional taxes that would result
if these earnings were repatriated.
F-27
Components of the Companys net deferred tax asset and
liability included in the Consolidated Balance Sheets consisted
of the following:
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
|
(In thousands)
|
|
|
Deferred tax assets:
|
|
|
|
|
|
|
|
|
Compensation and employee benefits
|
|
$
|
1,358
|
|
|
$
|
1,346
|
|
Accrued expenses and other future deductible items
|
|
|
3,151
|
|
|
|
5,412
|
|
Foreign operating loss carryforward
|
|
|
20,328
|
|
|
|
17,965
|
|
State and local operating loss carryforward
|
|
|
3,932
|
|
|
|
2,317
|
|
Federal operating loss carryforward
|
|
|
16,728
|
|
|
|
2,873
|
|
Deferred state income taxes
|
|
|
|
|
|
|
182
|
|
Contributions carryforward
|
|
|
68
|
|
|
|
68
|
|
Capital loss carryforward
|
|
|
12
|
|
|
|
18
|
|
Foreign tax credit carryforward
|
|
|
10,552
|
|
|
|
10,552
|
|
Unrealized foreign exchange losses
|
|
|
4,525
|
|
|
|
3,377
|
|
Stock option expense
|
|
|
674
|
|
|
|
455
|
|
Other
|
|
|
3,014
|
|
|
|
3,141
|
|
|
|
|
|
|
|
|
|
|
Total deferred tax assets
|
|
|
64,342
|
|
|
|
47,706
|
|
Deferred tax liabilities:
|
|
|
|
|
|
|
|
|
Deferred state income taxes
|
|
|
(63
|
)
|
|
|
0
|
|
Intangible assets
|
|
|
(2,413
|
)
|
|
|
(1,673
|
)
|
Depreciation and software costs
|
|
|
(9,437
|
)
|
|
|
(3,930
|
)
|
Open market repurchase
|
|
|
(990
|
)
|
|
|
(995
|
)
|
|
|
|
|
|
|
|
|
|
Total deferred tax liability
|
|
|
(12,903
|
)
|
|
|
(6,598
|
)
|
Valuation allowance
|
|
|
(28,559
|
)
|
|
|
(28,080
|
)
|
|
|
|
|
|
|
|
|
|
Total net deferred tax asset
|
|
$
|
22,880
|
|
|
$
|
13,028
|
|
|
|
|
|
|
|
|
|
|
As a result of certain realization requirements, the table of
deferred tax assets and liabilities shown above does not include
certain deferred tax assets at December 31, 2010 and 2009
that arose directly from tax deductions related to equity
compensation in excess of compensation recognized for financial
reporting. Equity will be increased by approximately
$3.1 million if and when such deferred tax assets are
ultimately realized. The Company uses tax law ordering for
purposes of determining when excess tax benefits have been
realized.
The Company has a Federal operating loss carryforward of
approximately $49.2 million with a recognized tax benefit
of approximately $16.7 million that will expire in 2027.
The deferred tax asset for state and local operating loss
carryforward of approximately $3.9 million relates to
amounts that expire at various times from 2011 to 2030. The
amount that will expire in 2011 is approximately $22,000. A
valuation allowance has been established for approximately
$551,000 of this tax asset based upon an assessment that it is
more likely than not, that realization cannot be assured in
certain tax jurisdictions.
The Company has foreign operating loss carryforwards of
approximately $15.1 million with a recognized tax benefit
of approximately $4.0 million that can be carried forward
indefinitely.
The Company has foreign operating loss carryforwards of
approximately $60.0 million with a tax benefit of
approximately $16.3 million for which a valuation allowance
has been established based upon an assessment that it is more
likely than not, that realization cannot be assured. The
ultimate realization of this tax benefit is dependent upon the
generation of sufficient operating income in the respective tax
jurisdictions. Of this benefit, approximately
F-28
$228,000 will expire at various times from 2011 to 2021 and
approximately $16.1 million can be carried forward
indefinitely.
The Company has a Federal foreign tax credit carryforward of
approximately $10.5 million that will expire in 2016. A
valuation allowance has been recorded against approximately
$8.5 million of this asset based upon the assessment that
it is more likely than not, that realization will not be assured
before expiration.
A valuation allowance has been established for other deferred
tax assets of approximately $3.2 million related to
operations in foreign tax jurisdictions based upon an assessment
that it is more likely than not, that realization cannot be
assured.
Yearly activity related to the Companys valuation
allowance is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
(In thousands)
|
|
|
Beginning balance
|
|
$
|
28,080
|
|
|
$
|
22,368
|
|
|
$
|
19,341
|
|
Additions charged to expense
|
|
|
752
|
|
|
|
1,025
|
|
|
|
9,080
|
|
Additions attributable to acquisitions
|
|
|
|
|
|
|
6,874
|
|
|
|
|
|
Reductions from utilization, reassessments and expirations
|
|
|
(273
|
)
|
|
|
(2,187
|
)
|
|
|
(6,053
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending balance
|
|
$
|
28,559
|
|
|
$
|
28,080
|
|
|
$
|
22,368
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Under current accounting requirements, at December 31,
2010, approximately $12.4 million of the valuation
allowance relates to prior year business combinations. If this
deferred tax asset is subsequently recognized, the Company will
be required to credit the current periods tax provision
rather than goodwill.
At December 31, 2010, 2009, and 2008, the Company had
certain unrecognized tax benefits recorded, gross of federal tax
benefit. A reconciliation of the beginning and ending amount of
unrecognized tax benefit is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
(In thousands)
|
|
|
Beginning Balance
|
|
$
|
1,768
|
|
|
$
|
1,764
|
|
|
$
|
5,447
|
|
Gross increases tax positions in prior period
|
|
|
|
|
|
|
|
|
|
|
230
|
|
Gross decreases tax positions in prior period
|
|
|
(180
|
)
|
|
|
|
|
|
|
(2,747
|
)
|
Gross increases tax positions in current period
|
|
|
387
|
|
|
|
451
|
|
|
|
384
|
|
Gross decreases tax positions in current period
|
|
|
|
|
|
|
|
|
|
|
|
|
Settlements
|
|
|
|
|
|
|
|
|
|
|
|
|
Lapse of statute of limitations
|
|
|
(1,001
|
)
|
|
|
(447
|
)
|
|
|
(1,550
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrecognized tax benefit balance at December 31
|
|
$
|
974
|
|
|
$
|
1,768
|
|
|
$
|
1,764
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Included in the balance at December 31, 2010, are
approximately $964,000 of unrecognized tax benefits, net of
federal tax benefit that, if recognized, would affect the
effective tax rate.
The liabilities for unrecognized tax benefits are carried in
other non-current liabilities on the Consolidated Balance Sheets
because the payment of cash is not anticipated within one year
of the balance sheet date for any significant amounts.
Interest and penalties associated with uncertain tax positions
are recognized as components of income tax expense on the
Consolidated Statements of Operations. There was no material
change to tax related interest and penalties during 2010 and at
December 31, 2010, the Company has recorded a liability of
approximately $145,000 for interest and penalties.
The Company files income tax returns in the U.S. federal
jurisdiction, and various states and foreign jurisdictions. With
few exceptions, the Company is no longer subject to
U.S. federal examinations by tax authorities for years
before 2007 and state and local or foreign income tax
examinations by tax authorities for years before 2006.
F-29
The tax years that remain subject to examination for the
Companys major tax jurisdictions are shown below:
|
|
|
|
|
United States
|
|
|
2007 - 2010
|
|
Germany
|
|
|
2006 - 2010
|
|
United Kingdom
|
|
|
2009 - 2010
|
|
Netherlands
|
|
|
2008 - 2010
|
|
The Company operates in various state and local jurisdictions.
Open tax years for state and local jurisdictions approximate the
open years reflected above for the United States.
The Company has a 50%-owned joint venture investment in Beijing
KendleWits Medical Consulting Co., Ltd. (KendleWits), a company
located in China. This investment is accounted for under the
equity method. To date, the Company has contributed
approximately $750,000 for the capitalization of KendleWits. In
2003, the Company determined that its investment in KendleWits
was permanently impaired and as a result recorded a non-cash
charge to reduce the carrying value of its investment to zero.
Future capital investment needs will be dependent upon the
on-going capitalization needs of KendleWits and the
Companys willingness to provide additional capital. The
Company is not obligated to make any additional investment in
KendleWits and currently has no plans to do so.
The Company operates its business in two reportable segments,
Early Stage and Late Stage. The Early Stage business currently
focuses on the Companys Phase I operations, while Late
Stage is comprised of contract services related to Phase II
through IV clinical trials, regulatory affairs and
biometrics offerings. The Late Stage segment changed its
reporting unit structure in 2009. The Late Stage reporting units
still meet the criteria for aggregation and there is no change
to segment reporting as a result of the reorganization. Support
and Other consists of unallocated corporate expenses, primarily
information technology, marketing and communications, human
resources, finance and legal, net of revenues earned for
billable administrative services performed.
Segment information for the years ended December 31, 2010,
2009 and 2008 is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Early
|
|
|
Late
|
|
|
Support
|
|
|
|
|
|
|
Stage
|
|
|
Stage
|
|
|
& Other
|
|
|
Total
|
|
|
|
(In thousands)
|
|
|
Twelve months ended December 31, 2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net service revenues
|
|
$
|
25,888
|
|
|
$
|
305,872
|
|
|
$
|
2,006
|
|
|
$
|
333,766
|
|
Reimbursable
out-of-pocket
revenues
|
|
$
|
2,106
|
|
|
$
|
112,387
|
|
|
$
|
|
|
|
$
|
114,493
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
$
|
27,994
|
|
|
$
|
418,259
|
|
|
$
|
2,006
|
|
|
$
|
448,259
|
|
Operating Income (loss)
|
|
$
|
(11,455
|
)
|
|
$
|
63,575
|
|
|
$
|
(53,318
|
)
|
|
$
|
(1,198
|
)
|
Total assets
|
|
$
|
32,528
|
|
|
$
|
390,608
|
|
|
$
|
66,775
|
(a)
|
|
$
|
489,911
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Early
|
|
|
Late
|
|
|
Support
|
|
|
|
|
|
|
Stage
|
|
|
Stage
|
|
|
& Other
|
|
|
Total
|
|
|
|
(In thousands)
|
|
|
Twelve months ended December 31, 2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net service revenues
|
|
$
|
37,473
|
|
|
$
|
370,178
|
|
|
$
|
9,037
|
|
|
$
|
416,688
|
|
Reimbursable
out-of-pocket
revenues
|
|
$
|
|
|
|
$
|
135,224
|
|
|
$
|
|
|
|
$
|
135,224
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
$
|
37,473
|
|
|
$
|
505,402
|
|
|
$
|
9,037
|
|
|
$
|
551,912
|
|
Operating Income (loss)
|
|
$
|
4,187
|
|
|
$
|
81,109
|
|
|
$
|
(49,722
|
)
|
|
$
|
35,574
|
|
Total assets
|
|
$
|
48,070
|
|
|
$
|
406,832
|
|
|
$
|
84,821
|
(a)
|
|
$
|
539,723
|
|
F-30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Early
|
|
|
Late
|
|
|
Support
|
|
|
|
|
|
|
Stage(b)
|
|
|
Stage
|
|
|
& Other
|
|
|
Total
|
|
|
|
(In thousands)
|
|
|
Twelve months ended December 31, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net service revenues
|
|
$
|
35,199
|
|
|
$
|
430,317
|
|
|
$
|
9,576
|
|
|
$
|
475,092
|
|
Reimbursable
out-of-pocket
revenues
|
|
$
|
|
|
|
$
|
203,489
|
|
|
$
|
|
|
|
$
|
203,489
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
$
|
35,199
|
|
|
$
|
633,806
|
|
|
$
|
9,576
|
|
|
$
|
678,581
|
|
Operating Income (loss)
|
|
$
|
6,177
|
|
|
$
|
105,140
|
|
|
$
|
(54,491
|
)
|
|
$
|
56,826
|
|
|
|
|
(a) |
|
Primarily comprised of cash and tax-related assets. |
|
(b) |
|
The Early Stage segment results for the twelve months ended
December 31, 2008 include the June (acquisition date)
through December operating results of DecisionLine. |
Financial information by geographic area is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Years Ended December 31,
|
|
Net service revenues
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
(In thousands)
|
|
|
North American Region:
|
|
|
|
|
|
|
|
|
|
|
|
|
United States
|
|
$
|
138,043
|
|
|
$
|
179,700
|
|
|
$
|
214,935
|
|
Other
|
|
|
16,047
|
|
|
|
21,166
|
|
|
|
14,411
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
154,090
|
|
|
$
|
200,866
|
|
|
$
|
229,346
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
European Region:
|
|
|
|
|
|
|
|
|
|
|
|
|
Germany
|
|
$
|
39,542
|
|
|
$
|
40,475
|
|
|
$
|
56,661
|
|
United Kingdom
|
|
|
30,518
|
|
|
$
|
37,792
|
|
|
$
|
42,303
|
|
Other
|
|
|
60,707
|
|
|
|
79,362
|
|
|
|
90,564
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
130,767
|
|
|
$
|
157,629
|
|
|
$
|
189,528
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Latin American Region:(1)
|
|
$
|
36,215
|
|
|
$
|
40,829
|
|
|
$
|
38,996
|
|
Asia/Pacific Region:
|
|
$
|
12,694
|
|
|
$
|
17,364
|
|
|
$
|
17,222
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Net Service Revenues
|
|
|
333,766
|
|
|
|
416,688
|
|
|
|
475,092
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Latin American region includes Mexico |
|
|
|
|
|
|
|
|
|
|
|
For the Years Ended December 31,
|
|
Identifiable Long-Lived Assets
|
|
2010
|
|
|
2009
|
|
|
|
(In thousands)
|
|
|
North American Region:
|
|
|
|
|
|
|
|
|
United States
|
|
$
|
45,379
|
|
|
$
|
41,711
|
|
Other
|
|
|
2,473
|
|
|
|
2,414
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
47,852
|
|
|
$
|
44,125
|
|
|
|
|
|
|
|
|
|
|
European Region:
|
|
|
|
|
|
|
|
|
Germany
|
|
$
|
587
|
|
|
$
|
743
|
|
United Kingdom
|
|
|
3,226
|
|
|
|
3,606
|
|
Other
|
|
|
2,457
|
|
|
|
3,107
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
6,270
|
|
|
$
|
7,456
|
|
|
|
|
|
|
|
|
|
|
Latin American Region:(1)
|
|
$
|
2,412
|
|
|
$
|
2,635
|
|
Asia/Pacific Region:
|
|
$
|
1,864
|
|
|
$
|
1,099
|
|
|
|
|
|
|
|
|
|
|
Total identifiable long-lived assets
|
|
$
|
58,398
|
|
|
$
|
55,315
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Latin American region includes Mexico |
F-31
No other country is material for separate presentation for any
period presented.
In 2010 and 2009, there were no sponsors who individually
accounted for more than 10% of the Companys consolidated
net service revenues.
Details pertaining to the Companys 2008 acquisition are
listed below. The Company had no acquisitions in 2010 or 2009.
The acquisition occurring in 2008 has been accounted for using
the purchase method of accounting.
Acquisition
of DecisionLine Clinical Research Corporation and related
company:
In June 2008, the Company completed its acquisition of 100% of
the outstanding common stock of DecisionLine Clinical Research
Corporation (DecisionLine), an Ontario corporation, and its
related company. DecisionLine, previously privately owned, is a
clinical research organization (CRO) located in Toronto, Ontario
specializing in the conduct of early phase studies. The
acquisition supports the Companys overall goal of
strategic business expansion and diversification into areas with
high growth opportunities such as Phase I studies. DecisionLine
was integrated into the Company as part of the Companys
Early Stage segment.
The aggregate purchase price was approximately $18,355,000 in
cash, including acquisition costs, plus net adjustments for
working capital and other items in accordance with the terms and
conditions of the Share Purchase Agreement of $1,276,000. In
addition, there was an earnout provision, as well as an
additional contingent payment upon receipt of certain tax
credits arising from pre-acquisition operations. In March 2009,
the above mentioned payment of certain tax credits was received,
and accordingly recorded as additional goodwill in the amount of
approximately $720,000 (equivalent of $900,000 in Canadian
dollars at the then current exchange rates). Additionally, in
May 2009, an agreement was reached to settle the outstanding
earnout provision for $4.3 million (equivalent of
$5 million in Canadian dollars at the then current exchange
rates) and accelerate the payment date for a portion of the
amount. This additional goodwill was recorded in the second
quarter of 2009.
The following table summarizes the estimated fair values of the
assets acquired and liabilities assumed at the date of
acquisition.
|
|
|
|
|
|
|
(In Thousands at the
|
|
|
|
Prevailing Exchange Rate
|
|
|
|
at June 2, 2008,
|
|
|
|
Except Contingent
|
|
|
|
Consideration Recorded
|
|
|
|
at Appropriate
|
|
Purchase Price Allocation
|
|
Exchange Rate)
|
|
|
Cash
|
|
$
|
1,562
|
|
Accounts receivable
|
|
|
5,922
|
|
Other current assets
|
|
|
1,398
|
|
Property, plant and equipment
|
|
|
2,913
|
|
Other long-term assets
|
|
|
1,196
|
|
Intangible assets
|
|
|
4,930
|
|
Goodwill
|
|
|
14,112
|
|
|
|
|
|
|
Total assets acquired
|
|
|
32,033
|
|
Advance billings
|
|
|
(3,503
|
)
|
Other current liabilities
|
|
|
(2,956
|
)
|
Other long-term liabilities
|
|
|
(898
|
)
|
|
|
|
|
|
Total liabilities assumed
|
|
|
(7,357
|
)
|
|
|
|
|
|
Net assets acquired
|
|
$
|
24,676
|
|
|
|
|
|
|
For the acquisition discussed above, results of operations are
included in the Companys Consolidated Statements of
Operations from the date of acquisition.
F-32
The following unaudited pro forma results of operations assume
the acquisition of DecisionLine occurred at the beginning of
2008:
|
|
|
|
|
|
|
Twelve Months
|
|
|
|
Ended
|
|
|
|
December 31, 2008
|
|
|
|
(In thousands, except per
|
|
|
|
share data)
|
|
|
Net service revenues
|
|
$
|
485,778
|
|
Income before income taxes
|
|
$
|
41,866
|
|
Net income
|
|
$
|
24,302
|
|
Net income per diluted share
|
|
$
|
1.62
|
|
Weighted average shares
|
|
|
14,993
|
|
Pro forma results for the twelve months ended December 31,
2008 reflect historical restructuring costs of approximately of
$480,000 ($307,000 net of tax).
The pro forma financial information is not necessarily
indicative of the operating results that would have occurred had
the acquisition been consummated as of January 1, 2008, nor
is it necessarily indicative of future operating results.
|
|
15.
|
QUARTERLY
FINANCIAL DATA (unaudited)
|
Earnings per basic share as presented on the 2010 and 2009
income statements do not equal the sum of earnings per share for
each quarter presented below due to rounding differences in each
quarter.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter
|
|
First
|
|
|
Second
|
|
|
Third
|
|
|
Fourth
|
|
|
|
(In thousands, except per share data)
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net service revenues
|
|
$
|
90,227
|
|
|
$
|
82,445
|
|
|
$
|
83,170
|
|
|
$
|
77,924
|
|
Gross profit
|
|
|
42,788
|
|
|
|
39,612
|
|
|
|
43,171
|
|
|
|
36,594
|
|
Income (loss) from operations
|
|
|
4,266
|
|
|
|
664
|
|
|
|
5,612
|
|
|
|
(11,741
|
)
|
Net income (loss)
|
|
|
1,211
|
|
|
|
1,863
|
|
|
|
1,549
|
|
|
|
(9,182
|
)
|
Net income (loss) per basic share
|
|
$
|
0.08
|
|
|
$
|
0.13
|
|
|
$
|
0.10
|
|
|
$
|
(0.62
|
)
|
Net income (loss) per diluted share
|
|
$
|
0.08
|
|
|
$
|
0.12
|
|
|
$
|
0.10
|
|
|
$
|
(0.62
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter
|
|
First
|
|
|
Second
|
|
|
Third
|
|
|
Fourth
|
|
|
2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net service revenues
|
|
$
|
108,103
|
|
|
$
|
107,351
|
|
|
$
|
104,588
|
|
|
$
|
96,646
|
|
Gross profit
|
|
|
50,126
|
|
|
|
52,147
|
|
|
|
55,674
|
|
|
|
48,155
|
|
Income from operations
|
|
|
8,137
|
|
|
|
6,978
|
|
|
|
15,533
|
|
|
|
4,926
|
|
Net income
|
|
|
887
|
|
|
|
3,193
|
|
|
|
8,826
|
|
|
|
2,331
|
|
Net income per basic share
|
|
$
|
0.06
|
|
|
$
|
0.22
|
|
|
$
|
0.59
|
|
|
$
|
0.16
|
|
Net income per diluted share
|
|
$
|
0.06
|
|
|
$
|
0.21
|
|
|
$
|
0.59
|
|
|
$
|
0.16
|
|
F-33
SIGNATURES
Pursuant to the requirements of Section 13 of the
Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
KENDLE INTERNATIONAL INC.
Candace Kendle, PharmD
Chairman, CEO and Principal Executive Officer
DATE SIGNED: March 16, 2011
Pursuant to the requirements of the Securities Exchange Act of
1934, this report has been signed by the following persons on
behalf of the Registrant and in the capacities and on the dates
indicated.
|
|
|
|
|
|
|
Signature
|
|
Capacity
|
|
Date
|
|
|
|
|
|
|
/s/ Candace
Kendle
Candace
Kendle, PharmD
|
|
Chairman of the Board of Directors, Chief Executive Officer and
Principal Executive Officer
|
|
March 16, 2011
|
|
|
|
|
|
*
Christopher
C. Bergen
|
|
Executive Vice President and
Chief Administrative Officer
|
|
March 16, 2011
|
|
|
|
|
|
/s/ Keith
A. Cheesman
Keith
A. Cheesman
|
|
Senior Vice President, Chief Financial Officer and Principal
Financial Accounting Officer
|
|
March 16, 2011
|
|
|
|
|
|
*
G.
Steven Geis, Ph.D., M.D.
|
|
Director
|
|
March 16, 2011
|
|
|
|
|
|
*
Donald
C. Harrison, M.D.
|
|
Director
|
|
March 16, 2011
|
|
|
|
|
|
*
Timothy
E. Johnson, Ph.D.
|
|
Director
|
|
March 16, 2011
|
|
|
|
|
|
*
Frederick
A. Russ, Ph.D.
|
|
Director
|
|
March 16, 2011
|
|
|
|
|
|
*
Robert
R. Buck
|
|
Director
|
|
March 16, 2011
|
|
|
|
|
|
*
Timothy
M. Mooney
|
|
Director
|
|
March 16, 2011
|
|
|
|
|
|
* /s/ Jarrod
B. Pontius
Jarrod
B. Pontius
|
|
as Attorney In-Fact
|
|
March 16, 2011
|
EXHIBIT INDEX
|
|
|
|
|
|
|
Exhibit
|
|
|
|
|
Number
|
|
Description of Exhibit
|
|
Filing Status
|
|
|
2
|
.1
|
|
Stock Purchase Agreement between the Company and Charles River
Laboratories International, Inc. dated as of May 9, 2006
|
|
*
|
|
2
|
.2
|
|
First Amendment to the Stock Purchase Agreement dated as of
August 16, 2006 between the Company and Charles River
Laboratories, Inc.
|
|
|
|
3
|
.1
|
|
Restated and Amended Articles of Incorporation
|
|
*
|
|
3
|
.2
|
|
Amended and Restated Code of Regulations
|
|
*
|
|
3
|
.3
|
|
Amendment of the Restated and Amended Articles of Incorporation
to Increase the Authorized Shares
|
|
*
|
|
4
|
|
|
Specimen Common Stock Certificate
|
|
*
|
|
4
|
.1
|
|
Shareholder Rights Agreement dated August 14, 2009 between
the Company and American Stock Transfer &
Trust Company LLC, as Rights Agent
|
|
*
|
|
4
|
.2
|
|
Indenture dated March 31, 2007 between the Company and
LaSalle Bank National Association
|
|
*
|
|
4
|
.3
|
|
Supplemental Indenture No. 1 dated July 16, 2007
between the Company and LaSalle Bank National Association
|
|
*
|
|
10
|
.1
|
|
Indemnity Agreement dated June 21, 1996 by and between the
Company and Candace Kendle Bryan
|
|
*
|
|
10
|
.2
|
|
Indemnity Agreement dated June 21, 1996 by and between the
Company and Christopher C. Bergen
|
|
*
|
|
10
|
.3
|
|
Indemnity Agreement dated June 21, 1996 by and between the
Company and Timothy M. Mooney
|
|
*
|
|
10
|
.4
|
|
Indemnity Agreement dated May 14, 1997 by and between the
Company and Charles A. Sanders
|
|
*
|
|
10
|
.5
|
|
Indemnity Agreement dated May 14, 1997 by and between the
Company and Philip E. Beekman
|
|
*
|
|
10
|
.6
|
|
Indemnity Agreement dated December 10, 1998 by and between
the Company and Robert Buck
|
|
*
|
|
10
|
.7
|
|
Indemnity Agreement dated December 10, 1998 by and between
the Company and Mary Beth Price
|
|
*
|
|
10
|
.8
|
|
Form of Indemnity Agreement by and between the Company and each
member of the Companys Board of Directors, except for
those Indemnity Agreements noted above and filed previously.
|
|
*
|
|
10
|
.9
|
|
Confirmation of Convertible Bond Hedge Transaction, dated
July 10, 2007, by and between the Company and UBS AG,
London Branch
|
|
*
|
|
10
|
.10
|
|
Confirmation of Convertible Bond Hedge Transaction, dated
July 10, 2007, by and between the Company and JPMorgan
Chase Bank, National Association, London Branch
|
|
*
|
|
10
|
.11
|
|
Confirmation of Issuer Warrant Transaction, dated July 10,
2007, by and between the Company and UBS AG, London Branch
|
|
*
|
|
10
|
.12
|
|
Confirmation of Issuer Warrant Transaction, dated July 10,
2007, by and between the Company and JPMorgan Chase Bank,
National Association, London Branch
|
|
*
|
|
10
|
.13
|
|
Lease Agreement dated February 27, 2008 by and between the
Company and Carew Realty, Inc.
|
|
*
|
|
10
|
.14
|
|
Credit Agreement dated as of March 15, 2010 by and among
the Company , various Lenders and JPMorgan Chase Bank, N.A., as
Administrative Agent
|
|
*
|
|
10
|
.15
|
|
Guaranty dated as of March 15, 2010 by and among various
Subsidiaries of the Company in favor of JPMorgan Chase Bank,
N.A., as Administrative Agent
|
|
*
|
|
10
|
.16
|
|
Pledge and Security Agreement dated as of March 15, 2010 by
and among the Company, various Subsidiaries of the Company and
JPMorgan Chase Bank, N.A., as Administrative Agent
|
|
*
|
|
|
|
|
|
|
|
Exhibit
|
|
|
|
|
Number
|
|
Description of Exhibit
|
|
Filing Status
|
|
|
10
|
.17
|
|
Amendment No. 1 to Credit Agreement with various lenders
and JPMorgan Chase Bank, N.A., as Administrative Agent dated as
of April 27, 2010
|
|
*
|
|
10
|
.18
|
|
Amendment No. 2 to Credit Agreement with various lenders
and JPMorgan Chase Bank, N.A., as Administrative Agent dated as
of January 21, 2011
|
|
Filed Herewith
|
|
10
|
.19
|
|
MANAGEMENT CONTRACTS AND COMPENSATION PLANS
|
|
*
|
|
|
|
|
(a) 1995 Stock Option and Stock Incentive Plan
|
|
*
|
|
|
|
|
(b) 1995 Stock Option and Stock Incentive Plan
Individual Stock Option Agreement for Incentive Stock Option
(contained in Exhibit 10.20(a))
|
|
*
|
|
|
|
|
(c) 1997 Stock Option and Stock Incentive Plan
|
|
*
|
|
|
|
|
(c)(1) Amendment No. 1 to 1997 Stock Option and Stock
Incentive Plan
|
|
*
|
|
|
|
|
(c)(2) Amendment No. 2 to 1997 Stock Option and Stock
Incentive Plan
|
|
*
|
|
|
|
|
(c)(3) Amendment No. 3 to 1997 Stock Option and Stock
Incentive Plan
|
|
*
|
|
|
|
|
(c)(4) Form of Restricted Stock Award Agreement
|
|
*
|
|
|
|
|
(d) Form of Protective Compensation and Benefit Agreement
|
|
*
|
|
|
|
|
(e) 2007 Stock Incentive Plan
|
|
*
|
|
|
|
|
(e)(1) Form of Performance-Based Stock Unit Agreement
|
|
*
|
|
|
|
|
(f) Annual Incentive Plan
|
|
*
|
|
|
|
|
(g) Nonqualified Deferred Compensation Plan
|
|
*
|
|
|
|
|
(h) 2003 Directors Compensation Plan
|
|
*
|
|
12
|
.1
|
|
Computation of Ratio of Earnings to Fixed Charges
|
|
Filed herewith
|
|
14
|
|
|
Code of Ethics
|
|
Available on
the Companys
website
|
|
21
|
|
|
List of Subsidiaries
|
|
Filed herewith
|
|
23
|
.1
|
|
Consent of Deloitte & Touche LLP
|
|
Filed herewith
|
|
24
|
|
|
Powers of Attorney
|
|
Filed herewith
|
|
31
|
.1
|
|
Certification of the Chief Executive Officer pursuant to
Rule 13a-14(a)
|
|
Filed herewith
|
|
31
|
.2
|
|
Certification of the Chief Financial Officer pursuant to
Rule 13a-14(a)
|
|
Filed herewith
|
|
32
|
.1
|
|
Certification Pursuant to 18 U.S.C Section 1350 as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002-
Chief Executive Officer
|
|
Filed herewith
|
|
32
|
.2
|
|
Certification Pursuant to 18 U.S.C Section 1350 as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of
2002 Chief Financial Officer
|
|
Filed herewith
|